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Summary  
Background: Cardiovascular disease (CVD) is the leading cause of death worldwide. 
Vitamin D is important for bones and for other body functions. Whether insufficient 
vitamin D causes CVD is unclear. Previous trials of vitamin D were unable to evaluate 
effects on CVD.  
Aims This thesis will (i) review the literature on vitamin D and CVD; (ii) evaluate the 
observational associations between plasma 25(OH)D levels and CVD; and (iii) describe 
the design and results of the BEST-D trial.  
Methods (i) Associations between baseline 25(OH)D levels and cause-specific mortality 
were evaluated in the Whitehall Resurvey of survivors undertaken in 1995, and findings 
included in a meta-analysis of similar studies. (ii) The BEST-D study was a randomised 
trial in older healthy volunteers of the effects of two doses of vitamin D3 (4000 IU or 
2000 IU daily) compared to placebo, on blood 25(OH)D concentrations and CVD risk 
factors including blood pressure and arterial stiffness. 
Results (i) The Whitehall Resurvey of 5409 men with mean age of 77 years, among 
whom there were 3215 deaths showed an approximately linear (log-log scale) inverse 
association of plasma 25(OH)D concentrations and both CVD and non-vascular causes of 
death between 30 to 90 nmol/L. The meta-analysis confirmed the associations of 
25(OH)D with CVD mortality. (ii) The BEST-D trial showed marked increases in 25(OH)D 
blood concentrations but no effects of taking higher doses of vitamin D3 for 12 months 
on blood pressure or arterial stiffness, compared to placebo. 
Conclusions 
Plasma 25(OH)D is inversely associated with both CVD and non-vascular mortality. No 
effects were found after oral intake of vitamin D3 on blood pressure or arterial stiffness 
after 1 year. Randomised trials using adequate doses of vitamin D3 are needed, to 
evaluate causal effects of taking vitamin D on CVD outcomes.
Total Word count: 29,663 (excluding references, Appendix, Tables and Figures) 
Abstract word count:  292 
Number of figures: 21   
Number of tables: 22 Colour pages:5 
                                                                                                             Why examine vitamin D and CVD                              
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Chapter 1  Introduction: Why examine Vitamin D and cardiovascular 
disease 
Rationale and Overview of thesis 
Low vitamin D levels are prevalent world-wide and there is a re-emergence of diseases 
like rickets and osteomalacia, which are associated with vitamin D deficiency. CVD is the 
single most common cause of death worldwide, with a number of established risk 
factors identified.1 However, identifying newer CVD risk factors remains relevant and 
may help with the understanding of CVD pathophysiology and could lead to newer 
therapeutic targets for prevention or treatment of CVD. Vitamin D insufficiency may be 
a potential new risk factor for CVD, and is potentially modifiable. 
 
Vitamin D is important for maintaining blood calcium levels and for healthy bones,2 but 
whether low levels of vitamin D, assessed by measuring plasma 25-hydroxyvitamin D 
[25(OH)D –the main storage form of vitamin D],2, 3 are causally related to CVD is unclear. 
New research shows that vitamin D influences about 10% of the human genome4 and 
those vitamin D receptors have been described in almost all tissues of the human 
body.5, 6 In tissues other than the liver and the kidneys, there is evidence of vitamin D 
metabolism which suggests a wider role for vitamin D beyond calcium regulation and 
bone health.7  
 
Observational studies of vitamin D (discussed in the next chapter) demonstrate higher 
rates of CVD deaths with increasing latitude from the equator, at higher altitudes and 
during winter.8 These observed variations in CVD death rates are not fully explained by 
  Why examine vitamin D and CVD 
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our current understanding of the pathophysiology of CVD or by its established risk 
factors. One possible explanation may be that these differences are related to the 
variation in circulating vitamin D levels according to the availability of sunlight. Sun 
exposure of skin is the main source of vitamin D for the human body and accounts for 
its seasonal variation. People living in regions at the extremes of latitude from the 
equator have reduced ultra-violet B (UVB) rays availability. The UVB availability is lowest 
during winter in these regions as the sun’s radiation has to travel through a greater 
thickness of the atmosphere given the low angle of the sun in winter (in relation to its 
position in summer); this leads to reduced or no vitamin D production and could be 
linked to the higher CVD deaths. If a causal link between low vitamin D and CVD is 
established, modifying vitamin D levels could be an effective public health measure for 
prevention of CVD. Increasing vitamin D levels through vitamin D supplements or 
fortification is feasible and cost-effective.  
 
Prospective studies report inverse associations of 25(OH)D levels with CVD risk factors 
and CVD deaths (reviewed in the next chapter), but the shape and strength of these 
associations, the consistency of the observations and the generalizability of the findings 
to the broader general population remain unclear. However, the evidence from clinical 
trials and genetic studies, reviewed in the next Chapter, is inconclusive and there is a 
case for more studies to test the causality of the reported associations.  
 
This chapter also introduces and discusses the concept of ‘optimal’ 25(OH)D 
concentrations, especially with a focus on cardiovascular and other health outcomes, 
and the controversies surrounding its definition.  
  Why examine vitamin D and CVD 
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The relationship between circulating 25(OH)D concentrations and cause-specific 
mortality was explored in a prospective analysis of the Whitehall resurvey participants 
(Chapter 3).9 Inverse log-linear associations of baseline 25(OH)D concentrations with 
both CVD and non-CVD causes of death were observed in this study. There was a lack of 
clarity if these were consistent and comparable to the findings from the other 
prospective studies reporting on CVD and all-cause mortality. Hence the Whitehall 
resurvey findings were included in meta-analyses of prospective studies (Chapter 4) that 
predominantly evaluated associations of baseline 25(OH)D concentrations with either 
all-cause mortality and CVD mortality, and found that these reported associations from 
the Whitehall study were consistent and congruent, and comparable to studies that 
included participants living in other regions of the world.9 
 
Evidence from randomised-controlled trials of vitamin D on the effects of 
supplementation on cardiovascular disease outcomes is limited. Most previous trials of 
vitamin D supplementation were designed to evaluate effects of on fractures and falls, 
or muscle strength and balance, and were conducted predominantly among the older 
people. These trials also typically assessed doses equivalent to vitamin D 400 IU to 800 
IU daily which would have been insufficient to raise 25(OH)D levels to concentrations 
associated with the lowest risks of CVD and all-cause mortality observed in the 
prospective studies, and hence may have lacked statistical to power to demonstrate 
effects on CVD outcomes. As alluded to previously, although the optimal levels of 
25(OH)D are a matter of debate, the early evidence from various observations suggest 
that plasma levels of 80-90 nmol/L may be ‘optimal’ for multiple health outcomes 
including CVD.9-11 Hence, the previous trials of vitamin D were unlikely to have achieved 
  Why examine vitamin D and CVD 
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significant differences in plasma concentrations of 25(OH)D between the treatment 
arms when using the typically small equivalent daily doses, and hence would not have 
been able to detect differences on CVD outcomes. Further well-designed, large trials 
using sufficient doses of vitamin D supplements12 are needed to evaluate the role of 
vitamin D supplements on CVD outcomes.  
 
Before designing another trial of vitamin D supplements, the dose of vitamin D 
supplement that would achieve concentrations considered to be the ‘optimal’ plasma 
25(OH)D levels, needs to be established. Typically a dose of 400 units of vitamin D will 
raise 25(OH)D levels by only 7-10 nmol/L13 and so to raise blood concentrations 
25(OH)D levels, associated with the lowest risks for multiple health outcomes including 
CVD ( i.e. >80-90 nmol/L), 9 doses of 2000 IU daily or more may be required11, 14, 15Data 
from the National survey suggests that older adults have plasma 25(OH)D of about 50-
55 nmol/L at the end of summer and the levels fall further in winter.16 The safety, 
efficacy and tolerability of such higher daily doses of vitamin D3 supplements (>2000 IU 
daily) especially when taken for longer periods have not been adequately assessed.13 
Chapter 5 of this thesis describes the methods and design of a dose-finding trial of 
vitamin D called BEST-D (Biochemical efficacy and safety of vitamin D) evaluating effects 
of two doses of daily vitamin D3 (cholecalciferol) 2000 IU and 4000 IU, versus placebo 
on plasma 25(OH)D levels.17 The results of BEST-D are reported in Chapter 6. 
 
To reliably establish a causal relationship between low vitamin D and CVD, appropriately 
designed randomised trials using adequate doses of vitamin D supplements are 
necessary, and some are already underway. However, the earliest results from these 
  Why examine vitamin D and CVD 
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trials evaluating effects on CVD outcomes are not expected until at least 2017.12 Given 
this context, assessing the effects of vitamin D on CVD risk markers may provide some 
insight into potential effects of vitamin D supplements on CVD outcomes, if any. Some 
observational studies have suggested that low vitamin D is associated with a higher 
blood pressure and higher arterial stiffness but the effect of supplementing with vitamin 
D is uncertain. We tested the effects of taking two daily doses of vitamin D3 (2000 IU 
and 4000 IU daily) versus placebo for 1 year on blood pressure and arterial stiffness 
among the participants in the BEST-D trial. Thus this thesis will seek to explore whether 
low vitamin D could cause CVD and test the effects of the vitamin D on CVD risk 
markers. The analysis of the findings, discussed in Chapter 7 will help inform the design 
of a future randomised trial of vitamin D evaluating the effects of vitamin D on CVD 
outcomes. 
 
Summary 
Evidence from observational studies of vitamin D, and the emerging laboratory and 
genetic evidence on the biology of the vitamin provides a strong basis for exploring a 
possible role for low vitamin D as a risk factor in the development of CVD. If low vitamin 
D causes CVD, modifying circulating levels of vitamin through supplementation could 
become an effective public health measure for preventing CVD. 
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Aims of thesis 
The main aims of this thesis are to: 
1. Review observational evidence from prospective studies reporting associations of 
blood 25(OH)D and CVD; 
2. Review the results from randomised trials of vitamin D and CVD outcomes; 
3. To describe the design of a dose-finding trial of vitamin D called BEST-D, and report 
the effects of taking vitamin D supplements for 12 months on blood pressure (CVD 
risk factor) and arterial stiffness (surrogate marker for CVD). 
  
  Why examine vitamin D and CVD 
21 
 
Outline of Chapters 
Chapter 1: Introduction: Why examine vitamin D and CVD 
Chapter 2: Vitamin D and CVD 
This chapter reviews the published literature on observational studies and clinical trials 
of vitamin D and cardiovascular outcomes. 
Chapter 3: Vitamin D and cause-specific mortality in the Whitehall resurvey 
This chapter presents the findings of a prospective study reporting on associations 
between baseline plasma 25(OH)D and cause-specific mortality over a 13-year follow-
up, among participants in the Whitehall resurvey.  
Chapter 4: Meta-analyses of prospective studies of vitamin D and the risks of CVD and 
all-cause mortality 
The findings from the Whitehall resurvey (Chapter 3) are put in perspective by including 
these in meta-analyses of other prospective studies reporting on baseline 25(OH)D and 
CVD or all-cause mortality.  
Chapter 5: The Biochemical Efficacy and Safety Trial of vitamin D (BEST-D) – design and 
methods to evaluate the effects of vitamin D on blood pressure and arterial stiffness. 
The design of this dose-finding trial of vitamin D and the methods for evaluating the 
effects of vitamin D supplements on blood pressure and arterial stiffness among 
participants of the Biochemical Efficacy and Safety Trial of vitamin D (BEST-D), is 
discussed.  
Chapter 6: Effects of vitamin D on blood pressure and arterial stiffness 
The effects of taking high dose vitamin D3 supplements daily for a year, on blood 
pressure and CVD are presented.  
Chapter 7: Analyses and Conclusion 
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Role of the author in this thesis 
All the work presented in this thesis is my own conducted under the supervision of 
Professor Jane Armitage and Professor Robert Clarke and with remote supervision from 
Professor Sally Lamb and as part of a larger body of collaborative projects on vitamin D, 
done at the CTSU, University of Oxford. 
 
I joined the CTSU as a Clinical Research Fellow to help with the running of the on-going 
large-scale CVD trials, and was given the opportunity to get involved in the planned 
BEST-D study. The study was designed as a pilot dose-finding study in preparation for a 
large randomised study to assess the effect of vitamin D supplementation on risk of 
fractures. With my background in cardiovascular medicine, and interest in the effect of 
vitamin D on CVD, in discussion with my supervisors, we decided to evaluate the effects 
of vitamin D supplements on cardiovascular risk factors in the planned study and 
modified the protocol. I was interested on the effects of weather and CVD and hence 
keen to explore the effects of vitamin D on CVD.  
 
Before the trial was established, I conducted a literature review of the prospective 
studies of vitamin D reporting on the associations of blood 25(OH)D concentrations and 
risk of deaths from CVD and all-cause mortality, and also worked with colleagues on 
evaluating the relationship between baseline plasma 25(OH)D levels and cause-specific 
mortality in a subset of survivors of The Whitehall study who were resurveyed in 1997 
by Professor Clarke. The data from Whitehall was interpreted in the context of a meta-
analysis of similar prospective studies of vitamin D that I undertook. Dr Jon Emberson 
(Senior statistician, CTSU), undertook the statistical analyses for this work), and 
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laboratory support was provided by Dr Michael Hill (Laboratory Scientific Director, 
CTSU) and his team at Wolfson laboratory, CTSU. I worked with Dr Harold Hin, (General 
Practitioner, Hightown Surgery, Banbury) who was the local investigator for the BEST-D 
trial and who helped with trial management at Banbury, including help with identifying 
and recruiting suitable study nurses and participants. 
 
The protocol for BEST-D was revised in the light of these findings to incorporate 
measures of the effects of vitamin D on CVD risk markers. I was involved in the planning, 
and design of the trial, and in seeking the approval from the relevant Ethics Committees 
and the Medicines and Healthcare products Regulatory Agency (MHRA). I evaluated the 
assessment methods used in the trial, and its logistics with help from Jenny Sayer (trial 
administrator). I worked with senior IT colleagues at CTSU (Dr Mike Lay – head of Heart 
Studies Group programming team; Jolyon Cox – senior researcher; and Rijo Kurien - 
programmer), in developing the be-spoke trial software. This was based on the 
questionnaire outlines I designed and developed (with input from Jane Armitage and 
Robert Clarke) for the trial. I also developed the trial-specific training materials and trial 
‘standard operating procedures’ (SOP).  
 
We secured two grants to support the work on CVD from the British heart foundation 
(BHF). The research proposal entitled ‘Does vitamin D supplementation improve 
markers of inflammation, innate immunity and arterial stiffness?’ developed in 
collaboration with the Wellcome Trust Centre for Human Genetics, Oxford, secured a 
BHF Project grant (PG/12/32/29544) for a sum of £ 112,140. This grant supports the 
work on evaluating effects of vitamin D supplements on genetic markers of 
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inflammation and immunity (not part of this thesis), and the effects on arterial stiffness. 
The BHF Centre for Research Excellence (BHF CRE), Oxford provided a grant for £ 50,000 
to evaluate ‘Effects of vitamin D supplements on cardiac contractile function’ in the 
BEST-D trial. This grant supports the evaluation of cardiac function of participants in the 
BEST-D trial at the end of the study using echocardiography (not included in this thesis). 
The research included in this thesis is from work where I have had a major contribution.  
 
Publications relating to this thesis 
1. Tomson J, Emberson J, Hill M, Gordon A, Armitage J, Shipley M, et al. Vitamin D and 
risk of death from vascular and non-vascular causes in the Whitehall study and 
meta-analyses of 12 000 deaths. Eur Heart J. 2013; 34(18): 1365-74 (Appendix 1). 
2. Clarke R, Newman C,Tomson J, Hin H, Kurien R, Cox J, Lay M, Sayer J, Hill M, 
Emberson J, Armitage J for the BEST-D Collaborative Group. Estimation of the 
optimum dose of vitamin D for disease prevention in older people: rationale, design 
and baseline characteristics of the BEST-D trial. Maturitas. 2015 Apr;80(4):426-31. 
3. Hin H, Tomson J, Newman C, Kurien R, Lay M, Cox J, Sayer J, Hill M, Emberson J, 
Armitage J, Clarke R for the BEST-D Collaborative Group. Optimum dose of vitamin D 
for disease prevention in older people: BEST-D trial of vitamin D in primary care (In 
submission). 
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Chapter 2 :  Vitamin D and Cardiovascular disease 
The burden of cardiovascular disease  
Cardiovascular disease is the leading cause of death globally,1 and accounts for more 
than a third of all deaths. Age-adjusted CVD death rates in developed countries such as 
the UK and USA are falling18-20, thought to be largely due to progress in implementing 
CVD preventive measures such as smoking cessation and control of established CVD risk 
factors. However, CVD death rates in the developing countries and emerging economies 
are rising1 and CVD prevention remains a key challenge for public health globally. This 
chapter reviews the literature on the relationship between CVD and vitamin D. 
 
Vitamin D as a risk factor for CVD 
The pathophysiology of CVD is not fully understood and is not entirely explained by 
classical CVD risk factors. 21-23 [In this thesis, CVD refers to coronary heart disease (CHD) 
and other cardiovascular disease e.g. stroke and peripheral arterial disease]. For 
instance, existing risk factors for CHD are thought to explain between 50-75% of all 
incident coronary heart disease (CHD).21-23 Hence, there is a need to evaluate other 
potential risk factors for CHD and/or CVD. It is also known that CVD can occur in people 
with either some or no established CVD risk factors,18 24 i.e. the risks of CVD is not zero 
in those with ‘low risk scores for CVD’. Although this may be explained by the effects of 
residual confounding, where pre-existing cardiovascular risk factors are not fully 
accounted for due to imprecise measurements or within-person variation, the 
unexplained risk may be due to the existence of other hitherto unidentified risk factors 
for CHD. Such novel risk factors if identified, may help explain the inconsistencies in the 
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literature of observed variation in CVD rates, such as the low incidence of CVD among 
people living in France compared to elsewhere in Europe despite similar prevalence of 
CVD risk factor levels;25 or the 50% higher risk of cardiovascular deaths among South 
Asians living in the UK compared to Caucasians.26, 27 Finally, new risk factors would 
enable us to better understand CVD pathophysiology and present newer targets for 
prevention and therapy.  
 
Evidence from recent research suggest vitamin D has effects on many tissues in the 
body as vitamin D receptors have been detected in almost all tissues.5 Vitamin D is also 
now shown to be metabolised in tissues other than those classically described, such as 
the liver, kidneys and bone, indicating a role in the wider human physiology.7, 28, 29 
Genetic studies confirm vitamin D influences a tenth of the human genes.4 Hence, it is 
possible that maintaining plasma levels higher than 25 nmol/L may be important for 
human health in general and for CVD.  
 
Additional evidence from ecological studies supports further evaluation of the role of 
vitamin D in the development of CVD. Ecological studies have reported inverse 
associations between deaths from ischaemic heart disease (IHD) and increasing latitude 
from the equator (Figure 2-1),8, 30, 31 but this is weak evidence for it being an effect of 
vitamin D. This trend is consistent with the relative lack of UVB availability from 
sunlight, as there is reduced UVB available with increasing distance from the equator. 
Several other studies also report higher rates of CVD deaths in winter compared to 
summer.32, 33 The reduction in UVB is worse during winter and more pronounced at the 
extreme of latitudes from the equator, as the UVB rays have to travel longer through an 
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increased thickness of the atmosphere, given the shallower angle at which the sun rays 
would fall at this time of the year.34 Hence, differences in circulating vitamin D levels 
may account for some or all of the observed differences in CVD death rates. 
 
Vitamin D metabolism 
The metabolism and physiology of vitamin D has been comprehensively reviewed 
elsewhere,2, 35, 36 but an outline of the relevant aspects is described below (Figure 2-2). 
Vitamin D is an essential vitamin and can be synthesised in the human body after 
exposure of the skin to ultraviolet B rays (UVB) from sunlight (UVB rays that have a 
wavelength spectra between 290–315 nm).2, 37 The UVB rays convert 7-
dehydrocholesterol, a precursor of cholesterol present in the skin, to pre-vitamin D3 
and subsequently to vitamin D3 (cholecalciferol). The process is both light and 
temperature-sensitive. Prolonged sunlight exposure or temperature converts vitamin 
D3 to other metabolites. Hence, production of vitamin D is regulated by both 
temperature and light changes. 
 
Vitamin D2, or ergocalciferol, is the main form of vitamin D obtained from plant sources 
and has less biological activity than vitamin D3. Vitamin D3 is also found in some foods 
like fatty fish and egg yolks. But diet is a poor source of the vitamin in general, as only 
small quantities of vitamin-rich foods are consumed. While some countries fortify foods 
with vitamin D, fortification is not currently implemented in the UK. 38, 39 Both vitamin 
D2 and D3 are transported in blood predominantly bound to the vitamin D-binding 
protein (VDBP), and metabolized to 25-hydroxyvitamin D [25(OH)D] by cytochrome 
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P450 dependant enzymes mainly, but not exclusively, in the liver. One of the liver 
enzymes, CYP27A1 is the most widely described catalyst promoting this hydroxylation 
step. Excess 25(OH)D is bound to vitamin D-binding protein in blood, the affinity of this 
binding capacity is variable and could impact on the bioavailability; some 25(OH)D may 
also be stored in fat and muscle, and released when required. Plasma 25(OH)D has a 
half-life of 2-3 weeks. Blood levels of 25(OH)D are widely used as a measure of vitamin 
D status in humans, rather than the active form of the vitamin D, which is 1,25(OH)D.40 
 
The active form of vitamin D, or calcitriol [1,25(OH)D], is formed after a further 
hydroxylation of 25(OH)D, predominantly in the kidneys. This step is catalysed by 
CYP27B1, an enzyme once thought to be present only in the kidneys, but which now has 
been shown to be present in several cell types, suggesting that vitamin D metabolism 
occurs in other tissues and could have actions there. For instance, CYP27B1 is present in 
macrophages and white cells and could suggest a role for vitamin D in immunity;28, 41 
Vitamin D has also important roles in the cell cycle influencing cell division, maturation, 
differentiation and death.42 Due to these varied actions in multiple tissues and the local 
metabolism and regulation, some consider vitamin D as a pro-hormone.  
 
The active vitamin, 1,25(OH)D, binds mainly to a nuclear receptor (vitamin D receptor, 
VDR),6 which in turn bind to the vitamin D response elements (VDRE) in genes. VDR 
belongs to the steroid/thyroid superfamily of receptors, and after binding with 
1,25(OH)D, brings about transcriptional changes through DNA and micro-RNA mediated 
transcriptional responses. The VDR receptors are of different shapes and are important 
in mediating different responses to 1,25(OH)D concentrations,43 such as the rapid 
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response, which typically causes increased gut absorption of calcium; or the slower 
response which includes the actions of genetic and transcriptional modification and 
takes longer to manifest. 4-7, 44 The VDR is found in cardiac myocytes as well as immune 
cells and platelets. Further, genetic expression is influenced and modified by other co-
activators and suppressors and possibly micro-RNAs.45 VDR can bind to both 1,25(OH)D 
and 25(OH)D. Hence, 25(OH)D can initiate some physiological actions of vitamin D. Both 
25(OH)D and 1,25(OH)D can trigger the ‘rapid response’, albeit the physiological role of 
this response is still under investigation. 
 
Production of active vitamin D is also regulated by the parathyroid hormone (PTH), 
which stimulates the renal production of 1,25(OH)D when circulating 25(OH)D is low 
(Figure 2-2). Vitamin D and parathyroid hormone (PTH), an 84-aminoacid polypeptide 
secreted by the parathyroid glands located in the neck, form parts of a feedback 
mechanism that controls bone and calcium metabolism. The blood levels of the active 
vitamin D, 1,25(OH)D, are normally about a thousandth of the concentration of 
circulating 25(OH)D. The levels of 25(OH)D determine plasma levels of active vitamin D 
[i.e. the higher circulating 25(OH)D, the higher the levels of 1,25(OH)D]. However, 
1,25(OH)D can down-regulate its own production locally.36 
 
The main physiological action of vitamin D is to maintain blood calcium levels within the 
normal range by promoting intestinal absorption and the renal re-absorption of calcium. 
Plasma concentrations of calcium are tightly controlled in the body to ensure a steady 
uninterrupted supply (an important role for vitamin D in vertebrates). When plasma 
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calcium levels fall, a number of mechanisms ensure adequate circulating levels of the 
ion (discussed below). 
 
A number of other factors influence circulating vitamin D levels. From an evolutionary 
perspective, melanin may be the most important.46 Melanin is a pigment molecule 
present in the superficial layers of the skin and gives it the dark colour, and depending 
on the distribution reduces the amount of UVB rays reaching the deeper layers of skin 
where vitamin D synthesis takes place. Hence, for a similar amount of UV light exposure 
lower vitamin D levels are seen in people with more skin pigmentation. There is 
evidence that fairer skin colour is an adaptation to enable endogenous production of 
vitamin D with migration of early man from equatorial regions to higher and lower 
latitudes.46 Further, the genes activated by vitamin D happen to be located in areas of 
the genome, protected and passed on over time with evolution – genes of positive 
selection.4 Hence, it is unclear if human beings would adapt to lower plasma 25(OH)D 
concentrations when migrating to areas of less UVB availability, or whether this 
adaptation has already occurred if any over the years.  
 
Calcium metabolism 
Calcium is vital for many functions in the human body, especially for bones, muscle 
contraction, nerve and cardiac impulse conduction and intra-cellular signalling.47, 48 The 
vast majority of calcium is present in bone as a calcium-phosphate complex, while the 
remainder constitutes only 1% of calcium in the human body and is predominantly in a 
circulating form.  
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Circulating calcium can be in the ionised or non-ionised forms.48, 49 The non-ionized 
calcium is bound to calcium-binding proteins like albumin and globulin in serum and 
calmodulin within the cell. The major ionic calcium complexes in serum are calcium 
phosphate, calcium carbonate, and calcium oxalate. However, it is the ionised calcium 
that is important in the regulation of serum calcium levels (and forms 50% of all 
circulating calcium), and this in turn is closely regulated through a negative feedback 
mechanism as described above.  
 
Parathyroid hormone is an 84-amino acid polypeptide secreted by the parathyroid 
glands in response to a fall in circulating calcium concentration and through a negative 
feedback mechanism influenced by circulating concentrations of phosphate and 
fibroblast growth factor-23 (FGF23).35,50 It acts by increasing renal reabsorption of 
calcium and stimulating the 1,25(OH)D production which in turn increases calcium 
absorption from the intestine and promotes bone remodelling. Additionally, PTH 
regulates skeletal growth factors which help with building bone tissue. 
A fall in serum calcium ions inactivates receptors situated in the parathyroid cells 
causing an increase in PTH secretion from the gland.51 This in turn helps restore serum 
calcium through bone resorption secondary to the increased osteoclast activity, by 
increasing the renal tubular calcium reabsorption and reduction in excretion, and an 
increase in gut absorption. The increased PTH levels also promote hydroxylation of 
25(OH)D and the consequent increase in 1,25(OH)D, the active form of vitamin D.  
The amount of calcium excreted in a day is typically around 200 mg/d for adults. The net 
absorption of calcium from the gut reaches 200 mg at a calcium supplement intake of 
around 1200 mg/d, which is the current recommendation for calcium intake in adults. 
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The proportion of calcium absorbed from the gut is positively correlated with circulating 
25(OH)D concentrations. Supplementation with vitamin D can significantly increase the 
actively absorbed fraction of calcium from the gut, even without achieving higher 
1,25(OH)D levels. 49, 52 To explain this, a self-regulatory model of calcium metabolism 
has been proposed, where sufficient calcium and 25(OH)D levels determine the rate and 
efficiency of calcium absorption.49, 52 Thus, when 25(OH)D levels are suboptimal, 
intestinal calcium absorption in response to adequate calcitriol levels is reduced 
perhaps through the selective influences on the active calcium transporters in the gut 
wall. When vitamin D is sufficient (i.e. in the presence of optimal circulating 25(OH)D 
levels) there is a down-regulation of 1,25(OH)D induced calcium absorption. 
 
Optimal levels of vitamin D  
Vitamin D adequacy is assessed by measuring blood levels of 25(OH)D and deficiency is 
usually defined as blood levels <25(OH)D nmol/L and below such levels  there is an 
increasing risk of developing rickets in children and osteomalacia in adults2 (although 
the Endocrine Societies have proposed using a higher cut-off of <50 nmol/L).53 In this 
thesis, I define insufficient levels as a plasma concentration of circulating 25(OH)D 
between 25-75 nmol/L (rationale explained below; for values in ng/ml, divide values by 
2.5).  
 
The significance of higher plasma concentrations than 25 nmol/L for health is unclear, 
but it is currently proposed that a plasma concentration of 25(OH)D of at least 50 
nmol/L is needed for optimal bone health.54 Maintaining higher plasma levels of 
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25(OH)D above the deficiency range may also be relevant to other health outcomes, 
such as CVD, cancer and infections.55 However, there is still no consensus on the 
definition of ‘optimal circulating levels of 25(OH)D’ as there is currently a debate on 
what constitutes optimal levels.53, 55 
 
Biochemical methods for defining optimal 25(OH)D concentrations have been proposed 
but are not perfect. One widely used method is to use the level of 25(OH)D 
concentration above which no further suppression of PTH concentrations occur through 
the negative feedback loop mechanism (typically at around 75 nmol/L concentrations), 
and to use this as an indicator of optimal levels.2, 51 However, in children and during 
puberty, PTH levels are found to be higher compared to those in adults. Renal 
dysfunction, exercise and the time of the day when samples are taken, all cause 
variations in estimated PTH levels and hence this method is imperfect. The blood 
25(OH)D levels at which no further increases in serum calcium is observed was also 
proposed but rejected.56 Serum calcium is tightly regulated and is controlled through 
the influences of multiple hormonal systems as described earlier, and hence the 
response tends to be variable. For instance, high PTH levels (such as in 
hyperparathyroidism) could raise calcium concentrations independent of calcitriol 
concentrations.56 One other proposed method is to use the level of 25(OH)D 
concentration beyond which, a further rise fails to elicit an increase in 1,25(OH)D 
concentrations, as being the sufficient level. However, concentrations of 1,25(OH)D fall 
only when 25(OH)D levels are very low; hence the relationship between 25(OH)D 
concentrations and 1,25(OH)D levels is not linear. Further, the concentration of 
1,25(OH)D varies due to factors which include calcium intake, presence of certain 
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granulomatous diseases or pregnancy (both of which raise 1,25(OH)D concentrations).57 
Further, changes in 1,25(OH)D concentrations do not seem to correlate well with the 
biological effects, but appear to correlate better and more consistently with circulating 
25(OH)D concentrations. This may mean that some of the vitamin D-mediated actions 
may also be due to the influences from the circulating 25(OH)D molecules; hence this 
method is not ideal. Heaney et al,51 suggested using the 25(OH)D level that results in the 
maximal intestinal calcium absorption instead, but studies have again not been able to 
provide consistent verification of a linear relationship.58  
 
Current efforts have increasingly focussed on defining optimal levels by establishing the 
circulating vitamin 25(OH)D concentrations associated with the lowest risks for various 
health outcomes.9, 11, 53 There has been much debate and conflicting evidence on the 
optimal levels.54, 59 The Institute of Medicine (IOM) conducted a systematic review of all 
vitamin D studies published and concluded that for optimum bone health, 600 IU of 
vitamin D daily was sufficient for most adults to achieve a plasma level of about 50 
nmol/L (20ng/ml), and that these levels were to be considered optimal.54 For other 
health outcomes, the review found limited or inadequate evidence to make 
recommendations, although effects of vitamin D supplements on other health 
outcomes were not within the remit or focus of this review.  
 
The prospective observational studies (discussed in Chapters 2 and 4) suggest that 
blood levels of 75-90 nmol/L are associated with the lowest risks of mortality. For the 
purposes of this thesis, deficiency is defined as plasma levels of <25 nmol/L; 
insufficiency as levels greater than 25 nmol/L but less than 75 nmol/L, and optimal 
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plasma levels as >75 nmol/L but while recognising that these definitions are not fully 
evidence-based. 
 
Prevalence of vitamin D insufficiency 
Insufficient 25(OH)D levels in the general population have been reported worldwide, 
but there are inconsistencies in the reports especially in the proportion of the 
population attributed to have insufficiency. Broadly, insufficiency of vitamin D appears 
to affect between 20-50% of many populations and is more common among people 
living in countries at the extremes of the hemispheres.60-64 In the United Kingdom, data 
from the National Diet and Nutrition Survey of British Adults show mean (SD) 
concentrations of 25(OH)D among older people (> 65 years of age) to be 55.5 (26.9) 
nmol/L in summer with about half these levels observed during winter.16 Among the 
very elderly people living in care homes, the mean levels are 32.8 (15.7) nmol/L. Hence 
using these definitions, about 5-20% of the population in the UK are deficient of vitamin 
D and 20-70% could have insufficient levels, and is more common among young adults, 
older people and ethnic minorities also.  
 
Insufficient levels of 25(OH)D are also not uncommon among people living in the 
sunnier regions of the world even in countries closer to the equator.60 In places like the 
middle east and some nations in Africa, the reported insufficiency of vitamin D may be 
related to the social customs, religious practices, costumes worn and specific dietary 
patterns.63 As low 25(OH)D levels have been reported from every region in the world 
where estimates were made,62, 63 insufficient vitamin D is a concern for public health 
globally. 
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Determinants of low concentrations of blood 25(OH)D  
Vitamin D deficiency was identified as a problem at the start of the 20th century,65, 66 
after observations that rickets was common among children living in cities, compared to 
those inhabiting rural areas. Vitamin D was identified and isolated by Adolph Windaus, 
and the eventual widespread fortification of food helped eradicate these bone diseases. 
However, fortification was stopped or reduced in many countries after concerns 
emerged over hypercalcaemia among young children in England.  
 
There is no single factor that explains the widespread prevalence of low vitamin D 
levels, and the causes are likely to be multifactorial. 39, 67, 68 69 70 Factors that reduce 
measured 25(OH)D concentrations include advancing age, female gender, increased 
body fat, darker skin type, 71-73 low fish oil diet, increased clothing, reduced duration of 
skin exposure to sunlight, and winter.60-62 Geographic location and lifestyle are 
important factors contributing to the prevalence of vitamin D insufficiency, but are 
difficult to modify. Lifestyle factors include the impact of increasing industrialisation and 
urbanisation with air pollution affecting sun exposure, sun-avoidance behaviour and use 
of sunscreen to reduce skin cancer risk, indoor work and recreation and religious 
practices imposing body cover.  
 
In the United Kingdom and for people living in countries farther from the equator 
(above and below 37 degrees latitude), UVB availability is low during winter (because 
the UVB rays travel longer through the atmosphere in winter due to the angle of the 
sun, and as a result the UVB rays get attenuated). Hence the low vitamin D levels seen 
in the population is worst during winter37, 68, 74-76 as no vitamin D is produced despite 
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sun exposure between the months of October and March in such locations.37, 77 
Furthermore, as ultra-violet A (UVA) rays from sunlight are less attenuated than UVB, 
these may reduce vitamin D3 already synthesised in the skin.68 
 
Smokers have been shown to have lower 25(OH)D circulating levels, but the 
mechanisms behind this association or the impact of it is unclear.78, 79 Other less 
recognised factors affecting 25(OH)D concentrations include vitamin D binding protein 
levels and the affinity of its binding, where the differential binding capacity for 25(OH)D 
is variable and could cause variations in available 25(OH)D. More studies are being 
conducted to understand the role of this carrier protein.80 Increased body fat content, 
washing,81, 82 and the age-associated reduced skin production of vitamin D383 are all 
associated with lower circulating 25(OH)D levels.   
 
Women have lower 25(OH)D levels than men and this is thought to be associated with 
the higher body fat content.84, 85 In a cross-sectional analysis of the Women’s health 
initiative (WHI) trial participants, abdominal obesity was significantly and inversely 
associated with 25(OH)D levels.86 It is not clear however, whether fat acts simply as a 
store of 25(OH)D14 and releases 25(OH)D into circulation when needed (similar to the 
actions of vitamin-D-binding globulins and skeletal muscle),40 or whether there are 
other actions of vitamin D in fat.87  
 
Effects of supplementation with Vitamin D on 25(OH) blood levels and safety  
Based on the available evidence, the average increase in 25(OH)D concentrations per 
400 IU (10 g) of vitamin D3 taken orally is about 7-10 nmol/L.11, 88 Previous trials 
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suggest 600-800IU daily is probably sufficient to maintain plasma 25(OH)D levels to >50 
nmol/L.54 In the UK, mean 25(OH)D levels among people over 65 years of age range 
between 32 (winter) and 55 (summer) nmol/L;16 hence daily vitamin D supplements 
much greater than 600 to 800 IU daily may be needed to achieve and maintain ‘optimal’ 
25(OH)D11 concentrations particularly in certain populations such as older and/or non-
Caucasian people . The current daily recommended intake for vitamin D in the UK is 200 
IU/day, but since 2012, the Department of Health has recommended that pregnant 
women, young children between the ages of 6 months to 5 years and older people 
above the age of 65, should take vitamin D supplements (up to 400 IU daily).89 
 
However, wide variations were found in the achieved 25(OH)D concentrations among 
African-American trial participants taking between 3800 IU and 5000 IU of vitamin D 
daily,90 when compared to other trials which included Caucasian older women,91 which 
could have implications when planning dosing of vitamin D supplements for trials, as 
higher doses of vitamin D may be necessary in certain sub-groups of people such as the 
obese, the dark-skinned and the elderly in particular. 
 
Daily dosing of vitamin D appears to be more efficacious in raising circulating 25(OH)D 
plasma concentrations compared to intermittent high doses orally or by injection.92 In a 
meta-analysis by Autier et al,93 wide variations in the achieved plasma concentrations of 
25(OH)D were found between studies using similar doses of vitamin D supplements.93 
The concomitant use of calcium, especially in those with higher baseline 25(OH)D 
concentrations resulted in smaller increases in circulating plasma 25(OH)D levels 
compared to those who did not take concomitant calcium supplements. Further, 
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vitamin D3 supplementation was found to be more efficacious than vitamin D2 in 
achieving target plasma 25(OH)D response.  
 
Doses of vitamin D up to 4000 IU daily are generally considered safe54 and up to 
100,000 IU has been given as intermittent doses.94 However, there is only limited safety 
data on the use of daily doses of vitamin D 2000-4000 IU daily and previous dosing trials 
have been small and of a short duration and used differing modes of administration.95, 96  
 
Some safety data are provided by the long-term fracture prevention trials. 97-99 In one 
large randomised trial bolus doses of 500,000 IU oral vitamin D3 were administered 
yearly to 2256 post-menopausal women over 70 years of age, and there was a 
significant excess in of falls and fractures ( RR for fractures, 1.2; 95% CI, 1.00:1.59; P = 
.047) in the treatment group compared to placebo;100 but no such hazards were 
reported with daily dosing of vitamin D supplements.101, 102 In the much larger WHI, a 
higher incidence of renal stones was reported among women taking 400 IU daily 
compared to placebo (hazard ratio: 1.17; 95% CI: 1.02, 1.34);103 but the use of 
concomitant calcium supplements means that it is not possible to know if it was the 
effect of vitamin D or the combination; but there were no other significant hazards 
identified.96, 104 Other shorter term trials have not reported major safety concerns when 
using daily doses of vitamin D supplements of up to 4000 IU daily.  
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Vitamin D and cardiovascular disease  
In this section, I review the literature reporting associations of vitamin D and CVD and 
risk factors for CVD, and aim to assess whether the associations are causal using the 
Bradford Hill’s criteria.105 
 
Observational associations of vitamin D with risk factors for cardiovascular disease  
In 1990, Scragg et al first reported an association between low vitamin D levels and the 
risks of myocardial infarction in a small age and sex-matched case-control study (32 
nmol/L vs. 35 nmol/L, p=0.017), 106but these results were from a small sample size, and 
could be due to reverse causation. In addition, cross-sectional studies broadly 
demonstrate an inverse association of 25(OH)D levels with CVD risk factors. 71, 107-111 In 
the third National Health and Nutrition Examination Survey (NHANES III)107, 111 of more 
than 13,000 people over the age of 20 living in the United States, plasma 25(OH)D levels 
were lower among those with established CVD risk factors such as smokers, those with 
hypertension, type 2 diabetes mellitus, obesity, impaired renal function, low albumin 
and in those with lower physical activity.107 The plasma levels were also found to be 
inversely related with age, body mass index (BMI), total cholesterol and C-reactive 
protein (CRP). 107 Individuals in the lowest quartile of plasma 25(OH)D, had a 30% higher 
risk of hypertension (OR 1.30; 95% CI: 1.13 – 1.49), were twice likely to have high fasting 
glucose levels (OR 2.15; 95% CI: 1.69 – 2.74) or be obese (OR 2.29; 95% CI: 1.99 – 2.63), 
and more likely to have higher triglycerides (OR 1.47; 95% CI: 1.30 – 1.65).111 These 
findings were similar in other prospective studies from Europe.64, 112 
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Low vitamin D levels were also found to be associated with reduced cardiac contractility 
and lower concentrations of natriuretic peptides (peptides released as a response to 
myocardial stretch and often used as a surrogate for diagnosing heart failure).113 114, 115 
Zittermann et al report that low 25(OH)D was more prevalent among patients with 
reduced left ventricular systolic function (and normal renal function) compared to 
controls.19, 114 Low levels were also seen in people with dark skin living in the Northern 
hemispheres, but whether these lower levels are responsible for the higher risks of CVD 
seen in these populations is unknown, 
71, 116-118 but could simply be the result of the 
migration of such populations, where the risks of CVD among the migrant people tend 
to match those of the hosts living in the locale.119  
 
Arterial stiffness is an index of distensibility of the arterial wall (in simple terms), and is a 
surrogate marker for CVD120 and has been associated with increased risks of CVD, 
independent of blood pressure.121-123 Despite the differing indices and methods of 
estimation of arterial stiffness between studies,124-126 cross-sectional analyses show 
significant inverse associations of 25(OH)D levels with arterial stiffness measures.  
 
Some prospective studies reporting baseline 25(OH)D concentrations showed baseline 
levels were predictive of the risks of incident hypertension110, 127, 128 and diabetes.129-132 
For instance, among the participants of the Health Professional Follow-up study and the 
Nurses’ Health Study, a 3-fold higher risk of developing hypertension was seen among 
those who were vitamin D deficient (<32.5 nmol/L) at baseline compared to those who 
had sufficient concentrations (HR 3.18; 95% CI: 1.39 to 7.29).110 This association was 
independent of age, BMI, and level of physical activity. Low vitamin D levels also 
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predicted diabetes onset in a study of 9841 patients over 29 years, with those in the 
lowest quartile of 25(OH)D showing a 35% increased risk of developing type 2 diabetes 
(RR 1.35 95% CI:1.09-1.66) compared to those in the top quartile.130  
 
However, in the Scandinavian TROMSO study, baseline 25(OH)D did not predict incident 
hypertension over 14 years, although the concentrations of 25(OH)D correlated well 
with baseline measures of blood pressure.133 Analysis of the participants in the 
Women’s Health Initiative (WHI) trial of post-menopausal women also showed 25(OH)D 
levels were not associated with changes in blood pressure or incident hypertension 
after 7 years.134 These discrepant results are difficult to interpret as baseline 
characteristics differ between the study participants recruited, and these differences on 
participant characteristics could affect other factors such as their motivation and 
adherence to treatment, geographic or climate factors, age and socio-economic status. 
For instance, the differences in the rates of use of concomitant treatment for blood 
pressure and diabetes control were different. Furthermore, the Health Professionals 
Study included predominantly male physicians living in the United States, the Nurses’ 
Health study included women, the TROMSO study involved community-living 
participants in Norway, and the WHI trial recruited post-menopausal women. Hence, it 
is difficult to reconcile the differences between these study outcomes.  
 
Only a limited number of studies reported on baseline 25(OH)D levels and incident CVD 
(by 2012); they often used varying definitions for CVD outcomes or used a composite 
outcome which included fatal and non-fatal events. In the Framingham Offspring 
study59 of 1739 participants (mean age 59 years), low 25(OH)D levels at baseline were 
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associated with an increased risk of developing CVD events over 5.4 years. The 120 CVD 
events reported in the study included fatal and non-fatal myocardial infarction and 
strokes. The risk of CVD was higher in those with 25(OH)D levels <37.5 nmol/L (HR 1.62; 
95% CI: 1.11-2.36), compared to those with 25(OH)D levels >37.5 nmol/L. In a much 
larger prospective analysis of 41504 electronic health records of the Intermountain 
Health Study registry,128 an increased risk of incident CVD ( this time a composite of 
death, coronary artery disease, heart failure, atrial fibrillation, stroke and peripheral 
vascular disease) was seen among those with baseline 25(OH)D levels <37.5 nmol/L, 
(adjusted HR 1.79; 95%CI: 1.53-2.10, p <0.0001) compared to those with > 75 nmol/L. 
Low vitamin D levels were also shown to be predictive of the risks of developing heart 
failure, myocardial infarction and stroke.135 In a European cohort of 548 patients with 
heart failure (aged 64–80 years), baseline 25(OH)D levels predicted death from any 
cause (HR 1.10 per 10 nmol/L decrease; 95% CI: 1.0–1.2).136 
 
However, these associations of low 25(OH)D levels with incident CVD are not consistent 
in all analyses.134, 137 Baseline 25(OH)D levels in older women participants of an 
Australian vitamin D supplementation trial were not found to be predictive of CVD 
outcomes.137 However, these results may have been confounded by the inclusion of 
participants who received vitamin D supplements137 and HRT.134  
 
The majority of prospective studies of vitamin D have evaluated mortality rather than 
incident events. A summary of the largest prospective studies (until Dec 2011) that have 
reported associations of baseline 25(OH)D with CVD or all-cause mortality are shown in 
Table 2-1. Two previous meta-analyses found insufficient evidence on the associations 
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between 25(OH)D and CVD outcomes, but had fewer than 10 prospective studies in 
each of their analyses on CVD outcomes.138, 139 
 
Finally, though most studies report an inverse association, a ‘curvilinear’ or U-shaped 
association between 25(OH)D levels and the risks of mortality are reported in some 
studies.107, 140 Higher risks of mortality were observed among those with concentrations 
of 25(OH)D higher than 100-120 nmol/L at baseline. The nature of these associations 
was more apparent when participants were grouped in centiles of baseline 25(OH)D 
concentrations. However, these analyses had few participants with circulating 25(OH)D 
concentrations >120 nmol/L, to be able to explore these relationships with certainty.  
 
Two large prospective studies have recently re-affirmed the possibility of a curvilinear 
or U-shaped relationship between vitamin D concentrations and the risks of all-cause 
mortality. 141, 142 When individual participant data was evaluated from participants from 
multiple prospective study cohorts, the hazard ratios for all-cause mortality at > 140 
nmol/L serum 25(OH)D was 1.42 (1.31-1.53) when compared to those with serum 
25(OH)D of 50-60nmol/L.141 In the NHANES III population,143 the lowest risks of 
mortality were seen at concentrations of about 90 nmol/L, but increased risks of 
mortality were observed at concentrations higher than 140 nmol/L. Chowdhury et al, 
noted that the inverse relationship with CVD deaths persisted through the range of 
plasma 25(OH)D distribution. 142 However, in the CopD study, there were only 146 
deaths (in over 3500 deaths) among participants with a 25(OH)D concentration >100 
nmol/L in this study.141 The explanations for these higher risks of mortality at higher 
concentrations of 25(OH)D remain unclear. Although no significant hypercalcaemia 
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occurs at such concentrations of 25(OH)D, the higher mortality risks could be related to 
clinically non-apparent hypercalcaemia. Equally these may reflect outliers, who may be 
taking higher dose supplements after being recently ill. No specific assumptions could 
be drawn from the available data other than that further trials are necessary to evaluate 
whether higher plasma concentrations (>100-120 nmol/L) could be associated with an 
increased risk of dying from any cause. 
 
The inverse associations of 25(OH)D with CVD risk factors reported in these cross-
sectional analyses and prospective studies may also be due to reverse causation where 
those who are relatively ill are more likely to remain indoors compared to those who 
are otherwise healthy, and hence have lower 25(OH)D levels in blood. It could also be 
that low 25(OH)D is a marker of ill-health or frailty. Hence people who are obese and 
are smokers have lower levels, but they are more likely to be unhealthy and ill than 
others. Exploring the temporality of the association of baseline 25(OH)D levels with 
incident CVD, may provide further information (Chapter 3). 
 
Possible mechanisms for low 25(OH)D causing CVD 
The potential mechanisms by which low vitamin D levels could cause CVD are reviewed 
elsewhere.8, 45, 144, 145 Below is an overview of the key mechanisms (Figure 2-3) that have 
been proposed, but the effects of vitamin D on blood pressure and arterial stiffness is 
reviewed further, as this thesis aims to explore effects of vitamin D supplements on 
these markers of CVD.  
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The Renin-Angiotensin system 
Vitamin D could affect the cardiovascular system through the actions on the renin-
angiotensin-aldosterone system (RAS) and through its key effects on blood pressure and 
on cardiac muscle structure. In vitamin D receptor knockout (VDRKO) mice, activation of 
the RAS caused raised blood pressure and left ventricular hypertrophy.146, 147 When 
adequate levels of vitamin D are available, RAS is inhibited and blood pressure remains 
normal; when levels are low, there is reduced RAS inhibition. The active form of the 
vitamin D, 1,25(OH)D, may also directly inhibit RAS.148 However, in humans with 
hereditary vitamin-D-resistant rickets, a rare genetic disorder where patients have 
resistance to vitamin D from birth, no activation of the RAS or evidence of cardiac 
muscle hypertrophy were found. In a case series published including follow-up of 17 
cases, all patients with the disease had normal blood pressure. These findings therefore 
contradict those from the animal studies and indicate that the effects in human beings 
may differ as the pathophysiological pathways may be different between mice and man. 
Some of the observed inhibition of RAS in VDR KO mice may have been mediated 
indirectly through the changes in the PTH and FGF-23 pathways. 
 
Effects of Parathyroid hormone or vitamin D 
A chronically elevated PTH concentration has been shown to be independently 
associated with increased risks of CVD, including hypertension, cardiac hypertrophy and 
myocardial dysfunction.149 Increased PTH levels were also associated with RAS 
activation and increased cardiac muscle hypertrophy. As elevated PTH levels can also 
occur in response to low circulating plasma 25(OH)D levels, some argue that PTH may 
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be an independent predictor of CVD when compared to low 25(OH)D levels;150, 151 
however, as PTH concentrations appear to be mainly driven by the circulating 
concentrations of calcium in the body, and that calcium levels are influenced by a 
number of other factors, it seems unlikely that hyperparathyroidism alone could explain 
or account for a significant proportion of CVD. In contrast, circulating 25(OH)D levels are 
influenced by a number of external and internal factors, has a broader role in 
pathophysiology and actions through a number of potential mechanisms that could 
influence the development of CVD. Finally, VDR down regulates the parathyroid 
hormone and the enzyme CYP27B1,152 and hence possibly has the higher control 
function in the calcium-vitamin D metabolism pathway.  
 
Atherosclerosis 
The development of atherosclerosis is predominantly an inflammatory process.153 There 
is evidence demonstrating a key role for vitamin D in the regulation of inflammatory 
and immune responses and is extensively reviewed elsewhere.7, 41, 45 The presence of 
VDR is now recognised in most immune and inflammatory cells. The metabolism of 
vitamin D (hydroxylation into active calcitriol and its breakdown to other inactive 
metabolites) is locally regulated in these tissues and appear to correlate well with the 
local needs and the circulating levels of 25(OH)D.  
 
There is evidence from animal models suggesting that low blood concentrations of 
vitamin D promotes atherosclerosis by the up-regulation of macrophage cholesterol 
uptake, worsening endothelial dysfunction, increased vascular smooth muscle cell 
proliferation and migration, endothelial activation and increased expression of 
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endothelial adhesion molecules.45, 154 In the presence of low vitamin D levels, anti-
inflammatory processes are inhibited and hence chronic inflammation continues 
unabated promoting CAD.45 VDR knockout mice exhibit up-regulation of metallo-
proteinases (enzymes linked to cardiac repair after injury). Adequate vitamin D may 
help promote anti-inflammatory processes, through effects mediated via interleukins, 
C-reactive protein, and anti-inflammatory cytokines such as IL-10. Adequate vitamin D 
inhibits IL-6 and TNF-alpha.7 By keeping a balance between the pro and anti-
inflammatory processes, adequate vitamin D may keep atherosclerosis under control. In 
summary, in animal studies low vitamin D appears to promote a pro-inflammatory 
milieu that may help drive pro-atherosclerotic processes in those with CVD risk factors 
and is evidence for the ‘paracrine’ function of vitamin D.  
 
Effects on calcium handling and cardiac function 
Another possible mechanism for the effects of vitamin D on CVD is through the effects 
on cardiac function such as contractility and automaticity, which are mediated through 
calcium ions. Vitamin D influences myocardial calcium metabolism in rats where calcium 
metabolism in the cardiac muscle is mediated by a vitamin-D dependant receptor.155 
Similarly, vitamin D deficient rats have increased collagen content in the myocardial 
tissue demonstrate higher blood pressure, cardiac muscle hypertrophy and cardiac 
fibrosis compared to rats with sufficient levels of vitamin D. Cardiac contractility may 
also be mediated as a result of the rapid response of the membrane based VDR binding 
of calcitriol.156 Vitamin D could influence cardiac muscle relaxation and indirectly the 
intracellular calcium influx by its effects on other pathways.45  
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Observational data also show associations between low 25(OH)D and reduced cardiac 
contractile function perhaps through the abnormal calcium handling,157 as low vitamin 
D levels may cause a dysregulation in the metabolism of these ions leading to abnormal 
cardiac function. The VDRKO mice exhibit impaired cardiac function (both relaxation 
and contraction).158 Children with rickets are known to develop cardiac failure which is 
reversible once vitamin D sufficiency is restored.159 Although there is no conclusive 
evidence for the effects of taking vitamin D on cardiac function, administration of 
vitamin D supplements was associated with a reduction in the pro-inflammatory 
cytokines among patients with heart failure. 160 
 
Arterial stiffness 
Arterial stiffness is associated with the risks of developing CVD. Increased stiffness is an 
indicator of biological aging and is seen more commonly among older people, those 
with CVD risk factors and those with established atherosclerosis.161 There are different 
theories as to why the vessels become stiffer, such as the stiffening of arterial walls with 
repeated mechanical stress, damage to the collagen fibres in the walls, the increased 
fibrosis as a result of cumulative damage or the increased calcification of the vessel 
walls. Further, the effects of low vitamin D concentrations on the arterial wall may be 
different from circulating levels as the cells such as the vascular smooth muscle and 
endothelial cells, and the macrophages produce active calcitriol locally.162 
 
Observational studies suggest that low vitamin D is associated with increased arterial 
stiffness.124, 126, 163 High vitamin D in humans, is associated with increased calcification 
mainly in the setting of chronic renal failure causing calcium deposits in the body,164 but 
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animal models suggest that low vitamin D levels could also promote vascular 
calcification.162 In mice with chronic kidney disease, supplementation of vitamin D 
sufficient to suppress PTH caused a reduction in the expression of osteoblasts in the 
aorta, but high doses caused calcification.165 The Klotho gene associated with 
premature aging in mice and humans is believed to influence vascular calcification along 
with influences from vitamin D and FGF-23.166 Klotho deficient mice show accelerated 
atherosclerosis and increased vascular calcification. In patients with chronic renal 
failure, low vitamin D and calcification are commonly associated. Hence the 
mobilisation of calcium in the presence of low vitamin D increases vessel wall 
calcification.162, 164  
 
Alternatively, the increased arterial stiffness in the presence of low vitamin D may be a 
result of cumulative vessel wall damage mediated by the effects on other co-existing 
CVD risk factors. Whether arterial stiffness is modifiable by administering vitamin D 
supplements is unknown and so evaluating the effects of vitamin D supplements on 
arterial stiffness could offer insights into potential mechanisms of vitamin D on CVD 
outcomes before randomised trials of vitamin D provide evidence on CVD endpoints.  
 
Evidence from randomised trials 
Effects on CVD risk factors 
Randomised trials of vitamin D have failed to confirm any beneficial effects of taking 
dietary supplementation of vitamin D on any of the CVD risk factors.139, 167 However, 
most trials of vitamin D supplements were conducted among the elderly and focussed 
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mostly on bone outcomes such as fractures and falls. There is only limited data available 
from the previous vitamin D trials of CVD outcomes, and the meta-analyses, 139, 167-169 of 
such randomised trials reported no effects for taking vitamin D supplements on blood 
lipids, glucose or blood pressure (discussed further below). So far, no studies have 
shown consistent effects of taking vitamin D supplements on markers of inflammation, 
endothelial function, CRP, renal function or diabetes. The authors however highlighted 
the paucity of reliable good quality trial data to address these questions,139, 167, 170 and 
there is a call for further trials.171 
 
There has been particular interest in the effects of vitamin D on blood pressure, given 
the studies in animals.148 One of the first vitamin D trials in humans to demonstrate 
blood pressure lowering, 148 older women (mean age 74) taking vitamin D (800 IU) with 
calcium (1200 mg) daily had significantly lower systolic blood pressure (reduced by 
9.3%) after 8 weeks, compared to those taking calcium alone.172 However, there is no 
consistent evidence from randomised-controlled trials that taking vitamin D3 
supplements lowers blood pressure.139, 173-177  
 
In an earlier meta-analysis178 of vitamin D trials and blood pressure lowering (11 trials, n 
= 716), the authors evaluated 8 trials where participants had mean baseline blood 
pressures >140/90 mm Hg, and found a non-significant reduction in systolic blood 
pressure [-3.6 mmHg, 95% CI: -8.0 to 0.7] and a significant reduction in diastolic blood 
pressure [-3.1 mmHg, 95% CI: -5.5 to -0.6] among those allocated to vitamin D. 
However, conflicting results were observed in a subsequent meta-analysis139 of 10 
randomised trials of vitamin D (9 trials using vitamin D supplements and one trial of 
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UVB treatment, n=37162), where no evidence of reduction in systolic or diastolic blood 
pressures (mean difference of -1.9 mm Hg for SBP; 95% CI: -4.2 to 0.4 mm Hg) were 
found. Only 2 trials in this analysis reported large effects in reducing blood 
pressure,172,179 but the largest number of participants (98%, n = 36282) contributing to 
these analyses were data from the Women’s Health Initiative (WHI) trial of post-
menopausal women examining the effect of taking 400 IU/d of cholecalciferol (with 
1000 mg/d of calcium) versus placebo, on the incidence of fractures and cancer in post-
menopausal women.180 After 7 years of follow-up no significant differences in mean 
levels of blood pressure were detected between the vitamin D and placebo allocated 
groups, or among women with hypertension, among the black participants, or among 
those who had lower vitamin D at randomisation. However, this trial may not be ideal 
to evaluate effects on CVD (discussed later) as the doses used were small and 
insufficient to achieve or maintain the ‘optimal levels’ of 25(OH)D. Hence, there is a 
substantial influence from this large trial with negative findings for vitamin D 
supplementation on this and other meta-analyses of the randomised controlled trials of 
vitamin D, which is important when contextualising the neutral results so far, for taking 
vitamin D supplements on various CVD outcomes. 
 
Three recent trials testing the effects of much higher doses of vitamin D supplements on 
blood pressure were recently published, but reported conflicting results. The VitDish 
trial177 used 3-monthly doses of 100 000 IU cholecalciferol or matching placebo, in 159 
Scottish participants with isolated systolic hypertension (mean age 77 years). No 
differences in blood pressure were found at the end of 1 year [mean baseline 25(OH)D 
was 45 nmol/L]. A Norwegian trial recruited 438 overweight and obese people (age 21 – 
  Vitamin D and Cardiovascular disease 
53 
 
70 years old), and randomised participants to receive 40 000 IU or 20 000 IU of vitamin 
D3 weekly or placebo.181 The mean baseline 25(OH)D levels were higher (58 nmol/L) 
and did not show any effects on blood pressure lowering after 1 year. However, in 
another trial of 283 African-American participants taking 2000 IU or 4000 IU vitamin D3 
daily or placebo,182 a significant reduction in systolic blood pressure of 1.4mm Hg with 
every 2.5 nmol/L rise in 25(OH)D levels was noted, after 3 months of treatment.  
 
These contrasting findings are difficult to interpret in the first instance, given the 
differences in the trial participant characteristics, the nature of the participants 
(hypertensive people, obese, African Americans) and the differences in the duration of 
treatment. However, the findings broadly indicate that the effects of vitamin D 
supplementation on blood pressure needs testing in larger trials, as there are at least 
some trials that show beneficial effects for taking vitamin D, and the reasons for the 
disparity may either reflect the inadequate sample sizes of the individual trials or the 
need for further participant characterisation to understand who would be suitable for 
vitamin D therapy; but the latter approach may be logistically more difficult. The meta-
analyses of vitamin D trials have not shown consistent benefits, but many included trials 
that used insufficient doses of vitamin D such as the WHI trial. Whether treatment with 
vitamin D supplements would be more effective with higher doses of supplements, or 
after a longer duration of treatment is unclear. The observational literature would 
support the hypothesis that the benefits to be had are greatest when a doubling from 
baseline concentrations of 25(OH)D could be achieved.  
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Since the thesis submission, a meta-analysis of 46 trials which included individual 
patient data from 27 trials (3092 patients),183 was published, and found no differences 
in blood pressure lowering after taking vitamin D3 supplements. The analysis also failed 
to identify sub-groups that could benefit from supplementation, when stratifying by 
baseline 25(OH)D levels, blood pressure or presence of diabetes. However, the analysis 
included trials that used any form of vitamin D supplement (vitamin D2, vitamin D3 or 
analogues), and the vast majority of participants with patient-level data had normal 
blood pressure at baseline, which may have attenuated any possible effects of blood 
pressure lowering given the healthier profile, and the smaller numbers. In the analysis 
of patient-level data (about 1500 participants on vitamin D treatment), there was a non-
significant lowering of systolic blood pressure among those taking vitamin D (effect size, 
−0.5; 95% CI: −1.3 to 0.4 mmHg). 
 
Effects on arterial stiffness  
Few randomised trials of vitamin D supplements have evaluated the effects on arterial 
stiffness and Table 2-2 shows a summary of the trials with at least 3 months or more of 
follow-up (until 2014). These published reports typically included small numbers of 
participants, had relatively short follow-up periods and used varying methods and 
indices for estimating arterial stiffness, and hence difficult to compare. Preliminary 
overall results indicate vitamin D has no effects on arterial stiffness. However, 2 trials 
reported improvements in arterial stiffness measures after vitamin D supplementation. 
In a study of young African teenagers, a daily intake of 2000 IU daily of vitamin D had 
showed a reduction in arterial stiffness after 4 months.184 In a Danish study of patients 
with hypertension,175 intake of 3000 IU daily over a 5 month period in winter was 
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associated with a reduction in central artery stiffness, but with no changes in the 
ambulatory blood pressure. Alternatively, it could mean that vitamin D does not have 
significant detectable effects on arterial stiffness, similar to the analyses of the effects 
on blood pressure. The effects of vitamin D on arterial stiffness need further testing in a 
large population and for a longer duration (ensuring that patient characteristics such as 
baseline blood pressure and concomitant treatment for blood pressure are taken into 
account in the analysis) before conclusions on any potential effects or the lack of it may 
be made.  
 
Effects on CVD  
No trials of vitamin D have so far been conducted to evaluate CVD as a primary 
outcome. Meta-analyses of results from randomised-controlled trials of vitamin D 
conducted so far have reported no beneficial effects of taking vitamin D on CVD 
outcomes including CVD deaths.139, 167, 170, 185 However, there is a lack of good quality 
evidence from the previous randomised trials of vitamin D on CVD outcomes. The 
baseline characteristics, the vitamin D supplement doses used and the numbers of 
events in the randomised groups in the largest trials of vitamin D, (with at least 1000 
participants each) are shown in Table 2-3 (adapted from meta-analyses.167, 170  
One of the recent analyses included around 40,000 patients,185 involving 4 trials 
reporting CVD outcomes, 6 trials on myocardial infarction and 7 trials on CVD mortality 
and reported no effects on CVD. The typical daily dose of vitamin D ranged between 320 
IU to 1400 IU in the trials included and the WHI trial contributed most to the analysis. 
Most previous trials of vitamin D supplements were primarily designed to evaluate 
effects on falls and fractures in older people, and not CVD outcomes.  
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The WHI trial180 the largest trial of vitamin D to date, contributes most to the evidence 
presented in the above meta-analyses on the effects of vitamin D on CVD outcomes. 
This trial included 36282 post-menopausal women who were allocated to vitamin D3 
200 IU twice daily (with calcium) or placebo and found no differences on CVD outcomes 
after 7 years (HR, 1.04; 95% CI: 0.92 to 1.18). The dose of vitamin D used in this trial180 
(400 IU daily) would have been sufficient to increase 25(OH)D levels only by about 7-10 
nmol/L.186 Given these factors, a significant difference in circulating levels of 25(OH)D 
between treatment and comparison groups [blood 25(OH)D was not measured at end 
of trial; participants were permitted open-label vitamin D supplements also] would not 
have been achieved at the end of the trial and hence it is unlikely that the trial could 
have identified any meaningful differences in CVD outcomes despite the long follow-up 
period. However, until further trials using higher vitamin D doses or enrolling large 
enough number of participants become available, the meta-analyses of trials of vitamin 
D and assumptions based on their findings will continue to be influenced by the null 
results of the WHI trial.187 
 
Effects on all-cause mortality 
The available evidence on the effects of vitamin D supplements on risks of death is 
based on a number of published meta-analyses evaluating the previous trials. The first 
meta-analysis188 included published data from 18 randomised trials of vitamin D alone 
or with calcium supplements, and showed a 7% reduced risk of death [Relative risk (RR) 
0.93; 95% CI: 0.87 – 0.99] for those taking vitamin D supplements. However, there were 
only 2 un-confounded trials of vitamin D in this analysis (other trials used vitamin D and 
calcium supplements).   
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The larger of the two unconfounded trials,189 recruited community dwelling older 
people in the UK, where participants received either 100,000 IU (equivalent to 800 IU 
daily) or placebo every 4 months. This trial reported a non-significant difference in all-
cause mortality (RR 0.88; 95% CI: 0.74 to 1.06), and in deaths due to CVD (RR 0.84; 95% 
CI: 0.65 to 1.10) among those taking vitamin D. 
 
Other meta-analyses142, 190, 191 of vitamin D supplement trials since published have 
broadly reported consistent trends in reduced mortality among those taking vitamin D 
supplements. However, in one analysis which included patient-level data from over 
70,000 patients, a trend towards benefit of lower mortality risks was noted when 
calcium was administered with vitamin D but not when vitamin D supplements were 
given alone.191 Another analysis that included data from 22 vitamin D trials showed a 
reduction in mortality with taking vitamin D3 supplements only but not for taking 
vitamin D2.142  
 
It is unclear whether or how the calcium supplementation could have influenced the 
findings in these analyses of vitamin D trials, as the use of calcium supplements was 
found to be associated with increased risks of myocardial infarction.192 Calcium intake 
significantly increased the risks of myocardial infarction by 31% (HR 1.31; 95% CI: 1.02-
1.67, p=0.035) when patient-level data from five trials and 8151 participants were 
examined. It is possible that concomitant intake of vitamin D and calcium could obscure 
the apparent benefits of taking vitamin D alone, but it is contrary to the findings from 
Reinmark et al.192 Furthermore, the mortality benefits may only be associated with 
vitamin D3142 intake and including data from trials using vitamin D2 could have led to 
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the discrepant findings. It may also mean that the mortality benefits due to calcium and 
vitamin D intake are greater than the risks of myocardial infarction associated with 
calcium supplements; hence for non-cardiovascular causes of mortality, taking vitamin 
D and calcium maybe beneficial. One other possible explanation could be that the 
additive effects of taking vitamin D and calcium could help normalise the parathyroid 
hormone levels more effectively (PTH is an independent risk factor for mortality).149, 150 
Given the evidence from genetic studies of possible mortality benefits with higher 
vitamin D status,193 a further trial using treatment groups taking vitamin D alone, and 
with concomitant calcium, could provide answers. A small number of trials using higher 
doses of vitamin D are already underway (See Table 2-4) to evaluate effects on a 
number of health outcomes including CVD and all-cause mortality, but the earliest trial 
results assessing effects on CVD outcomes are not expected until 2017. 
 
Vitamin D and CVD: Mendelian randomisation studies 
Few published Mendelian randomisation studies have examined the effects of vitamin D 
on CVD outcomes (Table 2-5). One of the recent studies194 examined the associations of 
vitamin D status and the risks of hypertension and reported increased 25(OH)D levels to 
be associated with a reduced risk for hypertension. For each 25(OH)D allele added to 
the model, a 0.1 mm reduction in systolic blood pressure (95% CI:–0·21 to –0·0001; 
p=0·0498) was noted and a decrease of 0.08mm Hg diastolic blood pressure (95% 
CI: -0·15 to –0·02; p=0·01). These findings will need further evaluation as the evidence 
from randomised clinical trials show no effects for taking vitamin D supplements on 
blood pressure.183  
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However, given the biology of the vitamin D and the range of actions linked with the 
VDR activation, evidence from Mendelian randomisation studies of vitamin D should 
also be interpreted with caution to avoid erroneous attribution of causality. One of the 
other major constraints for Mendelian studies of vitamin D is identifying suitable single 
nucleotide polymorphisms (SNPs) or alleles, that translate into large enough differences 
in circulating concentrations of 25(OH)D. In one evaluation for suitable SNPs for vitamin 
D status, the ‘per allele difference’ in plasma levels of 25(OH)D were only between 0.02 
to 0.08 nmol/L (roughly equivalent to the effect of taking 3.2 IU of vitamin D3 daily), and 
when adding up the alleles, the highest number of risk alleles translated to a difference 
of only about 10 nmol/L (roughly equivalent to taking 400 IU of vitamin D3 daily).195  
 
Finally, the population cohort studies also need to consider population admixture and 
the effects of it, as people living in geographic locations with low UVB availability for 
generations may have adapted already to counter the adverse effects of low vitamin D 
on normal physiology, and this could attenuate any causal effects.46 
 
Why further prospective studies of 25(OH)D and CVD might be informative 
There is a need to evaluate the shape and strength of the associations of baseline 
25(OH)D and CVD deaths in a larger prospective study. Although the preliminary reports 
from prospective studies of 25(OH)D broadly confirm inverse associations with CVD risk 
factors and CVD, factors such as reverse causation, the links with reduced physical 
activity and residual confounding need further exploration. 
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The strength and consistency of the reported associations between 25(OH))D and CVD 
outcomes need to be established. The approach in evaluating associations need to be 
more consistent; for instance, in methods used for the correction of seasonal 
adjustment for measured 25(OH)D levels, in applying methods to evaluate and minimise 
the effects of reverse causality on any risks identified, and using appropriate variables in 
the regression models. Further, the plasma 25(OH)D levels conferring the lowest risks 
for CVD mortality remains un-established; it is unclear if higher plasma levels of 
25(OH)D could be harmful. Finally, previous meta-analyses of prospective studies of 
25(OH)D have highlighted the paucity of good quality studies, to provide reliable 
information and hence the need for a further study. 
 
Conclusion 
In this chapter, we reviewed the published evidence from observational studies of 
vitamin D and CVD, and evaluated the evidence from randomised trials and Mendelian 
studies of vitamin D on CVD and related outcomes. The evidence from these previous 
studies remains inconclusive and further studies are needed to clarify if there is a causal 
role for low vitamin D for prevention of CVD. In the next chapter, the shape and 
strength of the associations between plasma 25(OH)D and CVD and cause-specific 
mortality are evaluated. 
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Figure 2-1:  Associations between geographic latitude and IHD rates in Europe  
(adapted from Zittermann et al8) 
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Figure 2-2:  Overview of vitamin D and calcium metabolism  
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Figure 2-3:  Potential mechanisms how low vitamin D causes cardiovascular disease 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RAAS, renin-angiotensin-aldosterone system; CVD: cardiovascular disease;  
Other unidentified paracrine effects? 
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Table 2-1: Prospective studies reporting on associations of baseline 25(OH)D and risks of CVD and all-cause mortality 
(Updated 2013) 
Author Year Country Characteristics Follow-up 
(Yrs)* 
Participants 
(no.) 
Males 
(%) 
Risk factors 
in fully 
adjusted 
regression** 
Anderson
128
 2010 US Evaluation of the electronic medical records database of 
the Intermountain Healthcare system. 
1.3* 27686 25 1347 
Bolland
137
 2010 Australia Women participants in a randomised trial; (78 women 
were treated with 10,000 IU of vitamin D3 for 10 days). 
5 1471 0 12 
Cawthon
196
  2010 US Prospective osteoporotic fractures in Men (MrOS study) ; 
men >65 yrs. 
7.3 1490 100 125 
Dobnig
197
 2008 Germany Patients referred for coronary angiography in the -The 
Ludwigshafen Risk and Cardiovascular Health (LURIC) 
study. 
7.7 3258  13467 
Ensrud
198
 2010 US Post-menopausal women >69 years. 4.5 4551 0 128 
Fiscella
71
 2010 US The National Health and Nutrition Examination Survey 
(NHANES). 
9 15363 48 Ns 
Ford
199
 2011 US Participants > 17 years in the National Health and 
Nutrition Examination Survey III (NHANES III) Mortality 
Study. 
3.8 7531 51 1234578 
Ginde
200
 2009 US Participants in the NHANES III survey who were > 65 
years. 
7.3* 3408 98 1234578 
Giovanucci
135
 2008 US Health professionals study. Nested case - control study 10 900 100 123467 
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of men aged 40-75 years. 
Grandi
201
 2010 Germany KAROLA study- (Langzeiterfolge der KARdiOLogischen); 
patients recruited from 2 German cardiac rehab clinics. 
8 1125 85 1234679 
Hutchinson
133
 2010 Norway Follow-up of TROMSO 4 study participants. 11.7 7161  137, prior 
cvd 
Jassal
202
 2010 US Adults living in Southern California - The Ranch Bernardo 
study. 
6.4 1073 74 123467 
Jia
203
 2007 UK People > 75 years living in Aberdeen. 5.7 399 52 12678 
Joergensen
130
 2010 Denmark Patients with type 2 diabetes < 66 years recruited from 
the Hvidore hospital. 
15 289 58 1347 
Kitamura
204
 2010 Japan Follow-up of 205 community-dwelling elderly people in 
the Yamato study. 
2 205 31 NS 
Kilkkinen
112
 2009 Finland The Mini-Finland Health survey. Men and women >= 
30years who were free of CVD at enrolment. 
27.1 6219 45 123 
Kuroda
205
 2009 Japan Japanese postmenopausal ambulatory women. 6.9 1232 0 1 
Marniemi
206
 2005 Finland Case-control study of 65-99 year old people living in 
Turku chosen from Social insurance register. 
10 765 47 1 
Melamed
107
 2008 US Participants of the Third National Health and Nutrition 
Examination Survey (NHANES III); Participants >20years; 
32% had prior CVD. 
8.7 13331 Ns 12347 9 
Michaelsson
140
 2010 Sweden Uppsala Longitudinal Study of Adult Men (ULSAM) study; 
elderly men living in the community; recruited 1991 – 
1995. 
12.7* 1194 100 1234678 
Pilz
114
 2008  Patients referred for coronary angiography in the 
LUdwigshafen RIsk and Cardiovascular health (LURIC) 
7.7* 3316 - 1347 
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study. 
Pilz 
207
 2009 Finland Hoorn study of older men and women; recruited 2000-
2001. 
6.2 614 ~50 1347 
Sambrook
208
  2006 Australia The Fracture Risk Epidemiology in the frail Elderly (FREE) 
Study of men and women living in residential care. 
2.2 1112 21 ns 
Sambrook
209
 2004 Australia Frail Older people living in nursing homes -FREE study. 2.6 842 182 ns 
Semba
210
 2010 Italy People>65 years living in InCHIANTI. 6.5 1006 - 12846 
Semba
211
 2009 US Womens health and aging studies I and II; older women 
living in the community. 
6 714 0 ns 
Szulc
212
 2009 France MINOS study of men > 50 years. 10 782 100 18 
Visser
213
 2006 Netherlands Longitudinal Aging study Amsterdam (LASA); participants 
>65yrs of age. 
6 1260 ~50 148 
Virtanen
214
 2010 Finland Kuopio IHD risk factor study (KIHD) - men and women 
free of CVD or cancer at baseline 
9.1 1136 ~50 123748 
Wang
59
 2008 US Framingham Offspring study; participants free of CVD at 
baseline. 
5.4 1739 45 13749 
Tomson
9
 2013 UK Resurvey of Whitehall study participants   13 5409 100 12346789 
Zittermann
215
 2009 Germany Participants recruited from hospital (67% with HF, 33.7% 
with CAD);  
1 510 - 1379 
 
Legend: *Indicates median follow-up. **Adjustment model codes: Each of the factors accounted for in the regression models used in the studies were attributed number codes as follows: 
Age and/or sex = 1; Season = 2; Hypertension = 3; Cholesterol or use of lipid-modifying drugs = 4; Race = 5; Medication use = 6; Diabetes or use of diabetic medications = 7; Socio-
economic /educational status = 8 ; C-reactive protein = 9 
 
  
  Vitamin D and Cardiovascular disease 
68 
 
Table 2-2: Randomised trials of vitamin D and arterial stiffness (with at least 3 months treatment) 
(updated July 2014) 
Author Mean 
age 
 
Number 
(n) 
Study characteristics Vitamin D dose, type 
and frequency 
Device Follow-up 
(months) 
Outcomes 
 
Mose216 68 64 Chronic renal failure patients 
on dialysis 
3000 IU oral vitamin D3 
daily 
PWV, AIX, central 
BP;ns 
6 No change in 
arterial stiffness  
Witham217 41 50 Healthy South Asian women 
living in UK with 25(OH)D 
<75 nmol/L 
Single dose of 100,000 
IU oral vitamin D3  
Carotid-radial PWV 
and AIX;   
Sphygmocor. 
2 No change in arterial 
stiffness  
Witham218 77 159 Patients 70 years or older with 
isolated systolic hypertension 
100,000 IU oral vitamin 
D3 every 3 months  
Carotid-radial PWV 
and AIX;   
Sphygmocor. 
12 No change in arterial 
stiffness 
Breslavsky219 66 47  Patients with type 2 diabetes 1000 IU oral vitamin D3 
daily 
Carotid-radial PWV 
and AIX;   
Sphygmocor. 
12 Improvement in AIx 
after 1 year 
Hewitt220 62* 60 Chronic renal failure patients 
on dialysis with 25(OH)D < 60 
nmol/L 
50,000 IU oral vitamin 
D3 once weekly for 8 
weeks; then monthly for 
4 months 
PWV 6 No change in arterial 
stiffness  
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Larsen 175 61 112† Danish patients with 
hypertension recruited during 
winter  
3,000 IU oral vitamin D3 
daily 
Carotid-femoral 
PWV or Aix. 
5 No change in arterial 
stiffness. Reduction in 
central blood pressure 
Gepner221 64 114 Post-menopausal women with 
25(OH)D >25 and <150  
nmol/L. 
2500 IU oral vitamin D3 
daily 
Carotid-femoral 
PWV and Aix 
4 No change in arterial 
stiffness  
Dong222 16 49 Healthy black teenagers 2000 IU oral vitamin D3 
daily 
Carotid-femoral 
PWV and Aix 
4 Modification of Aix, 
but not PWV after 4 
months 
Legend: * Median; † refers to the number of participants included in the (on treatment analysis); Aix = Augmentation index; PWV = Pulse wave velocity; ns – not specified. 
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Table 2-3: Largest randomised trials of vitamin D and CVD outcomes* 
(updated August 2014) 
Author, Year Mean 
age(yrs) 
N Participant 
characteristics 
Vitamin D dose Duration 
(months) 
Primary 
outcome 
Other 
outcomes 
Vitamin D arm 
(Events / total 
participants) 
Placebo arm 
(Events / total 
participants) 
Chapuy,2231992  84 3270 French women 
living in 
institutions 
Daily oral vitamin 
D3 (800 IU)+  
calcium (1.2 g) 
18 Fractures Death 258/1634 274/1636 
Lips,224 1996  
 
80 2578 Dutch women 
living in 
institutions 
 
Daily oral vitamin 
D3 (400 IU) 
 
42 Fractures Death 223/1291 251/1287 
Meyer,225 2002  
 
85 1144 Norwegian older 
people living in 
institutions 
Daily oral cod liver 
oil, more or less 
vitamin D3 (400 IU) 
 
24 Fractures Death 169/569 163/575 
Trivedi,1892003  
 
75 2686 Older men and 
women living in 
the community in 
Oxfordshire 
Oral vitamin D3 
(100 000 IU 
every 4 months) 
 
60 Fractures 
and all-
cause 
mortality 
MI or IHD 
Stroke 
Death 
224/1345 
105/1345 
224/1345 
233/1341 
101/1341 
247/1341 
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Porthouse,226 
2005  
 
77 3314 Women at risk of 
hip fracture living 
in the community 
Daily oral vitamin 
D3(800 IU)_calcium 
(1 g) 
36 Fractures Death 57/1321 68/1993 
Grant, 2272005   77 5292 Older people with 
previous fracture 
living in the 
community (UK) 
Daily oral vitamin 
D3 (800 IU only) or  
 
 
daily oral vitamin 
D3 (800 IU) calcium 
(1 g) 
60 Fractures MI or IHD 
Stroke 
Death 
 
MI or IHD 
Stroke 
Death 
78/2649 
118/2649 
438/2649 
 
44/1306 
60/1306 
221/1306 
84/2643 
104/2643 
460/2643 
 
39/1332 
48/1332 
217/1332 
 
Wactawski-
wende, 104  
2006 
 
62 3628
2 
Older women 
living in the 
community (US) 
Daily oral vitamin 
D3 (400 IU)calcium 
(1 g) 
 
84 Fractures 
and 
colorectal 
cancer 
MI or IHD 
Stroke 
Death 
411/18176 
362/18176 
744/18176 
390/18106 
377/18106 
807/18106 
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Smith,228 
2007 
 
79 9440 Older people  IM vitamin D3 
300 000 IU every 
year  
36 Fractures Death 355/4727 354/4713 
Lyons,2292007 84 3440 2,624 women and 
816 men living in 
care homes 
(Wales, UK) 
Four-monthly oral 
100,000 IU vitamin 
D2 
 
36 Fractures Death 947/1725 953/1715 
Sanders,1002010 76 2256 Community-
dwelling women≥ 
70 years with a 
high risk of 
fracture 
Yearly dose of 
500,000 IU of 
vitamin D3  
60 Falls and 
fractures 
MI or IHD 
Death 
17/1131 
40/1131 
13/1125 
47/1125 
Salovaara,230 
2010 
67 3432 Older women vitamin D3 800 IU + 
calcium (1g) 
36 Fracture Death 15/1718 13/1714 
*Only trials with more than 1000 participants and 1 year follow-up were included. 
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Table 2-4: On-going or planned trials of vitamin D evaluating CVD outcomes or risk factors    (updated in August 2013) 
 
Trial Participants Dose Duration 
/End of study 
Outcomes 
 
VITamin D and OmegA-3 
TriaL (VITAL),2010 
20000 men (≥60 years) and 
women (≥65 years) 
2000 IU daily 2016/2017 Cancer, CVD 
Vitamin D Assessment (ViDA), 
TBA 
5100 men and women aged 
between 54-80 years of age 
100,000 IU at 
baseline and then 
monthly 
2017 CVD, infections, fractures 
The Finnish Vitamin D (FIND), 
2012 
18000 Men≥60 and women 
≥ 65 years of age 
1600 IU or 3200 IU 
daily 
2019 CVD and cancer 
Vitamin D and Longevity trial 
(VIDAL), 2012 
800 people aged between 
65-84 years  
100,000 IU vitamin 
D3 monthly or 
placebo 
2 years CVD , cancer, deaths 
Prevention of Type 2 Diabetes 
With Vitamin D 
Supplementation in Subjects 
With Reduced Glucose 
Tolerance Detected in the 
Tromso Study, 2007 
517 participants with 
impaired glucose tolerance  
identified from the Tromso 
study 
20000 IU every week 5 years Development of type 2 diabetes 
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Table 2-5: Summary of Mendelian randomisation studies of vitamin D and CVD risk factors and CVD outcomes   (updated August 2014) 
 
Study Author Number of 
participants 
Dataset 
 
Vitamin D alleles Outcomes 
 
Ye
231
 46 368 Data from populations of European 
descent. Ely16 and EPIC-Norfolk studies; 
EPIC-InterAct, the DIAGRAM consortium, 
ADDITION-Ely, Norfolk Diabetes, and 
Cambridgeshire); Meta-Analyses of 
Glucose and Insulin-related traits 
Consortium (MAGIC) 
DHCR7 (related to vitamin D 
synthesis), CYP2R1 (hepatic 
25-hydroxylation), DBP ( 
known as GC; transport), and 
CYP24A1 (catabolism) 
Low 25(OH)D levels may not be 
causal of type 2 diabetes. 
Vimaleswaran 
232
 108 173  D-CarDia collaboration, the International 
Consortium on Blood Pressure (ICBP), 
the Cohorts for Heart and Aging 
Research in Genomic Epidemiology 
(CHARGE) consortium, and the Global 
Blood Pressure Genetics (Global BPGen) 
consortium. (individuals from 35 studies) 
CYP2R1 and DHCR7 Increased 25(OH)D might reduce the 
risk of hypertension. 
Afzal 
233
 96 423  White Danes aged 20-100. 5037 of these 
participants had type 2 diabetes. 
DHCR7 (related to 
endogenous production) and 
CYP2R1 (related to liver 
conversion) 
Genetic variants associated with low 
25(OH)D are associated with type 2 
diabetes. 
Low 25(OH)D mediates may explain 
link between obesity and increased 
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risk of diabetes. 
Strawbridge 
234
 3,418  Carotid Intima-Media Thickness and 
IMT-Progression as Predictors of 
Vascular Events in a High-Risk European 
Population (IMPROVE) cohort study. 
SNPs in the genes encoding 
vitamin D binding protein (GC; 
rs2282679 and rs7041) and 7-
dehydrocholesterol 
reductase/NAD synthetase-1 
(DHCR7; rs12785878 and 
rs3829251) were negatively 
associated with 25(OH)D 
levels. 
SNPs in GC and DHCR7 were 
associated with 25(OH)D. 
Husemoen
235
 9061  Danish population: Inter99 study (6405 
adults, 30-60 years) conducted in 1999-
2001, MONICA10 study (2656 adults, 41-
71 years) conducted in 1993-1994. 
Using variations in the vitamin 
D-binding protein gene and 
the filaggrin gene as 
instrumental variables 
Possible causal association between 
25(OH)D and adiponectin. 
Skaaby
236
 12911  Monica10 (2,656 individuals aged 40-71 
years), Inter99 (6,784 individuals aged 
30-60 years), and Health2006 (3,471 
individuals aged 18-69 years) conducted 
in 1993-94, 1999-2001, and 2006-2008, 
respectively. 
filaggrin gene mutations in 
European descendants R501X 
and 2282del4. R2447X 
mutation.  
Higher vitamin D status favours a 
better lipid profile. 
Vimaleswaran
232
 42,024 Genetic Investigation of Anthropometric 
Traits (GIANT) consortium. 
four vitamin D-related SNPs 
(DHCR7- rs12785878, CYP2R1- 
rs10741657, GC- rs2282679, 
and CYP24A1- rs6013897 
Higher BMI leads to lower 25(OH)D. 
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Trummer
237
 3316  Participants scheduled for coronary 
angiography between 1997 and 2000. 
Genotypes of SNPs in the 
group-specific component 
gene (GC, rs2282679), 7-
dehydrocholesterol reductase 
gene (DHCR7, rs12785878), 
and cytochrome P450 IIR-1 
gene (CYP2R1, rs10741657) 
Genetic variants associated with 
25(OH)D did not predict mortality. 
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Chapter 3 :  Vitamin D and cause-specific mortality in the Whitehall 
resurvey  
Introduction 
This chapter presents the findings from the Whitehall resurvey study, where 
associations of baseline plasma 25(OH)D concentrations with cause-specific 
mortality were evaluated (published paper included in Appendix 1). 
 
Rationale and Aims 
In the previous chapter, low concentrations of 25-hydroxy-vitamin D (25[OH]D) 
were found to be associated with higher risks of cardiovascular risk factors, CVD 
and all-cause mortality. However, a number of questions remain unanswered. The 
reported associations of 25(OH)D with CVD could be due to ‘reverse causation’ 
where, those who suffer from disease or chronic ill-health tend to remain indoors 
more often than others and hence have low vitamin D. Alternatively, these 
associations may reflect residual confounding from known cardiovascular risk 
factors. Earlier prospective studies were less able to use consistent methodology 
for seasonal adjustment of blood 25(OH)D levels,130, 133, 238 evaluate the effects of 
reverse causation;203, 239 use appropriate and comparable regression models,206 and 
select participants more representative of the healthy population (references are 
representative) minimising the chances of selecting those with pre-existing 
disease.197, 201 The study population size and the follow-up duration were limiting 
factors in evaluating the strengths and associations with cause-specific mortality.  
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The plasma 25(OH)D levels that confer the lowest risks for CVD outcomes are 
unclear and whether possible harm could occur at higher concentrations of 
25(OH)D is unknown. The relevance of measuring 25(OH)D concentrations in the 
general population, especially for non-skeletal outcomes is not known.  
 
In the present study, we aimed to evaluate the associations of baseline 25(OH)D 
and cause-specific mortality, among surviving participants of the original Whitehall 
Study who completed a resurvey in 1997 (detailed below).240 The aims of this 
analysis were to:  
(i) examine prospective associations of 25(OH)D with cardiovascular risk factors; 
(ii) establish the shape, strength and consistency of associations with CVD 
mortality, and cause-specific mortality; 
(iii) To evaluate the effects of reverse causation and residual confounding; and 
(iv) To establish the concentration of 25(OH)D associated with the lowest risks for 
CVD mortality. 
 
Methods 
Whitehall study and the Whitehall resurvey 
The Whitehall study was a prospective study of 19,019 male civil servants who were 
working in Whitehall, London and recruited between September 1967 and January 
1970.241 The study involved completing a questionnaire, a medical examination, 
and collecting blood samples. The pilot Whitehall re-survey was conducted by 
Robert Clarke from CTSU, University of Oxford, and involved 187 men selected from 
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amongst the survivors of the original Whitehall study, who were asked to send 
blood samples by post. Following this successful pilot in 1995, the resurvey was 
extended to include all surviving 8448 participants during 1997–98.242 The 7044 
(83%) respondents to this resurvey were asked to attend their local surgery to have 
blood and urine samples collected. Complete data on questionnaires and blood 
results were available on 5409 (77% of respondents) men for the present study.  
 
Data collection and characterisation 
The mailed questionnaires asked details of previous medical history (diagnoses of 
heart attack, angina, stroke, cancer and diabetes), self-reported health status, 
medications taken in the past month, lifestyle characteristics (e.g. smoking status 
and alcohol consumption), and last known civil service employment grade. All 7044 
(83%) respondents were sent a blood collection kit and asked to attend their local 
surgery to have a blood sample, and for measurements of blood pressure, height, 
and weight. The characteristics of the non-responders to the survey are 
summarised in Table 3-1 (adapted from Clarke et al).242 The non-responders were 
older, had a lower previous employment grade, and a higher systolic blood 
pressure. 
 
Cause-specific mortality follow-up 
Information on the cause of death was provided by the Office for National Statistics 
(England), and included the date and cause of death, until end of August 2010. 
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Deaths were classified using the International Classification of Disease [ICD] codes 
(also the commonest type of outcome recording in other large prospective studies).  
Blood collection and storage 
Whole blood samples (about 10 ml) were returned by post in sealed tubes 
(Vacutainer; Becton Dickson, Franklin Lakes, N) containing potassium EDTA with 
0.34mmol/L of aprotinin. These samples were mailed at room temperature to the 
CTSU Wolfson laboratory in Oxford, with 96% arriving within 48 hours of blood 
collection (mean time in post: 1.3 days [range 0-7 days]). The blood was 
centrifuged, and plasma aliquoted and stored at -400C. In addition, repeat plasma 
25(OH)D concentrations were available on 187 men who were participants of the 
pilot study. No data were collected on the precise time of day at which the blood 
samples were collected.   
The IDS-iSYS 25 (OH) D assay  
Plasma 25(OH)D concentrations were measured using an automated immunoassay 
on the IDS-iSYS analyser (Immunodiagnostic systems, Boldon, England). Circulating 
25(OH)D is stable in stored plasma samples.57 The IDS-iSYS 25 (OH) D assay 
standardisation is traceable to ultraviolet quantification and calibration was verified 
by comparison with an ID-LC-MS/MS method.  
 
Assay validation and performances were assessed at the CTSU Wolfson laboratory. 
The IDS-iSYS 25(OH)D assay was comparable for accuracy when using the NIST 
samples (National Institute of Standards and Technology samples) as reference. 
Testing the DEQAS samples (Vitamin D External Quality Assessment Scheme 
samples)243 indicated the IDS-iSYS assay was systematically overestimating 
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concentrations compared with the mean obtained for all 25(OH)D assays (Figure in 
Appendix 2). Hence, a linear correction, multiplying all values by 0.757, was applied 
to measured 25(OH)D concentrations. Precision checking was satisfactory and a 
brief summary of the methods used in the assay development by our Biochemistry 
colleagues is included in Appendix 2.  
Biomarkers associated with CVD risk 
Plasma concentrations of total cholesterol, low-density lipoprotein cholesterol (LDL-
C), high-density lipoprotein cholesterol (HDL-C), apolipoprotein A1 (Apo A1) and 
apolipoprotein B (Apo B) as well as biomarkers of inflammation (C-reactive protein 
[CRP], fibrinogen and albumin) and cystatin C were measured.244 Estimated 
glomerular filtration rate (eGFR, in mL min/1.73 m2) was calculated from cystatin C 
concentration using the formula eGFR = 80.35/cystatin C [in mg/L]–4.32.245 
 
Statistical methods  
Plasma 25(OH)D concentrations were analysed on the natural logarithmic scale to 
normalise the distribution. Since plasma 25(OH)D varied throughout the year with 
season, values were adjusted for month of blood sampling. This was done by adding 
to each participant’s log 25(OH)D measurement, the difference between the overall 
mean log 25(OH)D concentration (seen in all men) and the mean observed just 
among men sampled in the same month (calculated from the sample collection 
date). Since the majority of men were examined in the summer of 1997, when 
25(OH)D concentrations was highest, this adjustment tended to shift values 
towards those seen in summer rather than winter months. Participants were then 
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classified into five equal groups based on the season-adjusted 25(OH)D 
concentration. The means and prevalence of other baseline characteristics, 
adjusted for age, were estimated (with appropriate tests for linear trend between 
log 25(OH)D and the risk factor performed using, respectively, linear or logistic 
regression adjusted for age).  
 
To further assess the shape of the association between 25(OH)D and mortality, men 
in the top and bottom fifths were divided in half to better characterise the dose-
response relationships at the extreme concentrations. Relative risks (estimated by 
hazard ratios in Cox models) were estimated for each group relative to the lowest 
group and shown as “floating absolute risks” (merely ascribes a 95% confidence 
interval [CI] to the RR in every group).246 The average relative risk corresponding to 
a doubling in 25(OH)D concentration (approximately a 2 standard deviation 
increase on the log scale) was also estimated. The proportionality assumption of 
the Cox model was assessed using the method described by Grambsch and 
Therneau.247 Analyses were done before and after adjustment for age, prior history 
of disease (myocardial infarction, angina, stroke, cancer or diabetes), self-reported 
health status (on a four point scale), ability to perform particular activities of daily 
living (based on a 15-point questionnaire), smoking status (current smoker, ex-
smoker, never smoker), alcohol consumption, last known employment grade, blood 
pressure (both at entry to Whitehall study in 1967-70 and at resurvey in 1997-98, as 
well as treatment for hypertension at resurvey), body mass index, blood lipids and 
apolipoproteins (LDL-C, HDL-C, Apo A1, Apo B), markers of inflammation (C-reactive 
protein, albumin, fibrinogen), and eGFR.   
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To assess the effects of reverse causality, analyses were repeated separately in men 
with and without a prior history of disease (defined as above), while further 
analyses excluded deaths during the first five years of follow-up. All p-values were 
two sided and p-values <0.05 were deemed conventionally significant. Analyses 
were done using SAS version 9.1 (SAS Institute, Cary, NC, USA) and R version 2.11.1 
(www.r-project.org).  
 
Results 
Key results are presented here (published paper in Appendix 1).9 The Whitehall 
resurvey participants included 5409 men and their baseline characteristics are 
summarised in Table 3-2. The mean age of participants at resurvey was 76.9 (SD 
4.9) years, and about one-third (1841 men) had a history of prior vascular disease, 
cancer or diabetes. The majority (87%) were non-smokers, while 78% were self-
reported ‘current’ alcohol drinkers.  
 
Distribution of 25(OH)D concentrations at baseline 
Plasma concentrations of 25(OH)D varied by month of blood collection. Absolute 
values for plasma 25(OH)D concentrations varied widely during the year with peak 
levels being seen at the end of summer. Although the mean plasma 25(OH)D were 
relatively higher than expected in November and December. However, the number 
of samples collected was fewer and hence mean values may be skewed by extreme 
values from participants who may have had more exposure to sun in the preceding 
month. The mean concentrations after adjustment for month of blood collection 
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show a log-normal distribution (Figure 3-1). Median 25(OH)D concentration 
(standardised for month of blood collection) was 56 nmol/L (interquartile range 45-
67 nmol/L). Repeated measurements were available in 187 men, taken 1.5 years 
apart, and the self-correlation in log 25(OH)D was 0.64. 
 
At any given age, men with lower 25(OH)D concentrations were likely to have a 
history of vascular disease, cancer or diabetes, and diagnosed with hypertension or 
taking treatment for hypertension, than men with higher concentrations. Measured 
systolic blood pressure at resurvey in 1997 was only weakly related with 25(OH)D 
concentrations, and the slight increase in blood pressure across the quintiles may 
be a play of chance. The blood pressure at the initial examination for the Whitehall 
study in 1967-70 was unrelated with 25(OH)D concentrations. Men with higher 
25(OH)D had lower mean BMI, were less likely to have been of manual/clerical 
grade at retirement, had higher mean LDL-C, HDL-C, ApoA1 and albumin 
concentrations, and lower C-reactive protein and fibrinogen concentrations, than 
men with lower 25(OH)D concentrations.  
 
Association of 25(OH)D with vascular and non-vascular mortality 
Among the 5409 participants, 3215 men died over 50,000 person years of follow-up 
(death rate: 6.4% per year; mean follow-up among survivors 13 years), including 
1358 deaths (2.7% per year) from vascular causes and 1857 deaths (3.7% per year) 
from non-vascular causes. Among the 3568 men without a history of vascular 
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disease, cancer or diabetes, there were 727 deaths (2.0% per year) from vascular 
causes and 1124 deaths (3.1% per year) from non-vascular causes.  
 
After classifying men into seven groups based on season-adjusted 25(OH)D 
concentration, higher concentrations of 25(OH)D were inversely and, on the log-log 
scale, approximately linearly related to the risk of vascular mortality, at least 
throughout the range 40 to 90 nmol/L, of non-vascular mortality in age-adjusted 
models (Figure 3-2). The shape of these associations were broadly similar for both 
vascular and non-vascular mortality (with some attenuation of risk for non-vascular 
mortality with 25(OH)D > 80 nmol/L), and, for both outcomes, associations were 
consistent among men with and without a prior history of vascular disease, cancer 
or diabetes.  
 
Effect of adjustment for potential confounders 
Given age, a doubling in 25(OH)D concentration (corresponding to a ln(2) absolute 
difference – about 2 standard deviations – on the log-scale) was, on average, 
associated with a 34% lower risk of vascular mortality (RR 0.66, 95% CI 0.58-0.75) 
and a 36% lower risk of non-vascular mortality (RR 0.64, 95% CI 0.58-0.72) (Figure 
3-3). After adjustment for prior disease (including self-reported measures of health 
and frailty), established vascular risk factors, markers of inflammation and renal 
function, this was reduced to a 20% lower risk of vascular mortality (RR 0.80; 95% CI 
0.70-0.91) and a 23% lower risk of non-vascular mortality (RR 0.77; 95%CI 0.69-
0.86). The substantial change in the χ2 statistic associated with 25 (OH) D 
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concentrations with these adjustments (from 41.1 to 11.5 for vascular death and 
63.3 to 21.4 for non-vascular death) suggest that a large part of these associations 
was due to confounding, principally by prior disease. There was no evidence that 
the relative risks associated with a doubling in baseline 25(OH)D concentration 
varied during follow-up (p-values for test of proportionality assumption: p=0.48 for 
vascular mortality and p=0.13 for non-vascular mortality). Associations with 
particular types of vascular and non-vascular death (e.g. IHD, stroke, cancer and 
respiratory death), after adjustment for measured confounders, were broadly 
similar to the overall relative risks seen for vascular and non-vascular mortality 
(Figure 3-4). The findings for participants with no prior disease at resurvey were 
similar to those of the overall study population (Figures 3-5 and 3-6). Results were 
also broadly similar after exclusion of deaths within the first five years of follow-up 
(to further reduce the possible effect of reverse causality) (Figure 3-7).  
 
Conclusions 
In this prospective study of older men, baseline concentrations of plasma 25(OH)D 
were found to be predictive of the risks of both all-cause and cardiovascular 
mortality. In the next chapter, we included the findings of the Whitehall Study with 
data from other prospective studies reporting associations of vitamin D with 
cardiovascular or all-cause mortality. 
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Table 3-1: Characteristics of non-responders in the Whitehall resurvey* 
 
 Total number of 
participants 
Non-responders to long 
questionnaires (%) 
Blood samples not 
sent 
(%) 
Age at re-survey 
<75 
75-79 
80+ 
 
3027 
2940 
2570 
 
24 
24 
37 
 
19 
20 
33 
Estimated income in 1997 
£25300+ 
£18800 – 25299 
<18800 
 
2611 
2610 
2613 
 
23 
27 
32 
 
20 
23 
26 
Employment grade 
Administrative 
Executive/Prof/Dip 
Clerical / other 
 
555 
6743 
1239 
 
20 
25 
46 
 
14 
21 
38 
Residence 
London 
Outside London 
 
2591 
5946 
 
33 
26 
 
27 
21 
Smoking status 
Current/ex-smoker 
Never 
 
6455 
2078 
 
29 
24 
 
24 
20 
Systolic blood pressure 
Group I 
Group V 
 
2170 
1125 
 
25 
33 
 
20 
28 
All 8537 18 20 
*Among the non-responders, 9% actively refused participation, 2% had died by the time, 2% moved 
address and no information was available in 5%. 
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Table 3-2: Baseline characteristics of participants in the Whitehall resurvey  
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Figure 3-1:  Raw and unadjusted mean 25(OH)D concentrations by month of resurvey (left) and 
distribution of season-adjusted 25(OH)D (right) 
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Figure 3-2:  Age−adjusted relevance of measured 25(OH)D for vascular and non−vascular mortality 
in old age, overall and separately in men with and without prior disease 
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Figure 3-3:  Effect of adjustment for known risk factors on the association between measured 25(OH)D and vascular and  
non−vascular mortality
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Figure 3-4:  Association between measured 25(OH)D and cause−specific mortality after adjustment for measured confounders 
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Figure 3-5  Effect of adjustment for known risk factors on the association between measured 25(OH)D and vascular and non-vascular mortality among 
men without prior disease 
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Figure 3-6:  Association between measured 25(OH)D and cause-specific mortality after adjustment  
for measured confounders among men without prior disease  
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Figure 3-7:  Association between 25(OH)D concentration and cause-specific mortality after  
adjustment for measured confounders, excluding deaths in the first 5 years 
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Chapter 4 :  Meta-analyses of prospective studies of vitamin D and the 
risks of CVD and all-cause mortality 
 
Introduction 
This chapter evaluates the consistency of the findings from the prospective 
Whitehall study presented in Chapter 3 when compared to the results of other 
prospective studies reporting on CVD or all-cause mortality (Appendix 1). 
 
Rationale and Aims 
Low concentrations of 25-hydroxy-vitamin D (25[OH]D) at baseline were shown to 
be inversely associated with higher risks of cardiovascular deaths and all-cause 
mortality among older men living in the UK in the Whitehall study. These findings 
are intriguing as the associations lack specificity, in that baseline 25(OH)D 
concentrations are associated to both CVD and non-CVD causes of mortality. It is 
also unclear whether these reported associations among older men living in the UK, 
are similar to those reported in other studies which included people living in other 
geographical locations, women, or younger participants. If the reported 
associations between baseline plasma 25(OH)D levels and CVD mortality in the 
Whitehall study are similar to those reported elsewhere, the findings may be 
generalisable to the general population and the causality of these associations 
would need testing in randomised clinical trials. Further, it is unclear whether the 
shape and size of the associations reported from the Whitehall resurvey are similar 
in shape and consistency in other prospective studies. 
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In the present study, we evaluate the comparability and consistency of the 
associations of baseline 25(OH)D and cause-specific mortality from the Whitehall 
Resurvey, by including this data in meta-analyses of other prospective studies that 
reported on associations of baseline 25(OH)D and outcomes of cardiovascular and 
all-cause mortality.  
The main aims of this analysis were to:  
(i) examine the strength of the prospective associations of baseline 25(OH)D 
with cardiovascular mortality and all-cause mortality; 
(ii) examine the consistency of the relationships between baseline concentrations 
of plasma 25(OH)D and CVD and all-cause mortality. 
 
Methods 
Systematic search methods of prospective studies  
Published reports of prospective studies and case-control studies reporting on 
associations of 25(OH)D with either vascular or all-cause mortality were identified 
through a systematic electronic search of the three electronic databases (PubMed, 
Embase and Cochrane). The step-wise search methods used in PubMed is outlined 
in Figure 4-1. This search was complimented by searching the reference lists of the 
selected articles, and reviewing reference lists of studies included in previous meta-
analyses of prospective studies of 25(OH)D. The studies were included if they were 
in English and published before January 2012. We aimed to include all prospective 
studies that recruited participants with characteristics that were broadly 
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comparable with those of the general population, and excluded studies that 
selected participants predominantly from those with pre-existing conditions (see 
eligibility below). This was to minimise the effects of reverse causation on the 
outcomes reported.  
 
We included studies where participants were mainly older people living in the 
community, as older prospective studies of vitamin D included older participants 
and were designed to evaluate their bone outcomes; excluding such studies could 
introduce a bias (significantly reduces the sample size, potentially exclude 
information if the outcomes were either null or inconsistent). However, we 
excluded those that were conducted in the very frail and included the extremes of 
age.  
Selection criteria  
Inclusion criteria: 
Studies were included if: 
(i) It was a prospective (or nested case-control) study;  
(ii) It included more than 200 adult participants, predominantly recruited from 
the general population;  
(iii) The study reported data on baseline 25(OH)D concentrations and on risks of 
death from CVD or deaths from all causes.  
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Exclusion criteria: 
Studies were excluded if: 
(i) participant selection was predominantly from among patients with prior 
disease (cancer, vascular, or renal disease);  
(ii) participants were predominantly recruited from patients with CVD risk factors 
(diabetes and hypertension) only; 
(iii) they were studies that were conducted among very frail or nursing home 
residents (they were not considered to be representative of the general 
population); 
(iv) study included participants who were enrolled in clinical trials of vitamin D;  
(v) such studies were other meta-analyses.  
Studies were also excluded if they were reporting from the same population (e.g. 
the NHANES cohort); the largest study with the most deaths was included in such 
cases. 
 
Principle outcomes  
The key outcomes of interest were the relative-risks of: 
(i) CVD mortality 
(ii) All-cause mortality, based on baseline 25(OH)D concentrations. 
 
Studies included generally defined causes of death by ICD codes from either death 
certificates or by physician reviews; one large study reported a composite outcome 
which included CVD death.128 As the numbers of studies were limited and included 
studies that reported other outcomes, we also included an indication of the quality 
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of the information deduced from such studies by reporting on information about 
the number of participants studied, the duration of follow-up, the inclusion of the 
methodology for correction of seasonal variation in 25(OH)D concentrations, and 
the number and type of confounders used in the adjustment regression models.  
 
Relative risk ratios (RRs) from each report were extracted (commonly hazard ratios 
from Cox regression models) along with their 95% CI for vascular and all-cause 
mortality, and independently verified by two researchers (Robert Clarke and Joseph 
Tomson). For each study, the most fully adjusted RR and its 95% CI were recorded. 
Regression models that included calcium and phosphate in their adjustment were 
not included (as these are on the causal pathway; the established action of vitamin 
D is the regulation of calcium and phosphate metabolism).  
 
Consistent with PRISMA Guidelines, studies included in the meta-analyses were 
evaluated (Table 4-2) for: design (prospective or retrospective), characteristics of 
participants, representative of the general population (i.e. representativeness 
based on eligibility criteria), appropriate evaluation of relevant outcomes, duration 
of follow-up and the appropriate use of multivariate regression analyses. However, 
a formal scoring system was not used. It was difficult to ascertain the quality of 
outcomes evaluated in the published literature (including risks of detection and 
attrition biases). Hence, only studies that either included participants with pre-
existing disease (such as diabetes, cancer, kidney disease or CVD) or those with a 
significant likelihood of underlying chronic disease (e.g. extremes of age or frailty) 
were excluded.  
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Statistical analysis  
Where necessary, the RRs were recalibrated to correspond to the top vs. bottom 
quarter of the 25(OH)D distribution (most common approach in the studies 
included in the analyses).248 This was done by estimating the number of SDs that 
each published RR would correspond to [on some normal transformation of the 
underlying 25(OH)D distribution] before recalibrating the log RR (and its standard 
error) to correspond to a 2.54 SD difference (since 2.54 is the difference in mean 
values between the top and bottom quarters of a normal distribution). We 
contacted the principal investigators of selected studies to provide additional data 
on the SD of 25(OH)D concentration in their cohorts to facilitate standardized 
comparisons.  
 
Overall summary estimates of the effect were calculated using the Mantel–
Haenszel inverse-variance weighted method for meta-analysis. In the forest plots, 
studies were ordered according to the amount of statistical information they 
contributed to the overall result [and, for display only, were grouped as being: 
‘small’ (providing <1% of the total information provided by all the studies); 
‘medium’ (1 to <10%); or ‘large’ (at least 10%)]. Analyses were also carried out to 
assess the effects of differences in 25(OH)D on mortality after stratifying studies by 
age, gender and study size using meta-regression. All p values were two sided 
and p values < 0.05 were deemed conventionally significant.  
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Results 
Prospective studies included in the meta-analyses 
The meta-analyses (which included results from the Whitehall resurvey study) 
included 12 prospective studies with 4632 vascular deaths and 18 prospective 
studies with 11,734 deaths from all causes (Table 4-1). The information from the 
Whitehall study was the largest contributor to both the meta-analyses for the risks 
of mortality with more than 3000 deaths. The prospective study with the longest 
period of follow-up of 27 years was the Mini-Finland Survey, while the largest 
number of participants and the shortest follow-up of 1.3 years were in the 
InterMountain Healthcare study. Although we did not apply an eligibility criteria 
based on the quality of information provided given the paucity of studies, an 
indication of the nature and extent of the information provided by these studies are 
shown in Table 4-2. 
 
Relative risks of death between quartiles 
Participants with a baseline 25(OH)D concentration in the top quarter of 
distribution had on average, 21% (95% CI 13-28%) lower vascular mortality (Figure 
4-2) and 28% (95% CI 24-32%) lower all-cause mortality (Figure 4-3) when 
compared to the lowest quarter. However, the observed relative risks varied 
inversely with the amount of statistical information provided by each study (i.e. by 
study size). That is the more extreme estimates of the risks of dying were reported 
in smaller studies for both vascular and all-cause mortality outcomes. 
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All-cause mortality by age, gender and baseline 25(OH)D concentrations 
When studies were stratified by mean age of the included participants, no 
differences in risks for all-cause mortality were identified between extreme 
quartiles (Table 4-3). The mean age of the participants in the studies included 
ranged between 59 to 84 years. When stratifying by gender (Table 4-4), three 
studies included only women and four recruited only men. The relative risks for all-
cause mortality in studies recruiting women was 54% lower in women in the top 
quartile of plasma 25(OH)D than those women in the lowest quartile, while the 
relative risks were only 25% lower in studies recruiting only men between top 
versus bottom quartiles (p=0.05). However, when after adjusting for age, gender 
and study size, only study size remained a significant contributor to the 
heterogeneity in these analyses (Figure 4-4). No differences were seen in the 
relative risks of death, when studies were evaluated by the range of 25(OH)D 
concentrations between the extreme quartiles, or when stratifying them by 
published mean concentrations of 25(OH)D for the lowest quarter (published mean 
25(OH)D levels for each quartile was available only in 9 prospective studies 
reporting on all-cause mortality – data not shown). 
 
Conclusion 
The findings from the meta-analyses of prospective studies show a consistent shape 
and trend in the inverse associations between plasma 25(OH)D and the risks of both 
CVD and all-cause mortality, irrespective of geographic locale, gender or baseline 
25(OH)D concentrations. In the next chapter, we discuss the design of a dose-
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finding trial of vitamin D, BEST-D, where the trial aims to identify the dose of 
vitamin D3 supplement to be used in a future trial of vitamin D evaluating 
cardiovascular and other outcomes. 
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Figure 4-1: Identification of prospective studies of 25(OH)D and mortality  
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Figure 4-2: Meta−analysis of the relationship between 25(OH)D concentration and 
vascular mortality 
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Figure 4-3: Meta−analysis of the relationship between 25(OH)D concentration and 
all−cause mortality 
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Figure 4-4: Meta-regression analyses of prospective studies reporting differences in 
25(OH)D on risk of all-cause mortality, by age, sex and study size 
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Table 4-1: Summary characteristics of studies included in the meta-analyses of prospective studies 
Author,  Year Population characteristics Country N in 
study 
Mean 
 Age 
Follow-
up years 
Endpoints Number of events Level of 
adjustment
α
 
Total 
mortality 
CVD 
mortality 
Anderson,128 2010 Intermountain Healthcare  US 27686 66.6 1.3 All-cause mortality 1193 - 2+ S 
Cawthon,196 2010 Osteoporotic fractures in Men 
(MrOS) study. 
US 1490 73.8 7.3 All-cause mortality 
/ CVD mortality 
330 110  +  S 
Dobnig,197 2008 LURIC study - The Ludwigshafen 
Risk and Cardiovascular Health 
study. 
Germany 3258 
63.7 
7.7 All-cause mortality 
/ CVD mortality 
737 463 3+ S 
Ensrud,198 2010 Women in the study of 
osteoporotic fractures (SOF) 
US  4551 76.7 4.5 All-cause mortality 432 - 2+S 
Ford,199  2011 Third National Health and 
Nutrition Examination Survey  
(NHANES) mortality study 
US 7531 46 3.8 All-cause mortality 347 - 2+S 
Hutchinson,1332010 TROMSO study Norway  7161 58.9 11.7 All-cause mortality 
/ CVD mortality 
1359 513 3+ S 
Jassal,202 2010 The Ranch Bernardo study. US 1073 74 6.4 CVD mortality - 111  2+S 
Jia,203 2007 Aberdeen Community Health 
Index. 
 
 
UK 399 80 5.7 All-cause mortality 129 - 2+S 
Kestenbaum,2492011 Cardiovascular health study US 2312 74 14 All-cause mortality 
/ CVD mortality 
1226 389 1+S 
Kilkkinen,1122009 Mini-Finland Health survey Finland 6219 49.4 27.1 CVD mortality - 933 2+ S 
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Kitamura,204 2010 Yamato study Japan 205 83.6 2 All-cause mortality 42 -  3+  
Kuroda, 205 2009 Japanese postmenopausal 
women. 
Japan  1232 63.9 6.9 All-cause mortality 107 - 1+  
Melamed,1072005 Third National Health and 
Nutrition Examination Survey 
(NHANES III). 
US 13331 63.9 8.7 All-cause mortality 
/ CVD mortality 
1806 777 3+ S 
Michaelsson,1402010* Uppsala Longitudinal Study of 
Adult Men (ULSAM)  
Sweden 1075 71 12.7 All-cause mortality 
/ CVD mortality 
520 159 3+ S 
Pilz,207 2009 Hoorn study cohort. Netherlands 614 70 6.2 All-cause mortality 
/ CVD mortality 
51 20 3+ S 
Semba,210 2010 ‘Aging in the Chianti Area’ 
(InCHIANTI) study. 
Italy 1006 74 6.5 All-cause mortality 
/ CVD mortality 
228 107 3+ S 
Semba,211 2009 Womens health and aging 
studies I and II. 
US 714 70-
79 
6.5 All-cause mortality 100 - 3+S 
Szulc,212 2009 MINOS study. France 782 67 10 All-cause mortality 182 - 2+S 
Virtanen,214 2010 Kuopio IHD risk factor study 
(KIHD). 
Finland 1136 61.8 9.1 All-cause mortality 
/ CVD mortality 
87 35 3+ S 
Visser, 213 2006 Longitudinal Aging study 
Amsterdam (LASA). 
Netherlands 1260 55-
85 
6 All-cause mortality 380 - 3+S 
Wang,59** 2008 Framingham Offspring study US 1739 59.9 5.4 *Incident CVD and 
CVD mortality 
- 120 2+ S 
Tomson,9 2013 Whitehall study. UK 5409 77 13 All-cause mortality 
/ CVD mortality 
3215 1358 3+ S 
* In this publication, patients in the lowest tenth of the 25(OH)D distribution were compared with patients between the 10
th
 and 90
th
 centiles. The numbers shown therefore 
exclude patients in the top tenth of the 25(OH)D distribution. ** This study reported a composite vascular outcome of vascular death or non-fatal vascular event (MI, angina, 
coronary insufficiency, stroke, TIA, claudication or heart failure). α Level of adjustment: Age only +; Age AND at least 1 vascular risk factor (hypertension, diabetes, cholesterol) ++; 
Above AND a marker of physical status or social class +++. If adjusted for season or standardised for month/season of sampling = S. 
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Table 4-2: Quality assessment of the prospective studies vitamin D and mortality included in the meta-analyses 
 
Author Study Follow-up in years Representativeness 
CVD/mortality 
focussed outcomes 
Factors included in the 
adjustment model* 
Hutchinson,
 
2010 TROMSO study 11.7 Yes Y 13589 
Virtanen, 2010 Kuopio IHD risk factor study (KIHD). 9.1 Yes Y 123456 
Kuroda, 2009 Japanese postmenopausal women. 6.9 Somewhat Y 18 
Melamed, 2005 Third National Health and Nutrition 
Examination Survey (NHANES III). 
8.7 Yes Y 123456789 
Anderson, 2010 Intermountain Healthcare 1.3 Yes Y 12345 
Szulc, 2009 MINOS study. 10 Somewhat Y 12568 
Pilz, 2009 Hoorn study cohort. 6.2 Yes Y 12345689 
Michaelsson, 2010 Uppsala Longitudinal Study of 
Adult Men (ULSAM) 
12.7 Somewhat Y 12678 
Cawthon,
 
2010 Osteoporotic fractures in Men 
(MrOS) study. 
7.3 Somewhat Y 12 
Kestenbaum, 2011 Cardiovascular health study 14 Yes Y  
Semba, 2010  ‘Aging in the Chianti Area’ 
(InCHIANTI) study. 
6.5 Yes Y 1234568 
Semba, 2009 Womens health and aging studies I 
and II. 
6.5 Somewhat Y 1234568 race 
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Visser, 2006 Longitudinal Aging study 
Amsterdam (LASA). 
6 Yes Y 1689 
Ensrud, 2010 Women in the study of 
osteoporotic fractures (SOF) 
4.5 Somewhat No 12678 
Tomson, 2013 Whitehall study. 13 Somewhat Y 12345679 
Jia, 2007 Aberdeen Community Health 
Index. 
5.7 Yes Y 1258 
Kitamura,
 
2010 Yamato study 2 Somewhat No 18 
*Adjusted factors indicated by a digit: Age / sex = 1; Season = 2; HTN = 3; lipids = 4;  DM = 5; Smoking = 6; Socio-economic status = 7; Physical activity = 8; renal function = 9; 
Representativeness was based on the authors’ analysis whether the findings were generalisable to an age-matched general population based  on participants included, 
their characteristics and outcomes evaluated 
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Table 4-3: Hazard ratios for all-cause mortality when studies were stratified by age 
Author, year HR CI lower CI upper Mean age 
Hutchinson, 2010 0.83 0.68 1.02 58.9 
Virtanen,2010 0.43 0.17 1.10 61.8 
Kuroda, 2009 0.31 0.10 0.90 63.9 
Melamed, 2005 0.64 0.36 1.14 63.9 
Anderson, 2010 0.57 0.46 0.70 66.6 
Szulc, 2009 0.69 0.44 1.08 67 
Pilz, 2009 0.52 0.24 1.14 70 
Michaelsson,  2010 0.66 0.40 1.10 71 
Cawthon, 2010 0.90 0.60 1.36 73.8 
Kestenbaum, 2011 0.74 0.58 0.95 74 
Semba, 2010 0.47 0.23 0.97 74 
Semba, 2009 0.41 0.15 1.14 74 
Visser, 2006 0.82 0.54 1.26 75 
Ensrud, 2010 0.67 0.44 1.01 76.7 
Tomson, 2013 0.76 0.66 0.87 77 
Jia, 2007 0.50 0.22 1.10 80 
Kitamura, 2010 0.89 0.33 2.44 83.6 
Prospective studies ordered by increasing mean age of participants; HRs are for top versus bottom 
quartiles.
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Table 4-4: Hazard ratios for all-cause mortality when studies were stratified by gender 
Author, year HR CI lower CI upper Mean age 
Total 
participants 
Doubling 
25(OH)D 
between 
quartiles 
Males% 
Kuroda, 2009 0.31 0.1 0.9 63.9 1232       N 0 
Semba, 2009 0.41 0.15 1.14 74 714 N 0 
Ensrud, 2010 0.67 0.44 1.01 76.7 4551 N 0 
Studies in women 0.46 0.23 1.02 
  
 
 
Anderson, 2010 0.57 0.46 0.7 66.6 27686 Y 25 
Kestenbaum, 2011 0.74 0.58 0.95 74 2312 Y 30 
Kitamura, 2010 0.89 0.33 2.44 83.6 205 N 31 
Hutchinson, 2010 0.83 0.68 1.02 58.9 7161 N 40 
Virtanen, 2010 0.43 0.17 1.1 61.8 1136 Y 50 
Pilz, 2009 0.52 0.24 1.14 70 614 N 50 
Visser, 2006 0.82 0.54 1.26 75 1260 Y 50 
Jia, 2007 0.5 0.22 1.1 80 399 Y 52 
Melamed, 2005 0.64 0.36 1.14 63.9 13331 N 56 
Semba, 2010 0.47 0.23 0.97 74 1006 Y 75 
Studies in a mixed 
population 
0.64 0.38 1.18 
  
 
 
Szulc, 2009 0.69 0.44 1.08 67 782 N 100 
Michaelsson, 2010* 0.66 0.4 1.1 71 1075 N 100 
Cawthon, 2010 0.9 0.6 1.36 73.8 1490 N 100 
Tomson, 2013 0.76 0.66 0.87 77 5409 N 100 
Studies in men 0.75 0.53 1.1 
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Chapter 5 : The Biochemical Efficacy and Safety Trial of vitamin D 
(BEST-D) - design and methods to evaluate effects of vitamin D on 
blood pressure and arterial stiffness 
 
Introduction 
This chapter describes the design and methods of a dose-finding trial of vitamin D, 
called the Biochemical Efficacy and Safety Trial of vitamin D (BEST-D). The trial 
design was also used to evaluate the effects of supplementation with vitamin D on 
blood pressure and arterial stiffness, and contributed to the work presented in 
Chapters 5 and 6 (Trial protocol published is in Appendix 3). The methods used to 
evaluate effects on blood pressure and arterial stiffness are included in this chapter.  
 
Overview  
Rationale and Aims of the BEST-D trial 
About half of all women and a fifth of all men over the age of 50 years will 
experience a fracture in their lifetime and most will be related to the osteoporosis. 
There is uncertainty about whether supplementation with vitamin D for people 
with moderate vitamin D insufficiency can prevent osteoporotic fractures or other 
disease outcomes. Low circulating vitamin D levels in the population may be easily 
modified by supplementation with vitamin D.  
 
In the United Kingdom, low circulating vitamin D levels are due to the combination 
of poor vitamin D in the diet and the lack of adequate sunlight-mediated production 
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of the vitamin.250 Older people have higher risks of developing fractures and falls, 
and are also at higher risk of developing CVD compared to the young. Hence, if 
supplementation with vitamin D could modify risks of CVD, fracture or falls, the 
absolute benefits would be greatest in the elderly. 
 
Plasma 25(OH)D levels >90 nmol/L are typically found in young British adults at the 
end of the summer.251 Evidence from the Whitehall resurvey demonstrated that 
optimal plasma levels of 25(OH)D for both CVD and non-CVD mortality were around 
90 nmol/L.9 Even higher levels (about 115 nmol/L) are observed among people 
living closer to the equator.252 Mean levels of plasma 25(OH)D among the UK 
resident population is around 55 nmol/L and to achieve plasma 25(OH)D levels of 
90 nmol/L or more, the vitamin D supplement dose required to raise plasma levels 
to those seen at the end of summer will be at least 2000 IU daily. In order to 
maintain such higher concentrations (>90 nmol/L) throughout the year including 
winter, especially among the elderly, where plasma levels are lower than those 
observed in young people, even higher doses of vitamin D supplements of up to 
4000 IU daily may be required. However, the safety and efficacy of taking such 
higher daily doses of vitamin D supplements in the older people is largely unknown.  
 
The main aims of the Biochemical Efficacy and Safety Trial of vitamin D (BEST-D) 
were to compare the effects of daily supplementation with either 4000 IU vitamin D 
or 2000 IU vitamin D or placebo on biochemical markers of vitamin D status to 
determine the optimum dose to use in a large randomised trial of vitamin D 
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supplements evaluating effects on multiple health outcomes in older people living 
in the United Kingdom.  
 
The trial was also used to investigate the effects of vitamin D on cardiovascular risk 
factors including assessment of the effects of vitamin D on blood pressure and 
arterial stiffness which are included in this thesis.  
 
Rationale for evaluating effects of vitamin D on blood pressure 
As discussed in Chapter 2, there is considerable uncertainty about whether taking 
vitamin D supplements may lower blood pressure. Most of the available 
randomised evidence comes from trials that used ‘insufficient doses’ of vitamin D 
supplements and are unlikely to have achieved optimal plasma 25(OH)D levels. 
Moreover, many trials had short periods of follow-up and small number of 
participants. There are very limited available data on whether higher doses of 
vitamin D supplements, ranging between 2000 IU to 4000 IU daily when taken daily 
for 1 year, could help reduce blood pressure favourably. 
 
Rationale for evaluating effects of vitamin D on arterial stiffness 
Arterial stiffness is a surrogate marker of CVD120, 253 and is a measure of arterial 
distensibility (compliance). Increased arterial stiffness is associated with adverse 
levels of other CVD risk factors and is an independent predictor of CVD events and 
all-cause mortality.121, 122, 254 Arterial stiffness may be modified and these measures 
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have been used as surrogate markers of CVD in clinical trials of risk factor 
modification therapy.255  
 
Previous studies have reported that low vitamin D status is associated with an 
increased arterial stiffness (Chapter 2).124 Data from 198 men living in the UK 
indicated that plasma 25(OH)D levels were inversely correlated with central aortic 
pulse wave velocity (a measure of arterial stiffness).163, 256 As discussed in Chapter 
2, the association between low vitamin D and increased arterial stiffness could be 
linked to the vitamin D regulation of calcium metabolism, where low vitamin D may 
promote increased vascular calcification and, hence, the increased stiffening of 
arteries. Low vitamin D could also influence arterial stiffness indirectly, through 
effects on other CVD risk factors (such as blood pressure), or through pathways 
independent of the other known CVD risk factors. However, whether low vitamin D 
causes increased arterial stiffness is unproven and as these observed associations 
could be confounded. Further testing of the effects of vitamin D in a randomised-
controlled clinical trial is required to ascertain causality. Further, it is unknown if 
arterial stiffness could be modified. If arterial stiffness were modifiable by 
administering vitamin D supplements; this could provide indirect evidence on the 
potential effects of vitamin D supplements on CVD outcomes, and help in the 
interpretation of planned or on-going trials of vitamin D.  
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Arterial pulse wave analysis for arterial stiffness 
The ‘arterial pulse wave’ is a composite of a forward wave, formed after the 
contractile force of the heart (or propagative wave) and a retrograde ‘reflected 
wave,’ (Figure 5-1), caused by the reflection of the forward wave from points 
further along the arterial tree, typically at the major branches of the arteries (e.g. 
bifurcation of the descending aorta).257, 258 The inflection point, where the forward 
and reflected waves meet, depends on the extent of stiffness of the arterial wall 
and influences the velocity of propagation of the pulse wave. When arteries stiffen, 
the pulse wave velocity (PWV) increases, resulting in faster wave transmission (see 
Figure 5-1 for explanation). It is thought that the reflected wave helps ‘augment’ 
the central aortic blood pressure (causing a higher central pressure) when 
compared to the pressure in the peripheral arteries (for instance the brachial 
artery).259 
 
Selecting methods and indices of arterial stiffness for use in the BEST-D  
Measurement of arterial stiffness and the nature of the pulse is complex.260 Several 
indices (Table 5-1) have been derived using different methods to quantify changes 
in the properties of the arterial wall stiffness (reviewed in detail elsewhere161, 257, 
261). Aortic stiffness, commonly measured by estimating pulse-wave velocity, is 
considered the gold standard. Typically, pulse wave velocity is estimated by 
measuring the carotid-femoral pulse wave velocity, and is estimated by the time 
difference for the pulse wave reaching the carotid artery in the neck and the 
femoral artery in the groin (with the latter typically being delayed, reflecting the 
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speed of propagation of the wave). This measurement is, however, commonly 
conducted in a controlled-laboratory setting, with the participant in the recumbent 
position, and can be affected by factors such as caffeine and sleep deprivation,262 
and assessments recorded by a trained physiologist. Hence, this method was 
deemed unsuitable for use in the BEST-D trial which involved a community-based 
study of older people, with planned home visits.  
 
Newer methods of assessing arterial stiffness have recently been developed, mainly 
based on ‘pulse wave analyses’ where the pulse wave velocity is estimated 
indirectly from the analysis of the pulse wave morphology recorded at the 
peripheries (typically limb arteries).263 This commonly involves recording the pulse 
wave at a peripheral artery. The most widely used method to assess arterial 
stiffness is ‘radial artery applanation tonometry’, which estimates the pulse wave 
velocity by calculating the time taken for the reflected and forward waves to meet 
(Figure 5-1) based on the analyses of the recorded waves. However, many of these 
methods lack adequate validation studies (although such validation may emerge in 
future studies) and such methods lack wider acceptance and use in clinical practice 
or research.  
 
Another problem is the lack of comparability of different measures of arterial 
stiffness recorded at different sites the body. Whether the measures recorded at 
different points of the arterial tree are truly comparable or interchangeable is 
unknown, and previous comparisons indicate poor agreement between sites. This is 
likely because central large artery wall structure is comprised of more muscular and 
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elastic layers than the thinner, narrower walls of the peripheral arteries and 
arterioles. In other words, the distensibility of the larger more proximal arteries 
may not be similar to those in the limb peripheries by virtue of differences in their 
structure and anatomy. Other local factors may also influence this variability. For 
example, the arterioles in the digits may respond to local temperature changes and 
blood volume changes more than that of the central arteries. However, emerging 
data indicate, that although the pulsewave-analyses derived measures are not 
interchangeable, these ‘local stiffness measures’ may be independently predictive 
of CVD risk and hence still useful to provide prognostic data.264 
 
As participants in the BEST-D trial were older people, and the trial involved home 
visits undertaken by a study nurse, a suitable device for measuring arterial stiffness 
needed to be a portable, cost-effective, reliable, and simple-to-use method to 
record these measurements. Based on these considerations, novel methods 
estimating pulse wave velocity using peripheral limb arteries were deemed more 
appropriate and feasible than the central artery stiffness assessments. After 
evaluating the then available non-invasive methods for measuring arterial stiffness 
[radial tonometry, cardio-ankle vascular index (CAVI), brachial artery stiffness, 
digital pulse volume] in internal assessment pilots held at CTSU (Data not shown), 
technical, logistic and feasibility problems were identified with the radial tonometry 
and the CAVI assessment methods. For instance, ‘applanation tonometry’ required, 
adequate training of personnel (here a probe is held over the radial artery in the 
forearm to record a pulse wave), co-operation and patience from the participant 
who had to remain still during the recording, participant being recumbent, and 
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required repeated measurements before a ‘valid trace’ of adequate quality was 
obtained (Data not shown). The measurement of the cardio-ankle vascular index 
required the participants to remain recumbent and motionless during the duration 
of the measurement (for several minutes) and required a flat couch and a few 
minutes for preparation. Further, given the older participants in the BEST-D trial, 
frailty and presence of tremors were likely to be common and yielding poor quality 
traces. Hence, these methods were believed to be unsuitable for use in the BEST-D 
trial. The Tensiomed Arteriograph device and the Pulsetrace PCA II were believed to 
be more suitable and selected for use in the BEST-D trial.  
 
Arteriograph 
The Tensiomed Arteriograph (ARG) device (Figure 5-2)265, 266 was used to measure 
blood pressure and arterial stiffness from the right arm. The ARG records arterial 
pressure waveforms at the brachial artery using an ‘oscillometric method’. The 
device consists of a battery powered motor attached to a cuff, similar to a blood 
pressure cuff, connected using a blue-tooth link to the study laptop. The initial cuff 
inflation records the blood pressure in a similar manner to an automated blood 
pressure machine. During a further inflation, the brachial blood flow is occluded by 
raising the cuff pressure to 35 mmHg above the recorded systolic pressure. By 
creating a ‘stop-flow’ condition, the upper edge of the cuff is able to detect the 
pressure changes (and record the pulse waves over a period of 8 seconds) at the 
upper arm. The pressure changes are recorded by a high fidelity pressure sensor 
and the signals transmitted using a blue-tooth link to a laptop. The device also 
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provides measures of blood pressure and heart rate. Two key measures were 
derived for arterial stiffness from the ARG: 
 
(i) Pulse wave velocity (PWVao): The time taken for the forward wave and the 
reflected wave to meet, the return time (RT), was measured. The distance from the 
sternal notch to the upper edge of the pubic bone, the jugulo-symphisial distance 
(D), was used as an estimate of the distance from the aortic arch to the aortic 
bifurcation. The PWVao was calculated using the formula:  
PWVao (m/s) = D / (RT /2). 
 
(ii) Augmentation Index (AIx): Augmentation index is an index of the 
augmentation of the systolic pressure, at the central aorta, thought to be caused by 
the reflection of the pulse wave. AIx is the augmentation pressure expressed as a 
percentage of central pulse pressure. AIx, thus reflects properties of both central 
aortic stiffness (distensibility) and that of wave reflection. The value also depends 
on the state of the peripheral arteries and up to the point of reflection of the 
forward wave. The ARG software uses the following formula to calculate AIx:  
AIx = P2 - P1 / PP x 100, where P1 is the amplitude of the forward wave, P2 is the 
amplitude of the reflected wave and PP is the pulse pressure. 
 
These measurements were then recorded into the electronic case report. The 
software prompted a repeat reading, if the standard deviation of the recordings 
displayed as a SD value (this is automatically calculated by the ARG software as a 
measure of quality of the tracing, derived by comparing the waves recorded over an 
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8 second period) was >1. If further attempts failed to record a suitable 
measurement, the study nurse was permitted to proceed with the rest of the visit, 
and omitting the reading (as in these instances, the recordings were less likely to be 
consistent or reproducible in our prior testing). 
 
ARG device is validated for blood pressure and arterial stiffness.263, 267 Reported 
mean (SD) values for PWVao were 9.46 (1.8) m/s and for Aix were 30 (13), but these 
studies were predominantly conducted in younger people. In a UK study of 198 
men (age range between 40-80 years), mean PWVao was 6.9 m/s and Aix was 33% 
among Caucasians.256 The portability of the device, the ease of use, the minimal 
training required and the relative operator-independent measurements were the 
main advantages for the ARG. The disadvantages included the lack of published 
reports on validation and prognostic information, and that the measurements were 
only indirect indicators of central aortic stiffness, where much of the data on 
arterial stiffness was derived from. 
 
Pulsetrace PCA 2 
The Pulsetrace PCA 2 (Figure 5-2) uses photoplethysmography (infrared) to record 
changes in the ‘digital pulse volume’ (DWP).268 A finger probe, similar to those used 
to measure pulse oximetry, was placed on the right forefinger (or middle finger). 
The infrared sensor senses the pulse wave morphology, but likely to be a composite 
trace of the local digital pressure and volume changes, rather than exclusively 
reflecting vascular wall stiffness. The device provided two measures from the pulse 
wave analysis (Figure 5-3): 
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(i) Stiffness index (SI): defined as participant height / PPT, where PPT stands for 
the time between the peaks of the forward and reflected waves; and  
(ii) Reflective index (RI): defined as the height of the forward wave divided by the 
height of the reflected wave. 
 
The Pulsetrace device also suffers from having very little published validation and 
prognostic data, with much of the published literature being from a single group. 
From these limited earlier studies, the mean (SD) SI for 60 year olds was around 
12.2m/s and RI was 60 (5)% in a small sample; the range for SI was 6-10m/s (for all 
study participants; n=87; age 21-68 years)269 and for RI between 60-90%.270 
 
The Pulsetrace PCA 2 device has been used in 100,000 people in the UK Biobank 
study271 (which should provide normative and possibly prognostic data in future), 
but at present there is limited information. It is not known how comparable the 
digital volume pulse measurements could be with other measures of central arterial 
stiffness measurements, as the device records traces from the small digital arteries 
rather than the larger proximal or central arteries as assessed by other methods. 
Nevertheless, it could potentially provide useful information on local arterial pulse 
physiology, which may be equally of prognostic significance. As this method is 
operator-independent, highly portable, and requires minimal training, it was found 
to be suitable for use in the BEST-D trial.  
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Hypothesis and aims for the effects of vitamin D on blood pressure and arterial 
stiffness 
The study tested the hypothesis that dietary supplementation with high dose 
vitamin D (4000 IU and 2000 IU) for 12 months had no effect on arterial stiffness 
and blood pressure.  
The aims were to evaluate: 
(i) Effects of the 2 doses of vitamin D3 (2000 IU vs 4000 IU) versus placebo on 
blood pressure at 6 and 12 months of treatment; 
(ii) Effects of the 2 doses of vitamin D3 (2000 IU vs 4000 IU) versus placebo on 
arterial stiffness measured by the Arteriograph and Pulsetrace at 6 months. 
 
Methods  
BEST-D trial outline and study assessments  
The BEST-D trial was a randomised, double-blind, placebo-controlled dose-finding 
trial of vitamin D3. Eligible participants (Table 5-2) were older people (>65 years) 
living in the community of Oxfordshire, and randomised using a 1:1:1 allocation to 
receive either 4000 IU, 2000 IU of vitamin D3 or matching placebo for 12 months 
(Figure 5-4). The trial protocol of the BEST-D trial was published (Appendix 3) and 
the Data Analysis Plan is included in (Appendix 4).  
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Study visits and assessments 
Participant recruitment 
Potential participants were identified from the medical records of the participating 
GP practice (Hightown surgery) in Banbury, Oxfordshire from among patients 
registered at the GP Practice. The Practice is based in Banbury, a market town in 
Oxfordshire, which had about 10,200 registered patients, and most patients lived in 
urban areas with only small proportion living in semi-rural areas. The vast majority 
of patients had Caucasian ancestry (minority were Asian or other ethnic 
populations), and had a similar age and gender distribution to the national average 
for UK GP practices. However, the population was less affluent than the overall UK 
population (index of multiple deprivation score: 12.5 vs 21.8). This practice became 
the single recruiting practice for the study as, (i) the GP surgery was the pilot site 
and had a previous record of conducting studies and had collaborated with CTSU 
before;  and (ii) an initial search of the registered patients at the practice showed 
more than a thousand patients potentially meeting recruitment criteria for the trial; 
and (iii) the General Practitioner was one of the investigators and the site had 
adequate resources to accommodate the trial requirements for access and space; 
and finally, (iv) the recruitment targets were met before other NIHR sites were 
needed to be identified. Participants were invited by their general practitioner, Dr 
Harold Hin, the General Practitioner and local investigator for the study, to 
participate in the trial if they met eligibility criteria (Table 5-2). Patients were asked 
if they were willing to participate by sending them an invitation. The GP Practice 
sent invitations by mail which included an information leaflet, a response form and 
a freepost envelope. Potential participants showing intent to participate were 
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contacted by the receptionist and a brief ‘Screening questionnaire’ was completed 
to confirm willingness and suitability to participate in the trial. An appointment with 
the BEST-D study nurse was made to visit their homes at a suitable time.  
 
Randomization Visit 
At the first visit (Randomization Visit), the BEST-D study nurse visited the 
participants’ homes to discuss study procedures and sought informed consent if 
participants were still willing to participate. After obtaining informed consent, 
relevant medical history and eligibility were recorded onto an electronic case report 
form, using a customized software programme loaded into a secure laptop. These 
included demographic details, history of CVD, assessment of physical activity levels, 
muscle and joint pains, risk factors for CVD, assessment of dietary calcium intake in 
the previous week using a calcium questionnaire (developed based on the Nelson’s 
questionnaire272), and current use of prescribed or any over-the-counter 
medications. Anthropometric measurements included weight, height, arm 
circumference, and the sterno-symphysial distance. Blood pressure and arterial 
stiffness were measured using the Tensiomed Arteriograph and Pulsetrace PCA II 
devices. Blood samples were collected and stored at -80ᴼC. Participants were 
offered information leaflets on good diet sources of calcium. 
 
Eligible participants were randomised at this point by contacting the central 
coordinating office based at the CTSU via telephone. A treatment allocation number 
was provided after successful randomization, which when entered into the laptop 
enabled the double-blind dispensing of appropriate treatment from the supplies of 
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vitamin D supplements or placebo provided. Follow-up visit appointments were 
provisionally made. The visit assessments were stream-lined to enable collection of 
the most relevant and useful information in an efficient and timely manner, with an 
average visit taking just over an hour for the randomization visit and about 45 
minutes for the follow-up visits. In view of the older participants, visual aids were 
used to assist selecting appropriate responses with a visual analog scale and intake 
of dietary calcium assessments, to standardize the responses. A 4-point 
questionnaire was used to assess intake of dietary calcium, and to enable 
estimation, a visual aid depicting common portion sizes was used.  
 
Follow-up visits  
1 month: 
In a randomly selected group of 100 participants, a blood sample was taken at 1 
month after randomization. 
Follow-up visits: 
At the follow-up visits (Table 5-3), the study nurse recorded serious adverse events 
and changes to non-study medication at 6 and 12 months. Participants were also 
asked about self-reported physical activity and adherence with study medication, 
which was recorded as the participant having taken ‘most’, ‘some’, ‘very little or 
none’ of the study treatment. The reasons for discontinuation of any study 
treatment were recorded. The clinical assessments were broadly similar to those 
carried out at the randomization visit (see Table 5-3). At the 6 month visit, a 
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7-month supply of study medication and an appointment for the final visit were 
given. At the 12 month visit any unused treatment was collected.  
 
Blood pressure and arterial stiffness assessments 
At each visit all participants had measurements of their blood pressure and vascular 
stiffness recorded using the TensioClinicTM Arteriograph and the Pulsetrace PCA II 
devices (Figure 5-2). At the first visit only, height and weight (for BMI calculation) 
were recorded, together with mid-arm circumference, using a measuring tape, and 
the sterno-symphysial distance, using a bespoke wooden scale to record the linear 
distance between the anatomical landmarks between the sternal notch and the 
pubic symphysis. This was used as a surrogate measure of the length of the 
descending aorta, which reflects the distance travelled by the reflected pulse wave 
from the aortic bifurcation.  
 
For recording of blood pressure and arterial stiffness, participants were asked to be 
seated comfortably in a chair (with arm rests or near a table) and after 10 minutes 
of rest, the finger probe of the Pulsetrace PCA 2 was placed on the right forefinger 
to record the pulse wave over a 30-60 second period. This was followed by 
measurements of blood pressure and arterial stiffness made by placing a cuff over 
the upper arm, and recordings taken over 2 minutes using the TensioClinicTM® 
Arteriograph, the process being similar to a standard blood pressure assessment.  
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Whenever possible, the study visits were scheduled at the same time of the day to 
reduce the effects of diurnal variations in these measures. Participants were 
advised to avoid alcoholic beverages, tea and coffee before each visit.  
 
Outcomes 
Outcomes of the main BEST-D trial 
The primary efficacy assessment was an “intention-to-treat” analysis among all 
randomised participants on the proportion of individuals with levels of 25(OH)D 
above 90 nmol/L at the end of the study in each treatment group. A co-primary 
endpoint was the difference between those allocated 100 vs 50 µg daily, in the 
mean 25(OH)D levels at the scheduled study end. The study also assessed a number 
of secondary and tertiary outcomes (Table 5-4) as shown in Table 5-3. 
 
Blood pressure and arterial stiffness outcomes 
The comparisons involved “intention-to-treat” analyses among all randomised 
subjects of the effects of daily vitamin D3supplements 4000 IU vs placebo, vitamin 
D3 2000 IU vs placebo, and the difference between the two doses of vitamin D on: 
(i) The difference in the change from baseline in diastolic and systolic blood 
pressure and heart rate at 6 and 12 months. 
(ii) The difference in the change from baseline in arterial stiffness (pulse wave 
velocity, Augmentation Index, Stiffness index and reflective index) at 6 
months. 
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Trial registration and approval 
The trial was registered with the International Standard Randomised Controlled 
Trial Number Register (ISRCTN07034656). The trial protocol was approved by the 
NRES Committee South Central - Oxford B, and the study REC reference is 
12/SC/0243. MHRA approved the study on 18th June 2012 (Ref 21584/0295/001-
0001) and the trial EUDRACT Number is 2011-005763-24. BEST-D is included in the 
NIHR portfolio (reference CSP 67777) after receiving R&D approval on 13th August 
2012 from the Thames Valley Primary Care Research Partnership (Appendix 5).  
 
Statistical analyses 
Statistical analyses were performed according to a Data Analysis Plan (Appendix 4) 
agreed by the trial Steering Committee prior to any unblinding of study results.17 
The primary efficacy assessment for the main BEST-D trial was an “intention-to-
treat” analysis among all randomised participants of daily supplementation with 
vitamin D3 4000 IU vs vitamin D3 2000 IU on the proportion of individuals with 
levels of 25(OH)D above 90 nmol/L at the end 1 year. A co-primary endpoint was 
the difference between those allocated 4000 IU versus 2000 IU daily in the mean 
25(OH)D levels at the study end. If a 12-month value was not available, the 6-month 
value was used.  
BEST-D trial 
The main objective of the BEST-D trial was to find the dose of vitamin D3, that 
would achieve a 25(OH)D level of more than 90 nmol/L in at least 90% of the 
participants in the treatment arm. With 100 participants in each group, there was 
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>99% power at 2p<0.01 to detect a difference in the proportion of participants with 
a 12 month 25(OH)D level >90 nmol/L between those allocated 4000 IU and 2000 
IU daily. With 100 in each treatment group any common adverse effects from 
administering high daily doses would have become apparent (i.e. the trial should be 
able to detect adverse events that have a 1% chance of occurring every year).  
 
Power to detect effects on blood pressure and arterial stiffness  
Developing a sample size and power calculation for the evaluation of blood 
pressure and arterial stiffness effects was not possible, as it was difficult to estimate 
differences with treatment as there was hardly any data for a similar vitamin D trial 
to compare at that time. However, we calculated that based on assumptions that if 
the trial were to detect a 10% difference in systolic blood pressure (and/or pulse 
wave velocity) from baseline values, at least 70 participants would need to be in the 
vitamin D treatment arm and placebo arms respectively, to have a >90% power to 
detect this change (α 0.05). The current trial design would therefore have had 
sufficient power, even when reasonable adjustments for adherence and attrition 
were to be taken into account. Finally, the VitDish trial recruited fewer than 200 
participants in a contemporary trial of vitamin D therapy,177 and many other trials 
evaluating effects on blood pressure included even fewer participants. The current 
study would be the largest and longest study to test the effects of taking either 
2000 IU or 4000 IU vitamin D daily, on arterial stiffness. 
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Allowance for multiple comparisons 
No allowance was made for multiple comparisons in the assessment of the primary 
endpoints and a two sided p value of <0.05 was considered significant. For the 
secondary and tertiary analyses, allowance was made in their interpretation for 
multiple hypotheses testing taking into account, if relevant, the type of measure 
and evidence from other studies. But, the more extreme the p-value (or, 
analogously, the further the lower limit of the confidence interval is from zero) 
after any allowance has been made for the nature of the particular comparison, the 
more reliable the comparison and, hence, the more definite any finding was 
considered to be. Data are presented as means and SD. Differences between the 
paired measures at baseline and 12 months were compared using t-tests. 
 
Study treatment 
Participants were randomly allocated to receive either 4000 IU or 2000 IU vitamin 
D3 or matching placebo daily in a double-blind manner. The nurse telephoned 
CTSU, and provided relevant details (as a summary code generated by the 
computer program) which was used in a minimisation algorithm balanced for age 
group (<70, 70 to <75, ≥75 years), gender, smoking history (current versus ex or 
non-smoker), ethnicity (Caucasian vs non-Caucasian), BMI (<25, 25 to <30, ≥30 
kg/m2) and history of fracture (yes, no) to allocate participants to one of the three 
treatment arms. The allocation to treatment was also conveyed as an electronic 
code (blinded), which when entered into the bespoke BEST-D software (Edgehill) in 
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the laptop, was used to allocate treatment from the supplies carried by the nurse 
(through an in-built treatment dispensing module of the programme). 
 
Participants were given two treatment containers labelled differently, and asked to 
take one capsule from each container. Each container contained 210 capsules of 
either vitamin D3 (2000 IU) or placebo, sufficient to last 7 months. The varying 
combination of these containers facilitated appropriate treatment allocations in the 
three arms. The soft gel capsules were provided free of charge by Tischcon 
Corporation, Westbury, New York, USA. They were packaged in child-proof 
containers by Bilcare GCS (Europe) Ltd. The study nurses were responsible for 
appropriate storage, dispensing and documented disposal of unused and returned 
medications. 
 
Assessment of adherence with treatment 
Treatment adherence was evaluated by the study nurse at the 6 and 12 month 
follow-up by indicating whether the participant had taken Most, Some, Very little or 
none of the study treatment. The participants were also asked if they had missed 
any treatment in the last 7 days and to indicate how many days of treatment were 
missed. Biochemical safety was evaluated by the effects of vitamin D3 supplements 
on plasma PTH, calcium and phosphate levels. 
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Blood samples 
Blood collection 
Blood samples were collected into a 10ml EDTA tube and a 10 ml Lithium Heparin 
tube. In addition samples were collected at baseline and 12 months for future 
mRNA and DNA analyses. All participants with hypercalcaemia at baseline were 
excluded. 
 
Blood transport 
Samples were transported in an ice-cooled ‘blood sample box’ prepared with ice 
packs, and taken to the Horton Hospital Clinical Chemistry laboratory. The plasma 
samples were centrifuged for 10 minutes at 1200g before being fractionated into 
aliquots and stored in a -80ºC freezer. Samples were shipped periodically by courier 
using dry ice and with appropriate precautions for handling clinical hazardous 
materials, to the Wolfson laboratory in CTSU, Oxford for long-term storage and 
future analyses. 
Assays  
Blood was sent for assays as outlined in the protocol (Appendix 3). Only the 
relevant results of plasma 25(OH)D concentrations, as a response to vitamin D3 
supplements, are included in this thesis. 
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Safety monitoring 
Vitamin D toxicity  
Vitamin D toxicity could cause hypercalcaemia which may present with symptoms 
such as constipation, diarrhea, decreased appetite (anorexia), dehydration, 
polyuria, thirst, vertigo, fatigue, bone pain, muscle weakness, irritability, abdominal 
pain, nausea, vomiting, mental confusion, impaired renal function, kidney stones, 
and cardiac arrhythmias.273 However, there are no recognized adverse effects 
associated with 25(OH)D levels below 240 nmol/L92, 274 and previous reports of 
vitamin D toxicity with elevated serum calcium have only been observed with very 
high intake of vitamin D ≥ 40000 IU (1000 μg) a day and at blood 25(OH)D levels > 
200-300 nmol/L. 
 
Adverse events  
Non-serious adverse events 
Only adverse events not thought to be serious or related to the study treatment, 
but resulting in the participants stopping treatment were recorded at each follow-
up as non-serious adverse events. All other non-serious adverse events were not 
recorded as such events are common in this age group, and analysis of such events 
is unlikely to yield any useful information. 
 
Serious Adverse Events 
Serious Adverse Events (SAE) were any adverse events that were thought to be 
serious (causing death, disability, or hospitalization), and were recorded and 
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reported to regulatory authorities as appropriate via the annual Drug Safety Update 
Report (DSUR). Serious adverse events were defined as those adverse events that:  
- resulted in death;  
- were life-threatening;  
- required in-patient hospitalization or prolongation of existing 
hospitalization;  
- resulted in persistent or significant disability or incapacity;  
- resulted in congenital anomaly or birth defect; 
- were important medical events in the opinion of the responsible 
investigator including, for the present study hypercalcaemia, kidney 
stones and cancer. The normal serum calcium levels were considered to 
be between 2.15-2.55 mmol/L, based on laboratory reference ranges. 
 
The clinical investigator team had to ensure that all serious adverse events were 
reviewed as soon as possible and was classified as either ‘related’ or ‘unrelated’ to 
study treatment. 
 
Safety Data Monitor 
Any suspected serious adverse reactions (SSAR) were to be reviewed by the 
independent Safety Data Monitor (Professor Colin Baigent, CTSU, University of 
Oxford) who was responsible for making relevant recommendations to the Steering 
Committee after review.  
  BEST-D trial outline and methods 
142 
Data collection 
All data collected were recorded in electronic format on bespoke trial software 
(called Edgehill) developed by the CTSU IT team and the clinicians. The study 
laptops used by the study nurses were securely encrypted. Stored data were 
periodically backed-up electronically to the CTSU servers at University of Oxford.  
 
Study procedures and training 
The study team members were fully trained on all aspects of the trial. I was 
responsible for the design, creation and delivery of the training sessions for BEST-D 
trial procedures. The training sessions were held at CTSU, University of Oxford 
(Richard Doll Building, Roosevelt Drive). Training was provided at the start and 
before every phase of the study (e.g. 6 month visit, final visit etc). Training included 
presentations, printed training materials, relevant SOPs, training in laboratory 
methods, and hands-on training of trial equipment and software. If further support 
was necessary, this was provided by relevant study team members when required, 
either by phone or at the local surgery in Banbury. Contact details were also 
provided for emergency contact in case of technical or medical problems, and the 
study nurses were encouraged to be in contact as often as needed, either by email 
(bestd@ctsu.ox.ac.uk) or by telephone to the CTSU study team. 
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Conclusion 
The design of the BEST-D trial, and the state-of-the-art methods used to evaluate 
the effects of vitamin D supplements on blood pressure and arterial stiffness should 
maximize the chance of detection of beneficial effects of vitamin D on blood 
pressure and on arterial stiffness. The results of the BEST-D trial are presented in 
the next chapter. 
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Figure 5-1:  Pulse wave morphology and pulse wave analysis 
In a normal pulse wave, the first ‘forward’ or ‘propagated’ wave is caused by the contractile pushing 
force of the left ventricle. The notch marks the 'inflection point' where the reflected wave meets the 
forward systolic wave; these reflected waves arise as a result of reflections of the forward waves at 
arterial bifurcation points. The velocities of the forward and reflected waves increase when there is 
increased vessel wall stiffness. This translates into a shift of the inflection point. When arterial 
stiffness increases, the inflection point occurs earlier (shifts to the left in the diagram; it can also 
disappear entirely in extremely stiffened arteries).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reflected wave 
Forward wave 
Inflection point 
Time delay 
Time 
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Figure 5-2:  Tensiomed Arteriograph and Pulsetrace PCA II 
Arteriograph 
 
 
Pulsetrace PCA II 
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Figure 5-3:  Pulse wave analysis by the Pulsetrace PCA 2 (from device information 
leaflet) 
The calculations of the SI and RI from the pulse wave morphology are shown below. 
PPT is the time between the two peaks ‘the forward wave’ and ‘the reflected wave’. 
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Figure 5-4:  BEST-D trial outline 
 
4000 IU daily 
100 participants 
300 participants 
2000 IU daily 
100 participants 
Placebo 
100 participants 
1 month visit 6 month visit 
12 month 
Home visit 
12 month 
GP surgery visit 
12 month optional Echo test 
N = 150 
33 
33 
33 
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Table 5-1:  Comparison of different measures of arterial stiffness 
Measure Definition Formula 
Compliance The absolute change in vessel diameter for a given change in pressure dD / dP 
Distensibility The relative change in vessel wall diameter for a change in pressure dD (or dA) / dP x D 
Elastic modulus This is the inverse of distensibility dP x D / dD (or dA) 
Pulse wave velocity The speed with which the pulse wave travels between two points in a 
vessel 
L/t 
Stiffness index This is a ratio of the natural log of systolic blood pressure to diastolic 
blood pressure relative to the change in diameter 
Ln (SBP/DBP) / (D2-D1/D2) 
Young’s modulus Elastic modulus per unit area of vessel wall dP x D / dD x t 
dD – change in diameter; dP – change in blood pressure; dA – change in vessel area; L-Distance between 2 points in the vessel; t – time; Ln – natural log; D1 and D2 – initial 
diameter, and subsequent diameter.  
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Table 5-2:  Eligibility criteria for BEST-D: Patients were eligible if they meet all inclusion criteria, and if no exclusion criterion applies. 
Inclusion criteria Exclusion criteria 
- Age ≥ 65 years 
- Living in the community 
- Ambulatory 
 
- Nursing home residents 
- Regular use of vitamin D supplements with >400 IU (10 µg) vitamin D daily 
- Use of alendronate, risedronate, zoledronic acid, parathyroid hormone, or calcitonin 
- Medically diagnosed dementia 
- History of hypercalcaemia, hyperparathyroidism, lymphoma, sarcoidosis, active 
tuberculosis 
- History of renal calculus 
- Known to be poorly compliant with clinic visits or with taking medication 
- Recent history of alcohol or substance misuse or abuse 
- Medical history that might limit the ability of the subject to take the study treatment for 
the duration of the study (e.g. terminal illness) 
- Regular prescribed calcium supplements. 
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Table 5-3:  Summary of BEST-D trial procedures 
Month 0  
 
1  
 
6  
 
12  
Relevant medical history and  
assessment of eligibility 
X    
Informed consent if willing and eligible X    
Assessment of dietary calcium  X    
Height and weight X   X 
Blood pressure sitting, pulse wave 
velocity (brachial and digital arterial 
stiffness) 
X  X X 
Hand-grip muscle strength and muscle 
pain 
X  X X 
Assessment of fractures (no., site, date) 
and falls (no., date) 
  X X 
Geriatric Depression Score (4 point)   X X 
Heel-bone and wrist DEXA measuredπ    X 
Short Physical Performance batteryπ    X 
Blood sample taken for plasma 25(OH)D, 
PTH,* calcium, phosphate, albumin, 
alkaline phosphatase, creatinine and 
lipids† 
X X* X X 
hsCRP and nBNP and other markers of 
inflammation. 
X  X X 
Buffy coat for genetic studies X   X 
PAXgene Blood RNA tube for mRNA 
expression 
X   X 
Store plasma for future assays‡ X  X X 
Issue study treatment X  X  
Assessment of adherence   X X 
Serious adverse events and non-serious 
AEs due to study treatment cessation 
will be reported 
  X X 
*25(OH)D and PTH measured at 1 mo in a subgroup of 100 patients stratified by allocated treatment.  Only blood 
collection will be carried out at the 1 month.† Lipid profile includes total cholesterol, LDL-C, HDL-C, triglycerides, 
apolipoprotein A, apolipoprotein B. 
‡ Plasma stored for assays of bone markers, cytokines and RNA markers of inflammation (when additional funds are 
available).  25-hydroxy-vitaminD (25[OH]D); parathyroid hormone; (PTH), C-reactive protein (CRP);  n-terminal brain 
natiuretic peptide (nBNP). π All participants will be offered an appointment for these assessment to be done at the 
Hightown Surgery. 
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Table 5-4:  Secondary and Tertiary outcomes in BEST-D 
 
Secondary outcomes 
 
All secondary assessments will involve “intention-to-treat” analyses among all randomised subjects of the effects of daily supplementation with vitamin D3 100µg vs 
placebo, vitamin D3 50µg vs placebo, and the difference between the two doses of vitamin D on: 
(i) Mean blood levels of 25(OH)D during follow-up. 
(ii) The proportions of participants with blood 25(OH)D levels >90 nmol/L at the 6 and 12 month visits. 
(iii) The proportion of participants with PTH levels suppressed into the normal range (1.1-6.8 pmol/L) at the 6 and 12 month visits. 
(iv) The proportion of participants with calcium levels above the normal range (2.15-2.55 mmol/L) at the 6 and 12 month visits. 
(v) Other laboratory tests of safety: phosphate, albumin, creatinine, alkaline phosphatase. 
(vi) The changes from baseline in hsCRP, creatinine, nBNP, inflammatory cytokines (e.g. IL5, IL6, IL1β, IFNγ and TNFα) at 6 and 12 month visits, and mRNA 
expression markers of innate immunity at baseline and 12 month visits. 
(vii)  The difference in the changes from baseline in diastolic and systolic blood pressure, heart rate and arterial stiffness at 6 and 12 months. 
(viii) The difference in the changes from baseline in total cholesterol, LDL-C, HDL-C, triglycerides, apo-B and apo-A at 12 months. 
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Tertiary outcomes 
 
All tertiary assessments will involve intention-to-treat analyses among all randomised participants of daily dietary supplementation with vitamin D3 100µg vs placebo, 
vitamin D3 50µg vs placebo, and the difference between the two doses of vitamin D on: 
(i) The number of reported fractures at all sites, and at specific sites, during the 12 month treatment period. 
(ii) The number of reported falls during the treatment period. 
(iii) The change from baseline in muscle strength, and the differences between groups in physical performance and balance (assessed by the short physical 
performance battery) at 12 months. 
(iv) Differences in heel-bone and wrist DEXA between treatment groups at 12 months. 
(v) The change from baseline in vascular stiffness at 6 and 12 months. 
(vi) The differences in short version Geriatric Depression Scale (GDS) scores 
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Chapter 6 :  Effects of vitamin D on blood pressure and arterial stiffness  
Results 
Recruitment of study participants 
Among the registered patients at the practice, 932 were invited to participate, 313 (33%) 
agreed and were offered a visit from the study nurse. Of these, 305 participants were 
randomised to take study treatment between 24 September 2012 and 14 March 2013 
(Figure 6-1). Eight participants were not randomised (6 opted out and 2 were ineligible). All 
6 month visits were completed by September 2013. The final study visit for the last 
participant was held on 10 March 2014. Among the surviving participants, 296 completed a 
6-month visit, and 290 completed the final 12-month visit.  
 
Baseline characteristics of randomised participants 
Among the 305 participants, the mean (SD) age was 72 (6) years and 55% were aged 70 
years or older (Table 6-1). About 51% were men overall with almost equal proportion of 
men in each of the treatment groups. About 20% had a prior history of CVD, 9% had 
diabetes and 39% had hypertension. About half of participants were prescribed blood 
pressure lowering drugs and about a quarter took statin therapy. Routine use of calcium 
was low and over-the-counter vitamin D supplements were taken by a tenth of the 
participants. The baseline characteristics of the participants were similar across the three 
treatment arms for age, baseline systolic and diastolic blood pressure and BMI. Background 
history of hypertension and the use of anti-hypertensive medications were more common 
among those taking 2000 IU daily.   
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Adherence within treatment and completeness of data at 6 months 
The final follow-up visits were completed in 98% of the participants (Table 6-2) overall and 
in over 97% of participants within each of the treatment arms at 6 months (Figure 6.2). 
More than 85% of participants took their study treatment ‘every day’ or on ‘most days’ in 
the trial indicating good adherence.  
 
Blood pressure data were available for 98% of all participants, but arterial stiffness data 
from the Arteriograph and Pulsetrace were only available in about 80% of the participants 
(due to technical and logistical reasons) and with broadly similar proportions of missing 
readings between treatment arms. Readings were available in 81%, 88% and 89% 
participants in the 4000 IU, 2000 IU and placebo groups, respectively. Pulsetrace PCA 
readings were available in 75%, 80% and 78% of participants taking 4000 IU, 2000 IU or 
placebo, respectively.  
 
No adverse events for hypercalcaemia, hypercalciuria or renal stones were reported in any 
of the treatment groups. There were no significant differences in adverse events reported 
between groups, but all 3 deaths recorded in the trial were in the placebo group. More 
participants in the 4000 IU daily group reported infections but CVD events were 
comparable. 
 
Plasma 25(OH)D levels and key variables at baseline 
The mean (SD) baseline plasma 25(OH)D concentrations for all participants was 50.4 (17.5) 
nmol/L. Plasma concentrations of 25(OH)D were weakly correlated with physical activity 
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scores (self-reported physical activity on a scale of 1-10, 10 being for most active) and 
inversely correlated with weight and body mass index (Table 6-3) as may be expected with 
higher fat content. Baseline PWVao were weakly positively correlated with age, blood 
pressure (both systolic and diastolic) and with augmentation index, but not with the 
Pulsetrace measures (SI or RI) or with heart rate.  
 
Effects of vitamin D treatment on plasma 25(OH)D concentrations  
In the analysis of plasma 25(OH)D concentrations in the randomly selected 100 participants 
(Figure 6-2), 72% taking 4000 IU daily had a concentration >90 nmol/L, compared to 26% in 
those taking 2000 IU daily (9% among those taking placebo) after 1 month of treatment. 
After 6 months of taking treatment, mean (SD) 25(OH)D concentrations were 125 nmol/L, 
100 (45) nmol/L, and 52.5 nmol/L among those allocated 4000 IU vitamin D3, 2000 IU 
vitamin D3, and placebo, respectively (Table 6-4). By the end of 12 months, mean plasma 
concentrations were 137 nmol/L and 102 nmol/L, respectively for those taking 4000 IU and 
2000 IU daily compared to 53 nmol/L for those on placebo. This meant that while 88% of 
participants achieved >90 nmol/L among those who took 4000 IU daily, only 77% achieved 
these levels at the end of 12 months among those taking 2000 IU daily. There were no 
differences in adverse events, and there no events reported of significant hypercalcaemia, 
hypercalciuria or renal stones. The mean plasma concentrations of calcium and PTH were 
within normal ranges at the end of study (Figure 6-2). 
 
After 12 months of treatment among those allocated 4000 IU, 2000 IU or placebo, 88%, 70% 
and 1%, respectively, achieved a 25(OH)D level >90 nmol/L at 12 months (p<0.0001 
  Vitamin D, blood pressure and arterial stiffness  
157 
comparing 4000 IU daily versus placebo, comparing 2000 IU daily versus placebo, and for 
comparing 2000 IU daily versus 4000 IU). At 6 months, 86%, 64% and 2% respectively, 
achieved 25(OH)D >90nmol/L (p<0.0001 comparing 4000 IU daily versus placebo, comparing 
2000 IU daily versus placebo, and p<0.0003 comparing 2000 IU daily versus 4000 IU). In 
addition, with 100 patients randomised in each group, the trial had >90% power at 2p=0.05 
and ~80% power at 2p=0.01 to detect an increase in the proportion achieving a 12-month 
25(OH)D concentration >90 nmol/L from 70% among those allocated 2000 IU daily to 90% 
among those allocated 4000 IU daily.)  
 
Effects in pre-specified subgroups 
The effects of 4000 IU daily versus 2000 IU daily of vitamin D on plasma levels of 25(OH)D 
after 12 months were similar in all the pre-specified sub-groups, except when grouped by 
body mass index (BMI). The absolute difference in achieved plasma 25(OH)D levels between 
the two active doses was significantly smaller among those with higher baseline BMI (Figure 
6-3: p for trend <0.0001). The effects of 4000 IU versus 2000 IU dose of vitamin D on plasma 
levels of 25(OH)D were attenuated by one-third in those who were overweight and by two-
thirds in those who were obese, compared to those with normal BMI. In a post-hoc analysis 
of the effects of 2000 IU vitamin D versus placebo alone, no differences in plasma 25(OH)D 
was found in any sub-group. The differences in plasma levels of 25(OH)D at 6 and 12 months 
between those allocated 4000 IU versus 2000 IU daily and versus placebo were broadly 
similar when assessed by quartiles of baseline plasma 25(OH)D levels (Table 6-5). 
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Effects of treatment on blood pressure and heart rate after 6 months 
At the start of the study, the mean (SD) systolic blood pressure was 130.7 (19.2) mm Hg and 
the diastolic blood pressure was 76.5 (10.9) mm Hg in the randomised participants. While 
mean blood pressure was (Table 6-6) lower at 6 months compared to 12 months across all 
groups, there were no significant differences in final blood pressure or heart rate recorded 
at 6 and 12 months in any of the treatment groups. No differences in blood pressure or 
heart rate were identified when comparing those allocated vitamin D3 (either dose) or 
placebo, or between each of the allocated treatment arms. 
 
Effects on arterial stiffness by Arteriograph measurement 
Baseline mean (SD) PWVao was 9.7 (2)m/s and Aix was 35.4 (15) among participants in the 
placebo group. There were no significant differences in PWVao between those allocated to 
either of the vitamin D treatment groups or placebo after 6 months of treatment (Table 
6-6), but Pulsewave velocity was found to be significantly higher in those taking 4000 IU 
daily compared to placebo. However, there were no differences in PWVao between those 
taking 2000 IU daily and those taking placebo, and no differences in effects between the 
two vitamin D treatment groups. 
 
Effects on arterial stiffness by Pulsetrace PCA measurements 
Baseline values for mean SI was 9.5 (3) and for RI was 66.9 (12) in the placebo group. There 
were no significant changes or consistent trends observed in both these indices (Table 6-6), 
either within each treatment arm, or between treatment groups after 12 months of taking 
vitamin D treatment.   
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Effects of vitamin D by sub-groups 
No effects of taking either dose of vitamin D for 1 year was found on systolic blood pressure 
(Table 6-7) in any sub-group when analysed by tertiles of baseline plasma 25(OH)D 
concentrations, systolic blood pressure or age as recorded at randomisation. There were no 
effects on blood pressure for taking vitamin D supplements, among those reporting not 
using anti-hypertensive medications at randomisation. No effects were found when 
stratifying this group by tertiles of systolic blood pressure at randomisation either. 
 
Among those with plasma 25(OH)D concentrations >55 nmol/L (top tertile), PWVao 
increased with vitamin D intake, but the differences between treatment groups did not 
reach statistical significance. When all participants were grouped by tertiles of age, those in 
the lowest tertile at randomisation had significantly higher PWVao at 12 months, if they 
were allocated to any vitamin D treatment (Table 6-7).  
 
Among those not taking anti-hypertensive medications at randomisation, taking any vitamin 
D dose was associated with an increase in PWVao in all groups but these differences did not 
reach statistical significance. However, PWVao was significantly higher with vitamin D 
treatment among those in the lowest tertiles for age and systolic blood pressure at 
randomisation.  
 
For Pulsetrace derived measures of arterial stiffness (RI and SI), no differences between 
treatment groups were identified, nor any consistent trends on the analysis by the above 
sub-groups. 
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Conclusions 
In the BEST-D trial, where there was good adherence and tolerability of treatment, and 
dietary supplementation with vitamin D3 for 12 months significantly raised plasma 25(OH)D 
concentrations to greater than 90 nmol/L with no clinically evident adverse events or 
biochemical hazards associated with the intake. Moreover, supplementation with the two 
doses of vitamin D did not alter blood pressure or heart rate when compared to placebo, 
but appeared to increase pulsewave velocity albeit the effects did not reach statistical 
significance. Overall, the BEST-D study had limited power to detect significant effects of 
vitamin D on blood pressure and on arterial stiffness. Future work may involve pooling 
results from BEST-D with other similar trials of vitamin D to confirm or refute the results of 
BEST-D. 
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Figure 6-1:  Recruitment of participants in to the BEST-D trial 
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Figure 6-2:  Effect of vitamin D allocation on mean plasma 25(OH)D, intact PTH and 
albumin-corrected calcium 
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Figure 6-3: Effect of vitamin D allocation on mean plasma 25(OH)D levels by baseline sub-
groups 
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Table 6-1: Baseline characteristics of participants in the BEST-D trial 
Mean (SD) or n, % Allocated Treatment 
100µg D3 
(4000 IU 
50µg D3 
(2000 IU) 
Placebo Combined 
Number randomised 
102 102 101 305 
Age -  Mean (SD) 71.8 ( 5.5 ) 72.3 ( 6.1 ) 72.1 ( 5.6 ) 72.1 ( 5.7 ) 
Male - n (%) 52 (51%) 52 (51.0%) 52 (52%) 156 (51%) 
Current Smoker - n (%) 7 (7%) 7 (7%) 7 (7%) 21 (7%) 
Prior disease     
IHD* - n (%) 20 (20%) 11 (11%) 11 (11%) 42 (14%) 
Stroke/TIA** - n (%) 5 (5%) 8 (8%) 6 (6%) 19 (6%) 
Hypertension - n (%) 40 (39%) 44 (43%) 35 (35%) 119 (39%) 
Diabetes - n (%) 9 (9%) 9 (9%) 9 (9%) 27 (9%) 
Medication      
Anti-hypertensive - n (%) 44 (43%) 50 (49%) 40 (40%) 134 (44%) 
Statins - n (%) 30 (29%) 27 (27%) 21 (21%) 78 (26%) 
Anti-platelets - n (%) 18 (18%) 19 (19%) 15 (15%) 52 (17%) 
Vitamin D (<400 IU/d) - n (%) 6 (6%) 8 (8%) 11 (11%) 25 (8%) 
Calcium - n (%) 2 (2%) 1 (1%) 3 (3%) 6 (2%) 
Physical measurements     
Height ,cm 167 ( 10.0 ) 168 ( 9.8 ) 167 ( 10.1 ) 167 ( 10.0 ) 
Weight, Kg 76.8 ( 17.1 ) 77.7 ( 15.2 ) 78.6 ( 14.9 ) 77.7 ( 15.8 ) 
BMI ,Kg/m2 27.2 ( 4.7 ) 27.4 ( 4.1 ) 28.0 ( 4.6 ) 27.5 ( 4.5 ) 
Systolic blood pressure, 
mmHg 
132 ( 22 ) 132 ( 17 ) 129 ( 18 ) 131 ( 19 ) 
Diastolic blood pressure, 
mmHg 
77 ( 11 ) 77 ( 10 ) 76 ( 11.5 ) 77 ( 11 ) 
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Table 6-2:  Completed assessments, adherence and adverse events at 12 months of follow-
up in the BEST-D trial  
 Arm 1 
(4000 IU) 
N = 102 
Arm 2 
(2000 IU) 
N= 102 
Placebo 
 
N = 101 
Number of completed 
follow-up visits at 12 months 
98 100 98 
Number of completed 
vascular measures 
   
Blood pressure, n  
 
98 100 98 
Missing data    
Arteriograph,  % 19 12 11 
Pulsetrace, % 
 
25 20 22 
Adherence†, (%)    
Everyday 64 74 69 
Most 26 18 16 
Seldom/never 
Unknown 
 
5 
5 
5 
4 
9 
6 
Adverse Events 29 30 25 
CVD 3 2 2 
Infections 10 5 6 
Deaths 0 0 3 
    
    
†Adherence was recorded as ‘most’ if <30 days treatment was missed, and as ‘seldom or none’ if <30 days 
treatment was taken. Counts are of the number of patients experiencing at least one event of the given type. 
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Table 6-3:  Correlation between variables of interest in the BEST-D trial at baseline 
 Age Plasma 
25(OH)D 
Height Weight BMI SBP DBP HR PWVao Aix* SI* RI* PPT Physical 
activity 
Age 1 -0.06 -0.16 -0.08 0.04 0.09 -0.17 -0.02 0.13 0.09 -0.06 -0.03 0.06 -0.21 
25(OH)D -0.06 1 0.05 -0.14 -0.22 -0.02 0.02 -0.03 -0.06 0.03 0.01 0.04 -0.01 0.18 
Height -0.16 0.05 1 0.60 0.00 -0.05 0.15 -0.12 -0.05 -0.37 0.35 0.21 -0.08 0.02 
Weight -0.08 -0.14 0.60 1 0.80 0.08 0.24 0.01 0.05 -0.31 0.26 0.15 -0.11 -0.26 
BMI 0.04 -0.22 0.00 0.80 1 0.13 0.18 0.10 0.09 -0.14 0.06 0.03 -0.08 -0.34 
SBP 0.09 -0.02 -0.05 0.08 0.13 1 0.78 -0.08 0.21 0.43 0.16 0.17 -0.13 -0.06 
DBP -0.17 0.02 0.15 0.24 0.18 0.78 1 -0.02 0.20 0.32 0.26 0.25 -0.20 0.04 
HR -0.02 -0.03 -0.12 0.01 0.10 -0.08 -0.02 1 0.11 -0.46 0.05 -0.36 -0.16 0.02 
PWVao 0.13 -0.06 -0.05 0.05 0.09 0.21 0.20 0.11 1 0.28 0.01 -0.08 0.01 -0.05 
AIxao* 0.09 0.03 -0.37 -0.31 -0.14 0.43 0.32 -0.46 0.28 1 -0.13 0.07 0.06 0.04 
SI* -0.06 0.01 0.35 0.26 0.06 0.16 0.26 0.05 0.01 -0.13 1 0.67 -0.86 0.02 
RI* -0.03 0.04 0.21 0.15 0.03 0.17 0.25 -0.36 -0.08 0.07 0.67 1 -0.62 0.03 
PPT 0.06 -0.01 -0.08 -0.11 -0.08 -0.13 -0.20 -0.16 0.01 0.06 -0.86 -0.62 1 -0.01 
PA -0.21 0.18 0.02 -0.26 -0.34 -0.06 0.04 0.02 -0.05 0.04 0.02 0.03 -0.01 1 
25(OH)D = plasma 25 hydrox-vitamin D3; SBP= Systolic blood pressure; DBP = diastolic blood pressure; BMI=body mass index; HR = heart rate; PWVao = Pulsewave velocity 
(aortic); AIxao = Augmentation index (aortic); SI = Stiffness index; RI = reflective index; PPT = Peak to peak time. * indicates indices.PA= Physical activity was a self-reported 
score based on a visual analog scale of 1-10, with ‘1’ being inactive and ‘10’ being very active. 
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Table 6-4: Effect of vitamin D on mean (SE) plasma levels of 25(OH)D, iPTH, albumin-
corrected calcium and alkaline phosphatase 
 
 
4000 IU/day 
(n=102) 
2000 IU/day 
(n=102) 
Placebo 
(n=101) P
1
 P
2
 P
3
 
 
Plasma 25(OH)D, nmol/L       
Baseline 49 (1.5) 55 (2.2) 47 (1.5) - - - 
1 month 81 (1.9) 69 (1.8) 49 (1.9) <0.0001 <0.0001 <0.0001 
6 months 126 (2.4) 97 (2.4) 55 (2.4) <0.0001 <0.0001 <0.0001 
12 months 137 (2.4) 102 (2.4) 53 (2.4) <0.0001 <0.0001 <0.0001 
 
Plasma iPTH, pmol/L       
Baseline 3.93 (0.193) 3.86 (0.148) 3.76 (0.157) - - - 
6 months 2.98 (0.070) 3.25 (0.076) 3.91 (0.093) <0.0001 <0.0001 0.0092 
12 months 3.05 (0.080) 3.31 (0.087) 3.82 (0.100) <0.0001 0.0001 0.0283 
 
Plasma albumin-corrected  
calcium, mmol/L       
Baseline 2.33 (0.012) 2.33 (0.008) 2.32 (0.007) - - - 
6 months 2.36 (0.006) 2.35 (0.006) 2.32 (0.006) <0.0001 <0.0001 0.05 
12 months 2.36 (0.006) 2.34 (0.006) 2.32 (0.006) <0.0001 0.0106 0.0386 
 
Plasma alkaline  
phosphatase, IU/L       
Baseline 58 (1.7) 61 (1.6) 59 (1.9) - - - 
6 months 57 (0.7) 58 (0.7) 59 (0.7) 0.0247 0.13 0.46 
12 months 60 (0.9) 60 (1.0) 60 (1.0) 0.99 1.00 0.98 
 
Arithmetic mean (SE) shown for 25(OH)D and albumin-corrected calcium and geometric mean (approximate SE)  
shown for iPTH and alkaline phosphatase. Means at 1, 6 and 12 months are adjusted for the baseline values,  
with missing data imputed using multiple imputation. Mean iPTH and albumin-corrected calcium levels were not  
pre-specified outcomes. 
 
1
 P-value comparing 4000 IU daily versus placebo.  
 
2
 P-value comparing 2000 IU daily versus placebo.  
 
3
 P-value comparing 4000 versus 2000 IU daily.  
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Table 6-5:  Effect of vitamin D on plasma 25(OH)D concentrations at 6 and 12 months,  
by baseline quartiles of 25(OH)D 
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Table 6-6:  The effects of allocation to vitamin D supplementation on plasma 25(OH)D, 
blood pressure, heart rate and arterial stiffness after 6 and 12months of follow-up 
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Table 6-7:  Effects of vitamin D3 on blood pressure and arterial stiffness by baseline 
characteristics  
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Effects of vitamin D3 on blood pressure and arterial stiffness by baseline characteristics  
(cont…) 
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Chapter 7:  Analyses and Conclusion 
Introduction  
In this thesis, I explored the role of low vitamin D in the aetiology of CVD, by 
reviewing the observational studies and clinical trials of vitamin D and CVD 
outcomes, including evaluating causality of these associations. In the Whitehall 
prospective study, baseline plasma 25(OH)D concentrations and their relationships 
with cause-specific mortality was examined and found inverse log-linear 
associations. The meta-analyses of prospective studies included the findings from 
Whitehall, where the ‘optimal levels’ of plasma 25(OH)D concentrations for the 
lowest risks of CVD was observed to be around 80-90 nmol/L. The thesis reported 
on the outline and design of the BEST-D trial, a dose-finding study that compared 
the effects of two higher doses of vitamin D (2000 IU and 4000 IU daily) on 
biochemical outcomes in older people for one year, and helped identify the 
optimum dose of vitamin D supplement to test in a future large trial evaluating 
effects on CVD and other disease outcomes. There were no statistically significant 
effects of supplementation with vitamin D3 on blood pressure (a cardiovascular risk 
factor) and on arterial stiffness (a surrogate marker of CVD) in the trial of older 
people (BEST-D) after 1 year.  
 
Key aims of the thesis 
The key aims of this thesis were to review the evidence from prospective studies of 
vitamin D and CVD, and the effects of supplementation with vitamin D in 
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randomised-controlled trials on CVD outcomes. Another aim was to describe the 
outline and design of a dose-finding trial of vitamin D to determine the optimum 
dose of vitamin D3 to be used in a future trial evaluating effects on fracture, CVD 
and other disease outcomes. The final aim was to report the effects of 2 daily doses 
of vitamin D3 (2000 IU and 4000 IU daily), on blood pressure (CVD risk marker) and 
arterial stiffness (surrogate marker for CVD) when compared to placebo.  
 
Low vitamin D status and CVD 
The review of prospective studies of vitamin D demonstrated that low vitamin D 
was widely prevalent and optimal levels of plasma 25(OH)D for CVD outcomes was 
unknown. Most studies reported inverse associations between measured 25(OH)D 
concentrations at baseline and CVD outcomes including mortality, but many studies 
had few participants, and had inconsistent methodology of reporting and analysis 
of results. Hence there was still uncertainty whether these reported associations 
could be due to the effects of reverse causality or due to residual confounding. The 
shape and size of these associations were unclear and the plasma concentrations 
associated with the lowest risks for CVD mortality were not identified. Further, it 
was also possible that plasma 25(OH)D concentration was a marker of frailty and 
that these associations were simply coincidental and not causal.  
 
  Analyses and Conclusion 
175 
Whitehall study: Key findings 
Inverse associations of plasma 25(OH)D with CVD and non-CVD causes of 
mortality 
The Whitehall resurvey of 5409 older British men included 3215 deaths and was 
one of the largest and longest prospective studies at the time that examined the 
associations of baseline 25(OH)D with cause-specific mortality, and showed an 
approximately log-linear inverse association of plasma 25(OH)D concentrations with 
both CVD and non-CVD causes of mortality within the range of 30 to 90 nmol/L 
(Chapter 3). After adjustment for age, season, prior disease, markers of health and 
frailty, and other cardiovascular risk factors, a 2-fold higher plasma concentration of 
25(OH)D was associated with one fifth lower risk of CVD mortality (20% lower CVD 
mortality; 23% lower risks for non-vascular mortality). The change in the Chi-
squared statistic after adjustment for established risk factors would suggest that it 
is possible that these associations may reflect incomplete adjustment for 
established risk factors that were measured imprecisely, or for unknown risk factors 
that may not have been measured. However, the shape and strength of these 
associations were broadly similar among men with and without prior disease 
(defined as those with vascular disease, cancer or diabetes) as reported at baseline 
and the associations persisted after excluding deaths during the first five years of 
follow-up, another method for minimising the effects of reverse causation, and is 
similar to those that other studies detected.59, 197 
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It is possible that low vitamin D status could reflect frailty and that low plasma 
concentrations of 25(OH)D may simply reflect a sicker population with one or more 
co-morbidities with associated higher risks of death. As plasma 25(OH)D 
concentrations are lower in those who have low physical activity and in those who 
are obese, the associations with CVD may be due to confounding by these 
covariates. However, in the Whitehall study, excluding the deaths after 5 years of 
blood collection did not attenuate these associations, nor did the adjustment for 
self-reported health or frailty. In another prospective analysis by Dobnig et al, in 
those with low to average physical activity, low plasma 25(OH)D concentrations 
were associated with higher risks of CVD deaths.197, 275 
 
Meta-analyses of prospective studies of vitamin D 
We compared the findings from the Whitehall resurvey, which included only older 
men living in the UK, to those from other prospective studies that reported on CVD 
and all-cause mortality to evaluate consistency. The meta-analyses of prospective 
studies of 25(OH)D included about 4600 CVD deaths, and over 11,700 deaths from 
all causes. These meta-analyses confirmed a consistent trend in the inverse 
associations of plasma 25(OH)D concentrations with CVD mortality and with all-
cause mortality. Individuals in the top vs. bottom quarter of 25(OH)D 
concentrations had 21% (95% CI: 13–28%) lower CVD mortality and 28% (95% CI: 
24–32%) lower all-cause mortality. Although there was a significant trend in the 
effect size reported by study when studies were ordered by size, consistent with 
publication bias (where smaller studies tend to report more extreme findings), 
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other meta-analyses including one which examined individual participant-level data 
found similar inverse associations between baseline 25(OH)D and both CVD and all-
cause mortality.275 At the time, this report was one of the first meta-analyses of 
plasma 25(OH)D concentrations and all-cause and cardiovascular mortality.276 
 
When the published findings from studies that enrolled only women were 
compared with those that recruited men alone, the relative risks of all-cause 
mortality were greater in women with lower plasma 25(OH)D concentrations 
compared to those on the top quartile (Chapter 3). Women tend to have lower 
mean plasma 25(OH)D concentrations attributed mainly to their relatively higher 
body fat content, and hence the inverse associations of 25(OH)D with disease may 
be more pronounced in women. There is less clarity as to whether the low plasma 
25(OH)D concentrations from being female or obese, indicate increased risks of 
mortality, as optimal concentrations could be lower in such groups; but this will 
need testing in a future trial.277  
 
Optimal levels of plasma 25(OH)D concentration for CVD 
From the Whitehall resurvey and the meta-analysis of prospective studies, the 
lowest risks for CVD mortality were observed at plasma 25(OH)D concentrations 
between 80-90 nmol/L, which appear to indicate the optimal plasma 
concentrations for CVD and be the potential target plasma concentrations to 
achieve in a future larger trial of vitamin D supplements for prevention of CVD and 
other disease outcomes. These are broadly consistent with other analyses 
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published since,275, 278 and in line with recommendations for optimal plasma 
25(OH)D concentrations (>75 nmol/L) for other health outcomes.53 Some 
prospective studies have reported a possible J-shaped or curvilinear association of 
baseline 25(OH)D concentrations with all-cause and CVD mortality107, 143, 275 
especially when plasma 25(OH)D concentrations were higher than 120 nmol/L.140, 
141 The number of participants with such high concentrations in most meta-analyses 
were small,141, 275, 279 and these findings warrant further testing in large clinical 
trials. We were unable to confirm or refute these findings in the Whitehall study, 
again due to the limited number of participants with plasma 25(OH)D 
concentrations greater than 100-120 nmol/L. 
 
Lack of specificity of associations of 25(OH)D  
In the Whitehall study, given age, a doubling in 25(OH)D concentration (on the log-
scale) was associated with almost a third lower risk of CVD mortality and with a 
similar lower risk for non-vascular mortality. The relative risks for CVD and all-cause 
mortality between top versus bottom quartiles reported in other meta-analyses 
were generally higher than those reported in this study,142, 275, 278 but the similarities 
in the shape and strength of the associations of plasma 25(OH)D concentrations 
with both CVD and non-CVD causes of death would argue against a causal 
relationship of low vitamin D with CVD by conventional statistics..  
 
Vitamin D may influence CVD through a number of mechanisms but also though 
some fundamental mechanism that may be common to different disease conditions 
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(Chapter 2 and Figure 2-2). For example, the effects of vitamin D in modulating the 
immune response could influence the pathophysiology of a diverse range of 
conditions including CVD, cancer and infection.7 Vitamin D can affect multiple 
health outcomes, as VDRE in genes influences 10% of all the genes and there is 
evidence of local metabolism of the vitamin in multiple cell types especially those 
involved with inflammation and immunity. Alternatively, the effects of vitamin D on 
CVD may be mediated through mechanisms that are independent of known 
cardiovascular risk factors, and hitherto unidentified. Hence, the lack of specificity 
could be consistent with the biological actions of the vitamin and may not 
necessarily exclude causality.  
 
Limitations of the Whitehall study and meta-analyses 
Among the limitations of the Whitehall study, data on prior disease, health status 
and physical activity at re-survey were self-reported. Hence, while the strength of 
the associations was attenuated substantially after adjustment for these measures, 
it is possible that residual confounding by poor health status may have persisted 
despite the efforts to minimise the effects of it. Formal assessment of physical 
activity was not made at baseline, but participant-reported self-rated health and 
ability to undertake activities of daily living (based on a 15 point questionnaire) was 
used to adjust analyses. Self-reported physical activity is unreliable compared to 
more objective measures;280 other objective methods could have had an impact on 
the strengths of these associations. No data were collected on the precise time of 
day at which blood samples were collected in this study and, hence, it was not 
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possible to assess the effects of diurnal variation in plasma levels of 25(OH)D on 
disease outcomes.    
 
Any non-response bias (by preferentially excluding frail older people) should have 
minimized rather than accentuated the effects of reverse causality (Table 3-1). As 
causes of deaths were supplied by the Office of National Statistics some 
misclassification of the causes of death in this population could have occurred, 
which would dilute any real differences between the different causes of death.281 
However, most large prospective studies of vitamin D utilised a similar 
methodology for ascertaining the causes of death. 
 
Most men in the Whitehall analysis had a single baseline assessment of their 
plasma 25(OH)D concentration, but the correlation between repeated 
measurements of log plasma 25(OH)D concentration recorded in 187 men over a 
1.5 year period was 0.64. Other prospective studies have also found similar 
correlations for repeated measures of 25(OH)D concentrations, suggesting single 
measures of 25(OH)D can be utilised in prospective studies. 282, 283 Since individuals 
were classified on the basis of a single measurement of plasma 25(OH)D, it is 
possible that the true strength of the mortality associations observed with long-
term average or usual 25(OH)D concentrations may be substantially steeper. Hence, 
the mortality associations with long-term usual concentrations of 25(OH)D may be 
50% more extreme.240  
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The prospective studies of vitamin D included in the meta-analyses used differing 
assays for measuring 25(OH)D concentrations and hence the real risk reduction 
with doubling of plasma 25(OH)D, may differ to the risk reduction estimates 
described in our study. Other meta-analyses as discussed above, found greater risk 
reductions with increasing plasma 25(OH)D concentrations, and this may mean that 
the inverse associations between low vitamin D and CVD may be even greater.275 
 
Finally, a rigorous methodology for the epidemiological analysis was used in the 
Whitehall study and meta-analysis and although a number of strategies to minimise 
the effects of confounding and of reverse causality (within the limits of the study 
design) were utilised, prospective studies such as the Whitehall resurvey, are 
unable to provide conclusive proof on the causal relevance of plasma 25(OH)D 
concentrations in the development of CVD.  
 
Generalisability of Whitehall study findings 
Most men in this study were living in and around Greater London area at the time 
of blood collection. Although not representative of the wider UK population, in 
contrast to other large prospective studies, our study design would have reduced 
the likelihood of confounding by geographic factors and variations in sunshine 
exposure. The Whitehall resurvey only included older men, but when the findings 
were compared to those from other prospective studies (Table 4-2), the strength 
and shape of these associations were found to be broadly consistent with other 
studies which included participants from the general population, and with the 
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findings published in other subsequent meta-analyses. Only a handful of 
prospective studies were unable to find similar associations between 25(OH)D 
concentrations and all-cause mortality (Chapter 2, Table 2-1) but generally only 
when participants had higher mean 25(OH)D concentrations with a narrow range of 
distribution, or if they were recruited after acute events such as a heart attack.201 
 
Review of the randomised trials of vitamin D 
Need for good quality evidence on CVD outcomes 
Review of previously published trials of vitamin D showed that these trials were not 
designed to evaluate effects of vitamin D on CVD outcomes as the trials did not use 
sufficiently high enough doses of the vitamin D supplement to achieve or maintain 
‘optimal levels’ of plasma 25(OH)D. The previous trials were primarily designed to 
evaluate effects on non-CVD outcomes such as falls and fractures. Meta-analyses of 
vitamin D trials on CVD outcomes did not confirm benefits for taking vitamin D, but 
much of the data in these meta-analyses came from the WHI trial of post-
menopausal women, being the largest vitamin D trial to date (more than 36,000 
post-menopausal women), which showed no effects on CVD or blood pressure. As 
discussed in Chapter 2, the null results from this trial will influence any findings and 
inferences185, 284 made about the effects of vitamin D on CVD outcomes, until such 
time newer trials are able to provide further data. 
 
The effects of supplementation with vitamin D on blood pressure lowering remains 
controversial, with conflicting results being reported from the clinical trials of 
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vitamin D (which showed no effects on blood pressure lowering overall) and the 
Mendelian randomisation studies (that report a predisposition for lower blood 
pressure in those with a higher vitamin D status). From the few trials that were 
available, there were no effects of vitamin D on other CVD risk markers such as CRP, 
inflammation, or lipids, or the effects remain unclear (Chapter 2).167, 221 Whether 
vitamin D intake could modify arterial stiffness measures was not known, as only 
two small trials (Table 2-2), one in young African American teenagers222 and the 
other in 100 patients with type 2DM,219 reported a reduction in aortic stiffness 
measures. 
 
Vitamin D intake and mortality 
Several meta-analyses of randomised trials of vitamin D report a modest mortality 
benefit among those taking vitamin D supplements. However, there is a lack of 
clarity as to the type, frequency and dose of supplementation of vitamin D that is 
associated with such benefits. One analysis reported mortality reduction with 
calcium and vitamin D supplementation, but not for taking vitamin D alone,191 while 
another found benefits with vitamin D3 intake and not vitamin D2.142 Intermittent 
high doses of vitamin D intake was associated with an increased incidence of falls 
and fractures,100 and vitamin D3 was more efficacious in achieving target plasma 
25(OH)D concentrations compared to vitamin D2.93 There was very little data on 
the safety and efficacy of taking daily high doses of vitamin D3 for long periods,15 
especially in the older people. 
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The magnitude of possible benefits for reduction in all-cause mortality when taking 
vitamin D was unclear. The doses used in the previous trials were insufficient to 
achieve optimal plasma 25(OH)D concentrations, and yet the meta-analyses of 
these trials demonstrated a 1% to 7% relative risk reduction in mortality in those 
taking vitamin D.188, 190 Based on the Whitehall resurvey and the observational 
studies,9 even greater reduction in all-cause mortality may be possible if optimal 
plasma concentrations of 25(OH)D were to be achieved by the use of higher dose of 
vitamin D supplements. What is clear is that there is a need for a larger trial of 
vitamin D using a high enough dose to evaluate the effects on CVD outcomes. 
 
The dose of vitamin D supplement to be used 
Before a large trial of vitamin D to evaluate effects on CVD outcomes is to be 
undertaken, the daily dose of vitamin D3 that could achieve optimal concentrations 
of 25(OH)D in most people needed to be established. Review of the observational 
studies and meta-analyses, and our own analysis (Chapters 2-4) identified the 
lowest risks for CVD at plasma 25(OH)D concentrations of 80-90 nmol/L. 
Concentrations of 25(OH)D >75 nmol/L were associated with the lowest risks for 
other adverse health outcomes such as falls, fractures and cancer.11, 53 In the UK, as 
mean 25(OH)D levels among people over 65 years of age range between 
32-55 nmol/L, vitamin D3 supplements >2000 IU daily would be necessary to 
achieve optimal 25(OH)D concentrations. Data on safety and efficacy of such high 
daily doses of vitamin D3 were limited, especially for use in the UK. 
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The BEST-D trial – Key findings 
Optimal plasma 25(OH)D concentrations were achieved  
BEST-D (Biochemical Efficacy and Safety Trial of vitamin D) was the first randomized 
placebo-controlled trial to assess the effects of two higher oral doses of vitamin D3, 
4000 IU and 2000 IU (equivalent to 100 µg and 50 µg) daily, in older adults living in 
the UK for 1 year. The trial demonstrated a higher proportion of participants taking 
4000 IU daily maintained plasma concentrations >90 nmol/L at the end of 1 year 
compared to those taking 2000 IU or placebo, and the intake of such doses were 
not associated with clinically apparent adverse effects (Chapters 5 and 6). The dose-
response was curvilinear with a plateau in the achieved plasma 25(OH)D 
concentrations occurring after 4 weeks of vitamin D intake. This trial addressed a 
key gap in our knowledge on dose response of daily supplementation with high 
dose vitamin D3. 
 
This work adds to the literature on vitamin D dosing trials and provided information 
on the safety and efficacy of using higher doses in the older Caucasian people, living 
in the UK. In a recent dose-finding trial of 163 post-menopausal women, serial 
doses of increasing vitamin D between 400 IU to 4800 IU daily were given, and the 
peak doses corresponded to plasma concentrations of about 120 nmol/L after 1 
year, and were consistent with the results from BEST-D.91 However, hypercalcaemia 
and hypercalciuria defined by biochemical methods were detected in this trial 
which monitored urine and blood calcium every 3 months, but these events did not 
correlate with the dose of vitamin D administered, and no patients reported 
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significant adverse events. We found no reported adverse effects in the BEST-D 
participants, and found no significant hypercalcaemia at the end of 12 months. 
There are no other trials that I am aware of, which used doses between 2000 IU to 
3000 IU daily of vitamin D3 and reported significant adverse effects associated with 
such intake. The results from BEST-D now confirm that intake of up to 4000 IU of 
vitamin D3 in the older people are well tolerated and safe over 1 year. 
 
Effects on blood pressure and arterial stiffness with vitamin D intake 
Among BEST-D participants, taking 2000 IU or 4000 IU vitamin D3 daily for 1 year 
had no effects on systolic or diastolic blood pressure, heart rate, or on the 
measures of arterial stiffness compared to placebo. Despite significant differences 
in achieved plasma 25(OH)D concentrations, with an almost doubling of 
concentrations from baseline in the 4000 IU arm, no significant effects were 
detected on the CVD risk markers after 1 year either. In sub-group post-hoc 
analyses, taking either dose of vitamin D was associated with an increase in the 
Pulsewave velocity (measured by Arteriograph), and this was more apparent in 
those who were younger and in those with lower systolic blood pressure at 
enrolment. Other measures of arterial stiffness remained unchanged. These effects 
on arterial stiffness were not statistically significant after taking account of multiple 
testing. 
 
The lack of effects for vitamin D on blood pressure in the treatment arms or in any 
of the sub-groups of gender, baseline vitamin D status or blood pressure, is 
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consistent with the findings of a recent meta-analysis of trials of vitamin D and 
blood pressure,183 which found no effects on any pre-specified sub-groups. The lack 
of statistically significant effects for taking vitamin D on arterial stiffness measures 
was broadly consistent with other trials, especially those that have included older 
Caucasian participants (Table 2-2).175, 221 No other trial of vitamin D had used such 
higher daily doses of vitamin D (2000 IU and 4000 IU) and evaluated effects on 
arterial stiffness markers in the elderly. 
 
Explaining the lack of effects of vitamin D on CVD risk factors in the BEST-D trial 
Though concentrations of plasma 25(OH)D >90 nmol/L were achieved in the BEST-D 
study, and mean concentrations were in the optimal range for CVD, no beneficial 
effects of supplementation on CVD risk factors were observed with vitamin D 
intake. This is contrary to the observational data of vitamin D, but it may mean that 
the optimal concentrations need to be maintained for longer if any beneficial 
effects were to become apparent. Autier et al, noted mortality reduction benefits 
associated with vitamin D intake would need 6 years to become apparent.188 
 
Perhaps, the trial participants in BEST-D were predominantly healthy and hence no 
further beneficial effects of vitamin D intake on risk factors could have been 
possible. For instance, the blood pressure lowering effects may not have been 
apparent in this relatively normotensive population. Alternatively, there could have 
been insufficient power to detect small effects of vitamin D on blood pressure 
lowering and arterial stiffness (discussed below). In BEST-D, there was >90% power 
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(at 2p = 0.05) to detect a difference in BP of 10 mm Hg between those taking any 
vitamin D versus placebo. If the effects of vitamin D on blood pressure and arterial 
stiffness were smaller than anticipated, this would have been difficult to detect in 
this trial.  
 
Could the higher plasma concentrations achieved with vitamin D treatment ( 
>100 nmol/L in both groups) be associated with the lack of effects on CVD? In the 
Whitehall study, the log-linear inverse associations between plasma 25(OH)D and 
CVD mortality was observed in the range between 30-90 nmol/L; at higher 
concentrations the associations appeared to become attenuated (Figure 3-2). If 
higher plasma concentrations of 25(OH)D are associated with increased CVD risks as 
reported in some prospective studies, achieving ‘supra-normal’ concentrations 
could have attenuated any beneficial effects of supplementation with vitamin D. 
The mean concentrations of plasma 25(OH)D achieved in the BEST-D trial were 
higher than those previous trials that showed blood pressure lowering with vitamin 
D supplements.172 However, the post-hoc analyses of the BEST-D participants, 
found no blood pressure lowering effects even in sub-groups, when participants 
were grouped by baseline age, systolic blood pressure, or after excluding those who 
took anti-hypertensive treatment.  
 
Aspects of the BEST-D trial assessments of CVD risk markers may explain the null 
results, as the vascular measurements were conducted at participant homes rather 
than in a laboratory setting. Although, these methods for estimating arterial 
stiffness (Arteriograph and Pulsetrace PCA II) were relatively new and had little 
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validation for CVD outcomes, there was good correlation of repeated measures at 6 
months within the placebo group participants, and the standard error of the 
measurements were also small indicating the measures were robust. We also aimed 
to reduce the effects of diurnal variation and that of temperature fluctuations on 
blood pressure and arterial stiffness in a pragmatic manner, by ensuring follow-up 
appointments were scheduled at the same time of the day wherever possible. 
These assessments at participant homes could have introduced measurement 
variability, but mean (SE) values of the Arteriograph and Pulsetrace measures of 
arterial stiffness were broadly comparable to those from other published studies.  
 
Limitations of the BEST-D trial 
The BEST-D trial was designed predominantly to assess the efficacy, safety and 
tolerability of two higher doses of vitamin D3 supplements for use in a larger trial of 
vitamin D in future. However, as the study recruited older participants living at a 
single geographic location and registered under a single GP Practice, generalisability 
of the trial findings and of the effects of vitamin D on CVD to the wider UK 
population, which include younger people and those from other ethnic 
backgrounds, is uncertain. The dose of vitamin D to achieve optimal plasma 
25(OH)D concentrations in non-Caucasian populations may be different, as African-
American women appear to require >2000 IU daily to achieve optimal 
concentrations. 285 286 No data were collected on the precise time of day at which 
blood samples were collected in this study and, hence, it was not possible to assess 
the effects of diurnal variation in plasma levels of 25(OH)D on disease outcomes. 
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However, appointments were scheduled at the same time of day in serial visits to 
minimise diurnal variation in blood pressure and arterial stiffness, which also 
minimise the effects of diurnal variation in the effects of vitamin D on plasma levels 
of 25(OH)D.      
 
Although the main trial was designed to confirm biochemical effects, the trial 
design was suitable as a preliminary, explorative, pilot analysis to evaluate the 
effects of vitamin D on CVD risk markers. However, the design of the BEST-D trial 
may have obscured potential effects of vitamin D on blood pressure and arterial 
stiffness. The recruited participants were from a healthy cohort of patients, who 
were motivated, educated and interested in participation in the trial. Although the 
adherence was good with treatment and the follow-up visit completion being 
exemplary, this is also indicative of a highly motivated participant group, and who 
are likely to be healthier. Hence demonstrating CVD risk reduction may have been 
difficult. 
 
The minimisation algorithms used for the randomised allocation of double-blinded 
treatment did not include blood pressure, arterial stiffness or baseline 25(OH)D 
concentrations, and could have introduced iniquities in baseline characteristics that 
could have attenuated the effects of taking vitamin D. However, further, attempts 
to refine allocation with these above factors could have posed considerable 
logistical problems and it would not have been feasible to implement such complex 
allocation in a trial of this size. However, we conducted post-hoc analysis to further 
examine the effects of vitamin D supplements by sub-groups of baseline blood 
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pressure, arterial stiffness, plasma 25(OH)D concentrations, and use of anti-
hypertensive medications, and have interpreted these findings with caution, as 
such post-hoc analysis can introduce bias. 
 
Trials generally lack sufficient power to detect effects of vitamin D on CVD  
The lack of effects of vitamin D on CVD measures in BEST-D could reflect the 
inadequate sample size of the treatment groups, as only a >10% change in systolic 
blood pressure or pulsewave velocity would have been detectable. The BEST-D trial 
had >90% power to detect a 10% change in pulsewave velocity (about 1m/s) or a 
10% reduction in systolic blood pressure between any dose of vitamin D intake and 
placebo, but would not have identified smaller changes (power to detect <5% 
differences in pulsewave velocity was < 50% and in blood pressure was <70%). 
Despite this, our trial had more participants than most other vitamin D trials 
evaluating the effects on blood pressure, included in the recent meta-analysis.183 
However, as the Mendelian randomisation studies demonstrate a blood pressure 
reduction of only 2-3 mm Hg (with 10 nmol/L difference in plasma 25(OH)D 
concentration and in a cohort of more than 45,000 participants), the previous trials 
of vitamin D including BEST-D maybe significantly under-powered to detect such 
smaller magnitude of effects on blood pressure. However, achieving higher plasma 
concentrations of 25(OH)D with the use of higher doses of vitamin D could translate 
into a greater reduction in blood pressure (with time), but this is yet to be proven in 
a randomised controlled trial.  
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Higher concentrations of plasma 25(OH)D and the risks of CVD need testing 
We could not find evidence that higher plasma concentrations of 25(OH)D was 
associated with higher risks of CVD and/or all-cause mortality in the Whitehall study 
(Chapter 3, Figure 3-2), but there were only few participants with 25(OH)D 
concentrations >120 nmol/L in this study. The curvilinear or J-shaped association 
with all-cause mortality at 25(OH)D concentrations > 120 nmol/L described in other 
studies may be because sicker individuals may take more vitamin D supplements 
raising plasma 25(OH)D concentrations, but have shorter life spans.  
 
In the BEST-D trial, those taking any dose of vitamin D3 daily had higher arterial 
stiffness after 1 year, with mean plasma concentrations of 25(OH)D reaching above 
100 nmol/L in both vitamin D treatment groups ( and 120 nmol/L in the 4000 IU 
treatment group). Although these effects did not reach statistical significance, it is 
possible that the effects on arterial stiffness could be due to increased calcification 
of the vasculature. The increased arterial stiffness was more apparent among the 
young participants and in those participants with the lowest systolic blood pressure. 
This could mean that the effects of vitamin D were harder to detect in the other 
participants as they had stiffer vessels (due to advanced age or higher blood 
pressure). Furthermore, there was a dose-dependent rise in serum calcium levels in 
the BEST-D participants, but the serum calcium levels remained in normal range 
with no hypercalcaemia detected. The trial was not powered to detect differences 
in secondary outcomes and hence these findings need to be interpreted with 
caution.  
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Higher risks for falls and fractures with high intermittent doses of vitamin D are 
reported in trials and may be explained by the increased physical ability due to 
sufficient vitamin D status leading to higher chance of falls and fractures. However, 
it may also be due to the differences in handling of high dose vitamin D 
supplements by the body. For instance, vitamin D3 supplementation was associated 
with reduced mortality but not the intake of vitamin D2. Vitamin D production from 
sun exposure is self-regulating, and the continued exposure to heat and light causes 
breakdown of 7-dehydroxy-cholesterol. Perhaps, the lack of such temperature and 
light sensitive mechanisms to regulate the extraneous supply of vitamin D may 
cause altered calcium handling, and in the absence of clinically apparent 
hypercalcaemia.  
 
However, it would seem unlikely that higher plasma 25(OH)D concentrations could 
cause harm as plasma levels of 25(OH)D of 115 nmol/L are reported among the 
Masai and Hadzabe tribes living in equatorial East Africa, people thought to live 
with very little changes to their hunter-gatherer life-styles for centuries.252, 287 
Further, concentrations of 25(OH)D >120 nmol/L are achievable after prolonged 
sunlight exposure, and hence these concentrations are within physiologic ranges. 
What is not clear is whether such high levels among the Caucasian populations are 
necessary, or if they could have adapted to the lower UVB availability.46 In the 
Whitehall analyses, the range associated with the lowest risks of mortality was 
around 75-90 nmol/L and is consistent with analysis including participant data from 
the US and Northern Europe.9, 275 The observational associations may not 
necessarily indicate higher risks with supplementation of vitamin D, but no trials to 
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date have tested the effects of maintaining plasma 25(OH)D concentrations at such 
levels for long periods on CVD outcomes. However, the possibility that higher 
concentrations of plasma 25(OH)D could be linked with higher mortality risks, 
cannot be excluded and needs testing.  
 
Low 25(OH)D is not an indicator of frailty  
Studies that reported inverse relationships between plasma 25(OH)D and CVD 
outcomes have not been able to exclude the possibility that plasma 25(OH)D 
concentrations could indicate frailty or of inactivity. In the Whitehall study, 
correction for self-reported physical activity did not eliminate the observed risks. In 
the LURIC study, Dobnig et al found that in those who had average or below-
average activity levels, lower 25(OH)D was associated with higher risks of dying, 
when participants grouped by ‘below average’, ‘average’ and ‘above average’ self-
reported physical activity.197 However, the effects of lower risks of all-cause 
mortality with vitamin D supplements demonstrated in the trials of vitamin D could 
mean that vitamin D is a modifiable risk factor, and not an indicator of ill-health. 
Due to the lack of large adequately designed trials of vitamin D, there is simply 
insufficient data to conclude otherwise.  
 
Implications for further research 
The findings of the inverse associations of plasma 25(OH)D concentrations with 
higher risks of CVD mortality and with all-cause mortality are of considerable public 
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health interest, as low plasma 25(OH)D concentrations are common in the 
population and can be modified by vitamin D supplements.  
 
The discrepancy between the randomised trials of vitamin D showing lack of effect 
for taking vitamin D on CVD outcomes and mortality, and the Mendelian 
randomisation studies showing possible benefits of optimal vitamin D status, needs 
further evaluation.193, 194 Could the lack of effects on CVD reported from the vitamin 
D randomised trials be due to, the use of inadequate dose and duration of vitamin 
D supplements, the concomitant use of calcium supplements, the form and 
frequency of supplementation, or an inadequate sample size of the trials? Although 
a number of trials are already underway using higher vitamin D doses and 
evaluating CVD and other disease outcomes, (Chapter 2, Table 2-4) these individual 
trials may still not be able to find meaningful differences in mortality or other CVD 
outcomes and a meta-analysis of such trials may be needed.  
 
However, the sample size required to demonstrate a statistically significant effect 
may be even greater than all the participants in the on-going trials put together. A 
further large randomised trial may be the best approach to test and confirm the 
potential causal relevance of vitamin D for CVD. Even if the effects of 
supplementation with vitamin D on disease outcomes are modest, use of 
supplements to modify plasma 25(OH)D concentrations are effective and could be a 
cost-effective way of reducing risks of death from CVD and other causes, in the 
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general population. Importantly, it may afford a new therapeutic target for the both 
primary and secondary prevention of CVD. 
 
Whether a higher plasma concentrations greater than 120 nmol/L are associated 
with harm is not yet proven and needs testing. In the BEST-D trial, any intake of 
vitamin D appeared to increase arterial stiffness when compared to placebo, but 
these results were not statistically significant after taking account of multiple 
testing.  
 
In the UK, there is a need to test and establish the relevance of supplementation 
with vitamin D in relation to CVD and other health outcomes. The 
recommendations for vitamin D requirements for health may indeed be influenced 
by geographic location, ethnic background or physical factors, and may be different 
for different populations. People in the UK are at a particular disadvantage as they 
are unable to produce vitamin D after sun exposure during the winter months, and 
it is unclear whether these insufficiencies have a cumulative, additive and 
detrimental effect on health or it is simply the effects of an adaptation for living in 
areas of low UVB availability.  
 
Significance of the thesis findings 
The findings presented in this thesis provide valuable new information on the 
associations between vitamin D and CVD. The Whitehall study was one of the first 
reports to demonstrate the inverse associations between vitamin D and CVD 
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mortality, identify and suggest an optimal plasma 25(OH)D concentrations for CVD 
outcomes and the reported meta-analyses which confirmed the shape and strength 
of the associations between vitamin D and CVD was one of the first of such studies 
to evaluate the association from other prospective studies. However, given the 
limitations of a prospective analysis, this study was unable to confirm whether this 
is a causal association.  
 
The BEST-D trial is one of the largest dose-finding trials of vitamin D3, and the first 
to test the safety and efficacy of using two daily doses of vitamin D3 (4000 IU and 
2000 IU daily) among the older people living in the UK. The trial showed that both 
doses were likely to achieve and maintain plasma 25(OH)D concentrations 
>90 nmol/L throughout the year, although proportionally more participants had 
plasma concentrations >90 nmol/L in the group that received 4000 IU daily. Neither 
dose was associated with clinically detectable adverse effects or biochemically 
significant hypercalcaemia. This information will help design a larger trial evaluating 
the effects of vitamin D supplements on CVD outcomes in future. 
 
The trial demonstrated no significant effects of taking higher doses of vitamin D3 on 
blood pressure (CVD risk factor) or arterial stiffness. However, the trial was not 
powered to detect small differences in either of these measures, and a possible 
benefit or hazard for taking vitamin D supplements over the longer term cannot be 
confirmed or refuted based on the BEST-D trial findings. 
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Recommendations for future research 
There is substantial public health interest in addressing the question of causality of 
low vitamin D and CVD, and based on the evidence presented in this thesis, this 
need to be proven. An appropriately designed randomised controlled trial of 
vitamin D supplements evaluating effects on risk of fracture, CVD and other disease 
outcomes as primary outcomes is necessary. The appropriateness of modifying 
mean population 25(OH)D levels through fortification or supplementation, as a 
preventative public health measure needs further evidence. 
 
Such a trial will require a large number of participants to detect possibly modest 
but potentially worthwhile effects on disease outcomes. The design of such a trial 
has substantial logistic and cost implications and is challenging to obtain support. 
Perhaps innovative trial designs could be utilised, including embedding the trial in a 
previously recruited cohort study, such as the UK Biobank or GP register could 
simplify recruitment and follow-up of trial participants and reduce costs. So far the 
on-going trials of vitamin D will only recruit about 50,000 to 60,000 participants, 
but even larger trials may be required for a more robust analysis of benefit or harm 
on CVD and other health outcomes.  
 
Conclusions 
Plasma 25(OH)D concentrations were inversely associated with CVD mortality. 
Previous trials were unable to confirm whether these associations were causal. The 
BEST-D study has shown that two daily doses of vitamin D3 (2000 IU and 4000 IU) 
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are broadly safe and efficacious in raising plasma 25(OH)D concentrations in older 
people living in the UK. The trial also demonstrated that vitamin D had no effects on 
CVD risk markers after 1 year of intake. A large well-designed randomised 
controlled trial of vitamin D supplements evaluating effects on CVD and other 
disease outcomes such as fractures and cancer as primary outcomes is necessary, 
and such a trial will require a large number of participants and a long duration of 
treatment to detect effects on major disease outcomes. 
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Vitamin D and risk of death from vascular and
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Aims To examine the independent relevance of plasma concentrations of 25-hydroxyvitamin D [25(OH)D] for vascular
and non-vascular mortality.
Methods
and results
We examined associations of plasma concentrations of 25(OH)D and cause-specific mortality in a prospective study
of older men living in the UK and included findings in meta-analyses of similar studies identified by a systematic search
reporting on vascular and all-cause mortality. In a 13-year follow-up of 5409 men (mean baseline age 77 years), 1358
died from vascular and 1857 from non-vascular causes. Median season-adjusted baseline 25(OH)D concentration was
56 (interquartile range: 45–67) nmol/L. After adjustment for age and seasonality, higher concentrations of 25(OH)D
were inversely and approximately linearly (log–log scale) associated with vascular and non-vascular mortality
throughout the range 40–90 nmol/L. After additional adjustment for prior disease and cardiovascular risk factors,
a doubling in 25(OH)D concentration was associated with 20% [95% confidence interval (CI): 9–30%] lower vascular
and 23% (95% CI: 14–31%) lower non-vascular mortality. In meta-analyses of prospective studies, individuals in the
top vs. bottom quarter of 25(OH)D concentrations had 21% (95% CI: 13–28%) lower vascular and 28% (95% CI:
24–32%) lower all-cause mortality.
Conclusions Despite strong inverse and apparently independent associations of 25(OH)D with vascular and non-vascular mortal-
ity, causality remains uncertain. Large-scale randomized trials, using high doses of vitamin D, are required to assess the
clinical relevance of these associations.
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Introduction
Prospective observational studies have reported that low circulat-
ing concentrations of 25-hydroxyvitamin D [25(OH)D] are asso-
ciated with higher risks of cardiovascular disease,1–7 cancer,6,8–10
and all-cause mortality.5,7,11–13 However, as low 25(OH)D con-
centrations are correlated with several known vascular risk
factors, it is possible that any such associations with disease may
reflect confounding by these risk factors. Alternatively, these asso-
ciations with 25(OH)D may be due to reverse causation, as indivi-
duals with vascular disease or cancer, who may be frail or unwell,
may be more likely to stay indoors, and have low plasma 25(OH)D
concentrations due to inadequate sunlight exposure. Previous
meta-analyses of prospective studies reported a significant
inverse association of 25(OH)D with all-cause mortality,14,15 but
did not distinguish vascular from non-vascular causes of death.
The relevance of measurements of circulating 25(OH)D levels in
the general population, including those with vascular disease, is un-
certain. No large randomized trials of vitamin D have yet been
completed with vascular disease or cancer as the primary
outcome. Previous meta-analyses of randomized trials of vitamin
D reported only borderline statistically significant effects of
* Corresponding author. Tel: +44 1865 743743, Fax: +44 1865 743985, Email: robert.clarke@ctsu.ox.ac.uk
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2012. For permissions please email: journals.permissions@oup.com
European Heart Journal
doi:10.1093/eurheartj/ehs426
 European Heart Journal Advance Access published December 20, 2012
 at ESC M
em
ber on A
pril 25, 2013
http://eurheartj.oxfordjournals.org/
D
ow
nloaded from
 
vitamin D treatment on all-cause mortality,16,17 but were unable to
detect significant effects on vascular outcomes.18 These trials typ-
ically used daily doses of 400–800 IU of vitamin D3, which may not
be sufficient to optimize plasma 25(OH)D concentrations through-
out the year.19 If the inverse associations of 25(OH)D with vascu-
lar disease and other outcomes are causal and reversible by
treatment, then this could have important implications for public
health, particularly for countries in the Northern hemisphere20
where low vitamin D levels are highly prevalent.
We examined the associations of plasma concentrations of
25(OH)D with vascular and non-vascular causes of mortality in a
13-year follow-up of a prospective study of 5409 older men
living in the UK in 1997, and compared the results in meta-analyses
of similar prospective studies of 25(OH)D and vascular and all-
cause mortality. The aims of the present study were: (i) to
examine cross-sectional associations of 25(OH)D with other vas-
cular risk factors; (ii) to assess the shape and strength of the asso-
ciations of plasma 25(OH)D concentrations with vascular and
non-vascular causes of death, overall and separately in those
with and without any pre-existing disease; and (iii) to compare
these results in meta-analyses of prospective studies of
25(OH)D and vascular and all-cause mortality.
Methods
Study population
The Whitehall study is a prospective study of 19 019 male civil servants
who were working in London at the time of recruitment in 1967–
70.21,22 Following a successful pilot study in 1995, a resurvey was con-
ducted of all surviving 8448 participants in this cohort during 1997–98,
after approval by the relevant ethics committees of the participating
institutions. Data were collected for the resurvey using mailed ques-
tionnaires seeking details of previous medical history (diagnoses of
heart attack, angina, stroke, cancer, and diabetes), self-reported
health status, medications taken in the past month, lifestyle character-
istics (e.g. smoking status and alcohol consumption), and last known
civil service employment grade. All 7044 (83%) respondents were sub-
sequently sent a blood collection kit and asked to attend their local
surgery to have a sample collected and measurements of blood pres-
sure, height, and weight recorded. Complete data on questionnaires
and relevant blood results were available from 5409 (77% of respon-
dents) men for the present report. Compared with responders, non-
responders were older and had a lower previous employment grade,
but response rates were not associated with total cholesterol levels
recorded from 1967 to 70.23
Laboratory methods
Whole-blood samples (10 mL) were returned by mail in sealed
tubes (Vacutainer; Becton Dickson, Franklin Lakes, NJ, USA) containing
potassium ethylenediaminetetraacetic acid with 0.34 mmol/L of aproti-
nin. These samples were mailed at room temperature to the CTSU
Wolfson Laboratory in Oxford, with 78% arriving within 24 h and
96% arriving within 48 h of blood collection [mean time in post: 1.3
days (range 0–7 days)]. On arrival in the laboratory, the blood was
centrifuged, and plasma was aliquoted and stored at 2408C. Plasma
25(OH)D concentrations were measured using an automated im-
munoassay on the IDS-iSYS analyser (Immunodiagnostic systems,
Boldon, UK). In addition, 187 of these men had plasma 25(OH)D
concentrations measured on blood samples collected for the pilot
study for this resurvey, on average 1.5 years prior to the main resurvey.
The IDS-iSYS 25(OH)D assay standardization is traceable to ultraviolet
quantification and calibration was verified by comparison with an
isotope dilution liquid chromatography-tandem mass spectrometry
method. Over the testing period, proficiency testing with vitamin D
external quality assessment scheme samples indicated that the
IDS-iSYS assay was systematically overestimating concentrations com-
pared with the mean obtained for all 25(OH)D assays. Hence, a linear
correction, multiplying by 0.757, was applied to all measured 25(OH)D
concentrations. Plasma concentrations of total cholesterol, LDL chol-
esterol, HDL cholesterol, apolipoprotein A1 (Apo A1), and apolipo-
protein B (Apo B) as well as biomarkers of inflammation [C-reactive
protein (CRP), fibrinogen, and albumin] and cystatin C were measured
using standard methods.22 Estimated glomerular filtration rate (eGFR,
in mL/min/1.73 m2) was calculated from cystatin C concentration using
the formula eGFR ¼ 80.35/cystatin C (in mg/L)24.32.24
Cause-specific mortality follow-up
Participants were flagged for mortality at the Office for National Sta-
tistics (UK), which provided the date and cause [including International
Classification of Disease (ICD) codes] of all deaths occurring until end
of August 2010. The mean follow-up period among survivors was 13.1
years. Cause-specific mortality was coded using ICD-9 up to August
2002 and ICD-10 subsequently. Vascular deaths (heart disease,
stroke, and other vascular disease) were defined if coded as ICD-9
codes 390-459, 798 or ICD-10 codes I00-I99, R96, with all other
causes of death being defined as non-vascular. Deaths from ischaemic
heart disease (IHD: ICD-9 codes 410–414; ICD-10 codes I20–I25),
stroke (ICD-9 codes 430–438; ICD-10 codes I60–I69), cancer
(ICD-9 codes 140–208; ICD-10 codes C0–C97), and respiratory
disease (ICD-9 codes 460–519; ICD-10 codes J00–J99) were also
analysed separately.
Statistical methods
Plasma 25(OH)D concentrations were analysed on the logarithmic
scale. Since concentrations of plasma 25(OH)D varied throughout
the year, the values were adjusted for month of blood sampling. This
was done by adding to each participant’s log 25(OH)D measurement
the difference between the overall mean log 25(OH)D concentration
(seen in all men) and the mean observed just among men sampled in
the same month. Since the majority of men were examined in the
summer of 1997, when 25(OH)D concentrations tended to be
highest (see Supplementary material online, Figure S2), this adjustment
tended to shift values towards those seen in summer rather than
winter months. Men were subsequently classified into five equal
sized groups on the basis of their season-adjusted 25(OH)D concen-
tration, and the means and prevalences of other baseline characteris-
tics, adjusted for age, were estimated [with tests for linear trend
between log 25(OH)D and the risk factor performed using, respective-
ly, linear or logistic regression adjusted for age]. To assess the shape of
the association between 25(OH)D and mortality, men in the top and
bottom fifths were further divided in half for the purpose of the plot-
ting of dose–response relationships to better characterize any rela-
tionships at more extreme concentrations. Relative risks (RRs)
(estimated by hazard ratios in Cox models) were estimated for each
group relative to the lowest and are shown as ‘floating absolute
risks’ [which does not alter their values but merely ascribes a 95% con-
fidence interval (CI) to the RR in every group].25 The average RR cor-
responding to a doubling in 25(OH)D concentration (approximately a
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2 SD increase on the log scale) was also estimated. The proportionality
assumption of the Cox model was assessed using the method
described by Grambsch and Therneau.26 Analyses were done before
and after adjustment for age, prior history of disease (myocardial in-
farction, angina, stroke, cancer, or diabetes), self-reported health
status (on a four point scale), ability to perform particular activities
of daily living (based on a 15-point questionnaire), smoking status
(current smoker, ex-smoker, and never smoker), alcohol consumption,
last known employment grade, blood pressure (both at entry to
Whitehall study in 1967–70 and at resurvey in 1997–98, as well as
treatment for hypertension at resurvey), body mass index, blood
lipids, and apolipoproteins (LDL-C, HDL-C, Apo A1, and Apo B),
markers of inflammation (CRP, albumin, and fibrinogen), and eGFR.
To further assess the effects of reverse causality, analyses were
repeated separately in men with and without a prior history of
disease (defined as above), while further analyses excluded deaths
during the first 5 years of follow-up.
Meta-analyses of prospective studies
Data from the Whitehall study were included in meta-analyses of all
published reports of prospective studies that reported associations
of circulating concentrations of 25(OH)D with either vascular mor-
tality or all-cause mortality before January 2012. Eligible population-
based studies (see Supplementary material online, Table S1), based
on prespecified selection criteria, were identified by electronic litera-
ture searches (PubMed, Embase, and Cochrane databases) using a
systematic search strategy (see Supplementary material online,
Figure S1). Studies were to be included if they (i) involved a pro-
spective (or nested case-control) study design; (ii) included more
than 200 adult participants recruited from the general population;
and (iii) had data on 25(OH)D concentrations and risk of death
from cardiovascular or all-causes. Studies were excluded if they
were selected on the basis of (i) diagnosis of prior disease
(cancer, vascular, or renal disease); (ii) risk factors (diabetes and
hypertension); (iii) nursing home residents; (iv) participants in clinical
trials; or (v) meta-analyses of previous studies. Data were abstracted
from each report on RRs (commonly hazard ratios from Cox regres-
sion models) and their 95% CI for vascular and all-cause mortality,
and verified by two authors working independently. For each
study, the most fully adjusted RR and its 95% CI were extracted.
Any RR models that had been adjusted for calcium and phosphate
were not included (as these were considered to be on the causal
pathway). Where necessary, the RRs were recalibrated to corres-
pond to the top vs. bottom quarter of the 25(OH)D distribution
(most common approach taken in individual studies).27 This was
done by estimating the number of SDs that each published RR
would have corresponded to [on some normal transformation of
the underlying 25(OH)D distribution] before recalibrating the log
RR (and its standard error) to correspond to a 2.54 SD difference
(since 2.54 is the difference in mean values between the top and
bottom quarters of a normal distribution). Principal investigators
were contacted and asked to provide additional data on the SD of
25(OH)D concentration to facilitate standardized comparisons.
Overall summary estimates of the effect were calculated using the
Mantel–Haenszel inverse-variance weighted method for
meta-analysis. In forest plots, studies were ordered according to
the amount of statistical information they contributed to the
overall result [and, for display only, were grouped as being: ‘small’
(providing ,1% of the total information provided by all the
studies); ‘medium’ (1 to ,10%); or ‘large’ (at least 10%)]. All P
values were two sided and P values , 0.05 were deemed
conventionally significant. Analyses were done using SAS version
9.1 (SAS Institute, Cary, NC, USA) and R version 2.11.1 (www.r-
project.org).
Results
Baseline characteristics
Selected characteristics of the 5409 men included in the analyses
are summarized in Table 1. The mean age of participants at resur-
vey was 76.9 (SD 4.9) years, and about one-third (1841 men) had a
history of prior vascular disease, cancer, or diabetes at resurvey.
The majority (87%) were non-smokers, while 78% were self-
reported ‘current’ alcohol drinkers.
Distribution of 25-hydroxyvitamin D
concentrations at baseline
Plasma concentrations of 25(OH)D varied substantially by month
of blood collection, and, even after adjustment for month of
blood collection, concentrations had a log-normal distribution
(see Supplementary material online, Figure S2). Median 25(OH)D
concentration (standardized for month of blood collection) was
56 nmol/L (interquartile range 45–67 nmol/L) (Table 1). In a
sample of 187 men with repeated measurements taken 1.5 years
apart, the self-correlation in log 25(OH)D was 0.64. At any given
age, men with higher 25(OH)D concentrations were less likely
to have a history of vascular disease, cancer, or diabetes, and
less likely to have been diagnosed with hypertension or taking
treatment for hypertension, than men with lower concentrations.
Measured systolic blood pressure at resurvey in 1997 was only
weakly related with 25(OH)D concentrations, and blood pressure
at the initial examination for the Whitehall study in 1967–70 was
unrelated with 25(OH)D concentrations. Men with higher
25(OH)D also had lower mean body mass index than men with
lower 25(OH)D and were less likely to have been of manual/cler-
ical grade at retirement. In contrast, men with higher plasma
25(OH)D concentrations had higher mean LDL-C, HDL-C,
ApoA1, and albumin concentrations, and lower mean CRP and
fibrinogen concentrations, than men with lower 25(OH)D
concentrations.
Association of 25-hydroxyvitamin D with
vascular and non-vascular mortality
Overall among the 5409 participants, 3215 men died during over
50 000 person years of follow-up (overall death rate: 6.4% per
year; mean follow-up among survivors 13 years), including 1358
deaths (2.7% per year) from vascular causes and 1857 deaths
(3.7% per year) from non-vascular causes (Table 2). Among the
3568 men without a history of vascular disease, cancer, or dia-
betes, there were 727 deaths (2.0% per year) from vascular
causes and 1124 deaths (3.1% per year) from non-vascular
causes. After classifying men into seven groups based on
season-adjusted 25(OH)D concentration, higher concentrations
of 25(OH)D were inversely and, on the log–log scale, approxi-
mately linearly related to the risk of vascular and, at least through-
out the range 40–90 nmol/L, of non-vascular mortality in
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Table 1 Study characteristics, overall and by prior disease, and baseline 25-hydroxyvitamin D concentration
Baseline characteristics All men No prior disease Prior disease Fifth of baseline 25(OH)Da P†b
I II III IV V
Number of men 5409 3568 1841 1081 1082 1082 1082 1082
Age (years) 76.9 (4.9) 76.5 (4.8) 77.6 (5.0) 78.9 (5.2) 77.1 (5.1) 76.7 (4.6) 76.1 (4.5) 75.5 (4.3)
25(OH)D (nmol/L) 56 (45–67) 57 (47–68) 54 (43–65) 36 (5) 48 (3) 56 (2) 65 (3) 83 (18)
Medical history (%)
IHD 19.9 0.0 58.4 22.0 20.5 20.3 19.8 16.5 0.002
Stroke 7.2 0.0 21.1 9.3 6.6 6.7 6.7 5.9 0.001
CVD 24.9 0.0 73.3 28.1 25.4 25.4 24.6 20.7 ,0.001
Diabetes 5.9 0.0 17.4 8.8 6.7 5.8 2.8 4.0 ,0.001
Cancer (not skin) 7.9 0.0 23.2 10.1 8.1 7.4 6.8 6.5 0.006
Self-reported health good/excellent 77.4 85.3 62.0 67.1 75.8 79.9 80.5 85.5 ,0.001
Manual/clerical socio-economic grade at baseline 17.4 17.7 16.8 20.2 19.4 16.2 15.8 14.9 ,0.001
Lifestyle (%)
Current tobacco smoker 12.7 14.1 10.2 16.8 12.3 12.7 10.1 11.4 ,0.001
Current alcohol drinker 77.9 79.2 75.4 73.3 75.8 80.5 79.5 80.8 ,0.001
Blood pressure and body mass
Diagnosis of hypertension/use of blood 42.0 33.1 59.3 45.0 43.1 41.4 40.2 40.5 0.003
Systolic blood pressure (mm Hg) 144.8 (20.1) 145.4 (19.8) 143.7 (20.7) 144.0 (20.5) 144.6 (20.1) 145.2 (20.1) 144.9 (20.2) 145.5 (20.3) 0.05
Diastolic blood pressure (mm Hg) 80.2 (10.8) 80.9 (10.7) 78.8 (10.9) 79.6 (11.0) 80.4 (10.8) 80.1 (10.8) 80.1 (10.8) 80.5 (10.8) 0.10
Body mass index (kg/m2) 25.2 (3.2) 25.1 (3.2) 25.4 (3.3) 25.5 (3.3) 25.4 (3.2) 25.4 (3.2) 25.1 (3.2) 24.8 (3.2) ,0.001
Blood pressure measured in 1967–70 (30 years earlier; mm Hg)
Systolic blood pressure 130.8 (17.6) 129.5 (17.2) 133.3 (18.2) 130.5 (17.9) 130.9 (17.5) 131.3 (17.5) 130.5 (17.6) 130.5 (17.7) 0.57
Diastolic blood pressure 80.3 (12.1) 79.4 (11.7) 82.0 (12.6) 80.1 (12.3) 80.6 (12.1) 80.8 (12.1) 80.1 (12.1) 79.9 (12.2) 0.35
Laboratory measurements
LDL-C (mmol/L) 3.37 (0.79) 3.40 (0.78) 3.31 (0.80) 3.28 (0.79) 3.36 (0.78) 3.42 (0.78) 3.42 (0.78) 3.36 (0.78) ,0.001
HDL-C (mmol/L) 1.09 (0.38) 1.12 (0.37) 1.04 (0.38) 1.06 (0.38) 1.06 (0.38) 1.08 (0.38) 1.11 (0.38) 1.17 (0.38) ,0.001
Apolipoprotein A1 (g/L) 0.95 (0.15) 0.96 (0.14) 0.93 (0.15) 0.93 (0.15) 0.94 (0.14) 0.95 (0.14) 0.96 (0.14) 0.98 (0.15) ,0.001
Apolipoprotein B (g/L) 0.87 (0.23) 0.87 (0.23) 0.87 (0.24) 0.85 (0.23) 0.87 (0.23) 0.88 (0.23) 0.88 (0.23) 0.85 (0.23) 0.38
C-reactive protein (mg/L) 3.7 (7.7) 3.4 (7.2) 4.4 (8.5) 4.3 (7.8) 3.7 (7.7) 3.6 (7.7) 3.5 (7.7) 3.5 (7.7) ,0.001
Albumin (g/L) 39.7 (3.0) 39.8 (2.8) 39.3 (3.2) 39.3 (2.9) 39.6 (2.9) 39.7 (2.9) 39.9 (2.9) 39.9 (2.9) ,0.001
Fibrinogen (mmol/L) 3.5 (0.8) 3.5 (0.8) 3.6 (0.9) 3.6 (0.9) 3.6 (0.8) 3.5 (0.8) 3.5 (0.8) 3.5 (0.9) 0.02
Renal function
eGFR (mL/min/1.73 m2) 72.2 (15.3) 74.0 (14.4) 68.6 (16.4) 69.8 (14.7) 71.7 (14.4) 72.9 (14.4) 73.0 (14.4) 73.5 (14.5) ,0.001
Mean (SD), median (interquartile range), or n (%) shown.
25(OH)D, 25-hydroxyvitamin D; IHD, ischaemic heart disease (recall of diagnosis of myocardial infarction or angina); eGFR, estimated glomerular filtration rate; CVD, cardiovascular disease.
aWith the exception of age and vitamin D, estimates are adjusted for age differences across vitamin D groups.
†bTest of linear trend between log[25(OH)D] concentration and baseline characteristics after adjustment for age.
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age-adjusted models (Figure 1). The shape of these associations
were broadly similar for both vascular and non-vascular mortality
[albeit with some attenuation of risk for non-vascular mortality
with 25(OH)D concentrations above 80 nmol/L], and, for both
outcomes, associations were consistent among men with and
without a prior history of vascular disease, cancer, or diabetes.
Effect of adjustment for potential
confounders
Given age, a doubling in 25(OH)D concentration [corresponding
to a ln(2) absolute difference—2 SDs—on the log-scale] was,
on average, associated with a 34% lower risk of vascular mortality
(RR 0.66, 95% CI: 0.58–0.75) and a 36% lower risk of non-vascular
mortality (RR 0.64, 95% CI: 0.58–0.72; Figure 2). After adjustment
for prior diseases (including self-reported measures of health and
frailty), established vascular risk factors, markers of inflammation
and renal function, this was reduced to a 20% lower risk of vascular
mortality (RR 0.80; 95% CI: 0.70–0.91) and a 23% lower risk of
non-vascular mortality (RR 0.77; 95% CI: 0.69–0.86). The substan-
tial change in the x2 statistics associated with 25(OH)D concentra-
tion with these adjustments (from 41.1 to 11.5 for vascular death
and 63.3–21.4 for non-vascular death) suggest that a large part of
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Table 2 Cause-specific mortality (annual death rate:
% per year), overall and by prior disease
All men No prior
disease
Prior
disease
Number of men 5409 3568 1841
Total follow-up (years) 50 388 35 937 14 452
Cause of death
IHD 659 (1.3) 297 (0.8) 362 (2.5)
Stroke 378 (0.8) 221 (0.6) 157 (1.1)
Other vascular 321 (0.6) 209 (0.6) 112 (0.8)
Subtotal: any vascular cause 1358 (2.7) 727 (2.0) 631 (4.4)
Cancer 809 (1.6) 460 (1.3) 349 (2.4)
Respiratory 497 (1.0) 321 (0.9) 176 (1.2)
Other non-vascular 551 (1.1) 343 (1.0) 208 (1.4)
Subtotal: any non-vascular
cause
1857 (3.7) 1124 (3.1) 733 (5.1)
Total: any cause 3215 (6.4) 1851 (5.2) 1364 (9.4)
IHD: ischaemic heart disease.
Figure 1 Age-adjusted relevance of measured 25-hydroxyvitamin D for vascular and non-vascular mortality in old age, overall, and separately
in men with and without prior disease. Prior disease is defined as cardiovascular disease (recall of a diagnosis of myocardial infarction, angina, or
stroke), diabetes, or cancer. In the lower panels, only three risk groups are shown for each disease category to increase the statistical reliability
of such subgroup analyses. To convert 25-hydroxyvitamin D from nmol/L to ng/mL, divide by 2.496.
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Figure 2 Effect of adjustment for known risk factors on the association between measured 25-hydroxyvitamin D and vascular and non-
vascular mortality. (A) Recall of a diagnosis of ischaemic heart disease, stroke, cancer, or diabetes, plus self-reported health/frailty; (B)
smoking status (current/ex/never); drinking status (current/non); grade of employment; LDL-C, HDL-C, apolipoprotein A1, apolipoprotein
B, body mass index, and blood pressure [recall (in 1997) of a diagnosis of hypertension, treatment (in 1997) for hypertension and measured
systolic and diastolic blood pressure in both 1997 and in 1970]; (C) albumin, fibrinogen, and C-reactive protein, and (D) estimated glomerular
filtration rate.
Figure 3 Association between measured 25-hydroxyvitamin D and cause-specific mortality after adjustment for measured confounders. IHD,
ischaemic heart disease. Analyses are adjusted for smoking status (current/ex/never), drinking status (current/non), recall of a diagnosis of is-
chaemic heart disease, stroke, cancer, or diabetes, self-reported health/frailty, employment grade, LDL-C, HDL-C, apolipoprotein A1, apolipo-
protein B, body mass index, markers of inflammation (albumin, fibrinogen, and C-reactive protein), recall (in 1997) of a diagnosis of
hypertension, treatment (in 1997) for hypertension and measured systolic and diastolic blood pressure in both 1997 and in 1970, and esti-
mated glomerular filtration rate.
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these associations was due to confounding, principally by prior
disease. There was no evidence that the RRs associated with a
doubling in baseline 25(OH)D concentration varied during
follow-up (P values for test of proportionality assumption: P ¼
0.48 for vascular mortality and P ¼ 0.13 for non-vascular mortal-
ity). Associations with particular types of vascular and non-
vascular death (e.g. IHD, stroke, cancer, and respiratory death),
after adjustment for measured confounders, were broadly
similar to the overall RRs seen for vascular and non-vascular
mortality (Figure 3). The findings for participants with no prior
disease at resurvey were similar to those of the overall study
population (see Supplementary material online, Figure S3 and
S4). Results were also broadly similar after the exclusion of
deaths within the first 5 years of follow-up (to further reduce
the possible effect of reverse causality; see Supplementary mater-
ial online, Figure S5) and were similar when the original 25(OH)D
concentrations (i.e. before correction for seasonality) were used
in analyses instead of season-adjusted concentrations (see Supple-
mentary material online, Figure S6).
Meta-analysis of studies of
25-hydroxyvitamin D and vascular
and all-cause mortality
The meta-analyses (which included results from the current study)
included 12 prospective studies with 4632 vascular deaths and 18
prospective studies with 11 734 deaths from all causes. Participants
with a 25(OH)D concentration in the top vs. bottom quarter of
distribution had on average, 21% (95% CI: 13–28%) lower vascular
mortality (Figure 4) and 28% (95% CI: 24–32%) lower total mortal-
ity (Figure 5). Observed RRs varied inversely with the amount of
statistical information provided by each study (i.e. study size),
with more extreme estimates being seen among smaller studies
for both vascular and all-cause mortality.
Discussion
The Whitehall study, involving 3215 deaths, is one of the largest
and longest prospective studies reporting associations of
Figure 4 Meta-analysis of the relationship between 25-hydroxyvitamin D concentration and vascular mortality. *Numbers of deaths/people
in the whole study are reported for each study, but only half of these deaths would be expected to contribute to analyses of top vs. bottom
quarter. †This study included both fatal and non-fatal vascular events.
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25(OH)D with cause-specific mortality, and the most informative
study in the meta-analyses. This study showed an approximately
linear (on the log– log scale) inverse association of plasma
25(OH)D concentration with both vascular and non-vascular mor-
tality, at least within the range 30–90 nmol/L. After adjustment for
age, seasonality, prior disease, markers of health and frailty, and
other cardiovascular risk factors, a two-fold higher plasma concen-
tration of 25(OH)D, achievable by supplementation with high
doses of vitamin D, was associated with one-fifth lower risk of
mortality (20% lower vascular mortality and 23% lower non-
vascular mortality). The shape and strength of these associations
were broadly similar among men with and without prior vascular
disease, cancer, or diabetes and persisted even after excluding
deaths during the first 5 years of follow-up.
In contrast to previous meta-analyses that only reported on
associations with all-cause mortality, the present analyses of pro-
spective studies demonstrated a consistent trend in associations
of 25(OH)D with vascular and all-cause mortality. Our analyses
also showed a significant trend in effect size when the studies
were ordered by size consistent with publication bias (where
smaller studies are more likely to be published if their findings
are strikingly positive than if they are negative or null). With
Figure 5 Meta-analysis of the relationship between 25-hydroxyvitamin D concentration and all-cause mortality. *Number of deaths/people in
the whole study are reported for each study, but only half of these deaths would be expected to contribute to analyses of top vs. bottom
quarter.
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over 11 700 deaths, the current meta-analysis provides greater
statistical precision than the recent meta-analysis involving 5562
deaths.28
The similarities in the shape and strength of the associations of
25(OH)D with vascular and non-vascular causes of death observed
in the present study may argue against a causal relationship with
cardiovascular disease. It is possible that these associations may
reflect incomplete adjustment for known risk factors that were
measured imprecisely, or for unknown risk factors that may not
have been measured. The possibility that associations could still
reflect some reverse causality (despite the exclusion of deaths oc-
curring within 5 years of blood collection in the present study) also
cannot be entirely excluded.
Alternatively, the effects of vitamin D on vascular disease may be
mediated by mechanisms that are independent of known cardio-
vascular risk factors. Increased vascular stiffness or vascular calcifi-
cation may be one such mechanism, given the role vitamin D plays
in calcium metabolism.29 Moreover, as vitamin D receptors are
found in a wide range of tissues, vitamin D may possibly influence
diverse causes of death by some fundamental mechanism that is
not yet fully understood. For example, vitamin D is believed to
modulate the immune response which could influence deaths
from cardiovascular and non-vascular causes, including cancer
and infection.30
Among the limitations of this study, data on prior disease and
health status at resurvey were self-reported. Hence, while the
strength of the associations were attenuated substantially after ad-
justment for these measures, it is possible that residual confound-
ing by poor health status may persist. Formal assessments of
physical activity were not made at baseline, but participants
reported their self-rated health and ability to undertake activities
of daily living (based on a 15-point questionnaire) and analyses
were adjusted for these responses. Any non-response bias (by
preferentially excluding frail older people) should have minimized
rather than accentuated the effects of reverse causality.
Causes of deaths were supplied by the Office of National Statis-
tics which may also have resulted in some misclassification of the
causes of death in this population, which would tend to dilute
any real differences between the different causes of death.31
Most men in this study were still living in and around the
Greater London area. Although not representative of the wider
population, this should reduce the likelihood of confounding by
possible geographical factors associated with both hours of sun-
shine and mortality risk. Moreover, the results were broadly con-
sistent with other studies included in the meta-analyses. Since
individuals were classified on the basis of a single measurement
of plasma 25(OH)D, it is possible that the true strength of the
mortality associations observed with long-term average or usual
25(OH)D concentrations may be substantially steeper.32 The cor-
relation between repeated measurements of log 25(OH)D
recorded in 187 men over a 1.5 year period was 0.64. Hence,
the mortality associations with long-term usual levels of
25(OH)D may be expected to be 50% more extreme than
those classified on the basis of single baseline measures.32
Although our analyses of the observational studies have included
strategies to minimize the effects of confounding and of reverse
causality (within the limits of the study design), such studies are
unable to assess the causal relevance of 25(OH)D with vascular
or non-vascular mortality. As yet, randomized trials have not
been able to confirm or refute a causal role for vitamin D supple-
mentation for either cardiovascular disease or cancer prevention.
In a meta-analysis of 18 randomized-controlled trials, involving
57 311 participants, allocation to vitamin D for 5.7 years was
associated with a modest 7% lower overall mortality (RR 0.93,
95% CI: 0.87–0.99).16 In a recent Cochrane meta-analysis, involv-
ing nearly 11 000 deaths, allocation to vitamin D supplements did
not significantly reduce mortality (RR 0.97, 95% CI: 0.94–1.00).
Similarly, no beneficial effects of vitamin D supplements on risk
of coronary heart disease or stroke were reported in the
Women’s Health Initiative (WHI) trial, in which 36 282 post-
menopausal women were randomized to 400 IU vitamin D3 daily
vs. placebo.33 Furthermore, in the RECORD trial of 5292 older
people randomized to 800 IU vitamin D3 daily vs. placebo, there
was no evidence of any beneficial effects on mortality (RR 0.93;
95% CI: 0.85–1.02), or vascular disease (0.91; 95% CI: 0.79–
1.05).34
In the Whitehall study, the optimal concentration of 25(OH)D
appeared to be 80–90 nmol/L. While a recent meta-analysis
reported an increased risk of mortality with concentrations
above 87.5 nmol/L,28 there were too few individuals with
25(OH)D levels greater than this in the present study to have suf-
ficient statistical power to confirm or refute such an association.
However, it is likely that larger doses of vitamin D, than those
tested in previous trials, will be required to maintain concentra-
tions of 25(OH)D. 80 nmol/L associated with the lowest risk
in the observational studies.19 For example, among men in the
lowest fifth of the 25(OH)D concentration in the present study,
doses .2000 IU of vitamin D3 daily may be required to double
plasma 25(OH)D concentrations. Large trials are currently asses-
sing whether daily supplementation with 2000–3000 IU of
vitamin D3 can reduce the risk of vascular disease, cancer, and
other outcomes,35 but it is unclear if even higher doses of
vitamin D may be required to maintain blood concentrations of
25 (OH)D. 80 nmol/L throughout the year.
The reported inverse associations of 25(OH)D with higher risks
of all-cause mortality, and now with vascular mortality, are of con-
siderable public health interest, because low 25(OH)D concentra-
tions are common in the population and may be easily reversed by
supplements. However, the lack of specificity of the associations of
25(OH)D with particular causes of death in the present study casts
doubt on the causal relevance of these associations. Large-scale
trials using high doses of vitamin D supplements are required to
determine whether such observed associations are causal and re-
versible or have other beneficial effects. Hence, it would be
prudent to remain cautious about altering public health strategies
to increase population mean levels of 25(OH)D pending the
results of these trials.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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•  The IDS iSYS 25-OH D assay was shown to be suitable for measurement 
of samples from the Whitehall study. 
•   The Whitehall results show an inverse association between vitamin D 
levels and the risk of vascular and non-vascular mortality. This has led to a 
further study to investigate the safety and efficacy of high dose vitamin D and 
clarify the relevance of vitamin D in chronic disease in older people. 
BACKGROUND 
Vitamin D and the risk of vascular and non-vascular mortality 
A Gordon, J Tomson, S Clark and M Hill 
CTSU Clinical Trial Service Unit & Epidemiological Studies Unit Richard Doll Building, Old Road Campus, Oxford OX3 7LF, UK 
Moderate vitamin D deficiency (25 Hydroxy vitamin D, 25-OH D) affects about 
half the UK population and has been linked with increased risks of 
cardiovascular disease (CVD), cancer and impaired bone health and cognitive 
impairment (Figure 1). Limited vitamin D synthesis by the skin, due to 
inadequate exposure to sunlight, and inadequate dietary intake are the 
principal cause of these low levels.  
THE WHITEHALL RE-SURVEY STUDY 
RESULTS 
REFERENCES 
1Putting cardiovascular disease and vitamin D insufficiency into perspective 
Armin Zittermann*, Stefanie S. Schleithoff and Reiner Koerfer. Department of Cardio – Thoracic 
Surgery, Heart Center North-Rhine Westfalia, Ruhr University of Bochum, Bad Oeynhausen, Germany 
2Journal of Epidemiology and Community Health, 1978, 32, 244-249 Employment grade and coronary 
heart disease in British civil servants 
M. G. Marmot, Geoffrey Rose, M. Shipley, and P. J. S. Hamilton 
Accuracy 
Investigation of NIST standard reference material 968 
The NIST reference material was analysed in triplicate. The mean, coefficient 
of variation and recovery was calculated and compared to the 
manufacturer’s allowable limits4 (Table 1).  
Precision 
Within batch precision: Different samples were selected that represented 
low, medium and high concentrations for Vitamin D and analysed within the 
same run (Table 2).  
Between batch precision: Different samples were selected that 
represented low, medium and high concentrations for Vitamin D and 
analysed across multiple runs (Table 3). 
 
Whether vitamin D deficiency is a consequence of disease or a contributing 
factor is not clear as chronic illnesses may affect access to sunlight and diet. 
Large scale population studies may address this question, however, the gold 
standard method for the measurement of  25-OH D, LC-MS/MS is 
expensive, time-consuming and not suitable for high-throughput testing.  
 
Alternative automated immunoassay methods are available and we have 
investigated the IDS-iSYS system for the analysis of 25-OH D.  
 
Research funded by:  
The 1967-1970 Whitehall Study investigated social determinants of health 
among 18000 British male civil servants, with specific information on 
cardiovascular disease and mortality rates2. The Whitehall re-survey is a 
follow-up study (1997) with stored plasma from 5500 surviving participants 
(mean age 75 years). 
 
Moderate vitamin D deficiency has been linked with higher risk of myocardial 
infarction, stroke and death from cardiovascular disease, however, whether 
this association is causal is unknown.  
 
Using the Whitehall resurvey samples, we have examined the relevance of 
circulating 25-OH D levels to vascular mortality and also non-vascular 
mortality. 
Investigation of DEQAS EQA samples 
DEQAS EQA samples were analysed in duplicate and the results compared 
to DEQAS data (Figure 3). The observed results show a mean positive bias 
of 29.9% against the all methods mean which is within the acceptable limits 
specified by DEQAS. Compared to the LC-MS/MS a positive bias of 21.8% 
was observed. 
Functional Sensitivity 
The mean concentration for a sample whose between batch CV crosses the 
20% threshold is approximately 5.2ng/ml (Figure 4). The manufacturer 
claims the lower analytical range of the assay to be 5ng/ml.  
Linearity 
Six plasma pools derived from mixing proportional amounts of low vitamin D 
level plasma and high vitamin D level plasma sample material were analysed 
in quadruplicate. The recoveries were calculated to be between 104.36% 
and 111.14%. These are comparable to the manufacturers claims (102 – 
107%).  
Recovery 
The mean % recovery was 98.47% with a SD of 7.49. This equates to a 
proportional systematic error of 1.53%. The DEQAS evaluation criteria for 
routine assessment allows a bias of 10%6. Recovery is therefore acceptable. 
Whitehall sample results 
Measurement of the Whitehall study samples showed a log linear inverse 
relationship between plasma 25-OH D levels with vascular and non-vascular 
mortality throughout range. A 2-fold higher plasma level of 25-OH D was 
associated with approximately 25% lower relative risk of vascular and non-
vascular death (Figure 6). 
CONCLUSIONS 
Figure 1: Possible pathways between Vitamin D deficiency and chronic 
disease. adapted ref: 1 
Table 2: Within batch precision results. 
Table 3: Between batch precision results. 
Figure 4: Relationship of sample concentration against 
between batch CV 
Figure 5: Linearity plot for the reference range. 
Figure 6:  Relative risk plot 
•  To describe a formal validation of the IDS-iSYS 25-OH D assay. 
 
•  To assess the relationship of 25-OH D with vascular and non-vascular 
mortality in the Whitehall prospective study of older men. 
Assay validation 
 
Assay validation is the process of demonstrating that analytical procedures 
are suitable for their intended use.  
 
The assay performance is judged by comparison to recommendations for the 
types and size of analytical errors that are allowable; without invalidating the 
usefulness of the test results. 
 
The following elements were assessed for the IDS-iSYS 25-OH D assay: 
  
i. Accuracy (Figure 2a) 
 An assessment of how close the IDS-iSYS system is to obtaining a true 
25-OH D value was made using NIST reference material and proficiency 
testing. 
AIM 
METHODS 
Figure2a: Accuracy and Precision.  Figure2b: Functional Sensitivity.  
iii.  Functional Sensitivity (Figure 2b) 
 The lower limit of the working range was estimated as the mean 
concentration for a sample that has a between batch CV = 20%. 
 
iv. Recovery 
 The proportional systematic error was determined from pairs of samples, 
the first sample analysed as a reference, the second sample spiked with 
a high concentration of 25-OH D.  
 
v. Linearity 
 The linearity across the normal population reference range (10-50ng/ml3) 
for 25-OH D was investigated. 
ii. Precision (Figure 2a) 
 The reproducibility of repeated 25-OH D measurements  were 
investigated at three levels of sample concentration for 25-OH D for both 
within and between batch precision. 
Measurement of 25-OH D in Whitehall samples 
 
Whitehall samples (n=5500) were analysed for 25-OH D in batches of 40 
using the automated  IDS-iSYS system.  
 
Internal quality checks included running control samples with each batch, 
paired samples, which were blinded to operator, across the population group 
and re-testing 5% of samples.. 
A significant over recovery for level 2 is observed which is explained by the 
use of horse serum in the preparation of this sample.  
Table 1. Comparison of observed results with NIST   
Figure 3: Correlation of observed results against 
DEQAS data   
Low cellular calcitriol levels 
Cell 
proliferation 
Inadequate UVB exposure and low dietary vitamin D 
intake 
Low circulating levels of 25-Hydroxy vitamin D 
Increase in 
RAS 
Increase in 
TNF-α & IL-6 
Decrease in IL-
10 
Increase in 
PTH 
Decrease in 
MGP synthesis 
Increase in the 
inflammatory 
processes 
Hypertension 
Stroke 
Heart attack 
Cardiovascular Disease/Cancer/Impaired bone health/ 
Cognitive impairment 
Tissue calcification 
Sample Mean (ng/ml) Expected CV Observed CV Recovery 
Level 1 22.74 5.5 3.43 95% 
Level 2 19.72 5.5 13.19 140% 
Level 3 35.74 5.5 3.32 79% 
Level 4 36.13 5.5 5.7 102% 
Sample Mean (ng/ml)  Expected CV Observed CV N 
Low 6.21 12.1 12.91 20 
Mid 27.15 5.5 4.63 20 
High 58.81 7.3 2.82 20 
Sample Mean (ng/ml) Expected CV Observed CV N 
Low 13.27 16.9 12.68 47 
Mid 32.79 10.4 8.34 47 
High 63.19 8.9 7.55 48 
3 Tietz textbook of clinical chemistry, second edition. 
4 NIST Certificate of Analysis SRM 972 Vitamin D in Human Serum. 
5 IDS-iSYS 25-Hydroxy Vitamin D assay Kit and Controls insert sheets 
6 Specifications for trueness and precision of a reference system for serum/plasma 25-hydroxyvitamin 
D analysis. 
D. Stockl et al / Clinica Chimica Acta 408 (2009) 8-13 
 
The mean and coefficient of variation was calculated and compared to the 
manufacturers claims5. 
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Abstract  
Background: Previous large trials of vitamin D for  prevention of fractures and other 
disease outcomes have reported conflicting results, possibly because the doses 
tested were insufficient to maintain optimum blood levels of vitamin D (25[OH]D) 
predicted by the observational studies.   
Methods: The present report describes the design and baseline characteristics of a 
trial comparing the biochemical and other effects of daily dietary supplementation 
with vitamin D in preparation for a large trial for the prevention of fractures, 
cardiovascular disease and cancer. 
Methods: The trial will compare the biochemical and other effects of daily dietary 
supplementation with 100µg or 50µg vitamin D3 or placebo, when administered for 
12 months, in 305 ambulant community-dwelling older people living in Oxfordshire, 
England. The primary analyses will compare 12-month mean plasma concentrations 
of 25(OH)D as well as the proportion of participants with a 12-month concentration 
>90 nmol/L between participants allocated 100µg and participants allocated 50µg 
daily. Secondary analyses will compare the two active doses (both separately and 
when combined) with placebo. Additional end-points include biochemical 
assessments of safety, blood pressure, arterial stiffness, falls, fractures, heel and 
wrist bone density, grip strength and physical performance and echocardiographic 
assessments of cardiac function in a random sample of participants.  
Results: About one-third of eligible participants agreed to participate in the trial. The 
mean age was 72 (SD 6) years with equal numbers of men and women. About one 
third reported a prior history of fracture or hypertension, one-fifth reported a prior 
3 
 
cardiovascular event, and one tenth reported diabetes or a fall in the previous 6 
months.  
Conclusions: The results of this trial will help determine the optimum dose of 
vitamin D to test in a larger trial investigating whether vitamin D supplementation can 
reduce the risk of fractures, cardiovascular disease or cancer.   
 
 Keywords: Vitamin D supplementation trial, 25-hydroxyvitamin D, parathyroid 
hormone. 
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Introduction 
Osteoporosis causes substantial morbidity and mortality in older people, but whether 
chronic insufficiency of vitamin D is a reversible determinant of osteoporosis and 
related risk of fractures is controversial. Observational studies indicate that low 
plasma levels of 25-hydroxyvitamin D [25(OH)D] are associated with higher risks of 
fractures and with vascular and non-vascular mortality (1-4), but it is unclear if these 
associations are causal. Randomized trials assessing the effects on fracture and 
other health outcomes have generally failed to demonstrate beneficial effects of 
vitamin D supplementation (5-14). However, few such trials have used sufficient 
doses of vitamin D3 to achieve and maintain what might be considered optimum 
plasma levels of 25(OH)D.  
Although controversial, the available evidence suggests that the optimum plasma 
levels of 25(OH)D may be around 75 to 90 nmol/L. Firstly, parathyroid hormone 
(PTH) levels are linearly and inversely associated with plasma 25(OH)D levels until 
such levels reach about 75 nmol/L (15, 16). Secondly, prospective observational 
studies indicate that the risks of vascular and non-vascular mortality are lowest at 
plasma 25(OH)D levels of around 90 nmol/L (4). Thirdly, mean peak plasma 
25(OH)D levels at the end of summer in young British adults are also about 90 
nmol/L(17). At plasma 25(OH)D levels below a cut-off point of about 75 nmol/L, the 
average increase in 25(OH)D per 10µg of additional vitamin D3 has been estimated 
to be about 7-10 nmol/L(16, 18). Hence, from a typical level of 25(OH)D of 55 (SD 
26) nmol/L found in older UK adults (19), a dose of vitamin D3 of at least 50µg (2000 
IU), and possibly as much as 100µg (4000 IU), may be required to achieve and 
maintain blood levels >90 nmol/L throughout the year in most people in the UK (20).  
5 
 
The aims of the BEST-D trial are to determine the optimum dose of vitamin D that is 
safe and effective to test in a large trial of vitamin D for prevention of fractures, 
vascular disease and cancer in older people living in the community. The primary 
objectives are to compare the effects on blood concentrations of 25(OH)D and the 
proportion of participants with 25(OH)D concentrations >90 nmol/L after one year of 
daily supplementation with 100 µg (4000 IU) or 50 µg (2000 IU) vitamin D3 versus 
placebo. The aim of the present report is to describe the rationale and design of the 
BEST-D trial and the baseline characteristics of the trial participants.   
 
Methods  
Inclusion and exclusion criteria 
Ambulant community-dwelling men and women aged 65 years and older were 
identified from a single general practice in Oxfordshire and mailed an invitation letter 
to participate in the trial. The invitation letter included a screening questionnaire to 
check eligibility and a study information leaflet. Those who returned the screening 
questionnaire and were potentially eligible were provided with an appointment for a 
randomization study visit. Figure 1 outlines the number of participants enrolled in 
each stage in the study.  
 
People were ineligible if they were: nursing home residents; regular users of vitamin 
D supplements more than 10 µg (400 IU) vitamin D daily; prescribed calcium 
supplements, bisphosphonates, parathyroid hormone (PTH), or calcitonin; had 
medically diagnosed dementia or history of hypercalcaemia, hyperparathyroidism 
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lymphoma, sarcoidosis, active tuberculosis or renal calculus; were judged by their 
doctor as likely to be poorly compliant with clinic visits or medication; or had a history 
of alcohol or substance misuse or a history that might limit their ability to take the 
study treatment (e.g. terminal illness). All participants provided written informed 
consent.  
 
Outcomes 
The co-primary outcomes are mean plasma 25(OH)D concentrations at 12 months 
and the percentage of participants with a 12-month 25(OH)D concentration >90 
nmol/L. Secondary outcomes are: (i) mean plasma 25(OH)D concentrations at 1 and 
6 months; (ii) percentage of participants with plasma 25(OH)D concentrations >90 
nmol/L at 1 and 6 months; (iii) PTH within the reference interval (1.1-6.8 pmol/L) at 1, 
6 and 12 months; (iv) albumin-corrected calcium concentrations above the reference 
interval (2.15-2.55 mmol/L) at 1, 6 and 12 months; and (v) mean plasma 
concentrations of albumin, phosphate, creatinine and alkaline phosphatase at  6 and 
12 months; (vi) mean concentrations of lipids (total cholesterol, LDL-C, HDL-C, 
triglycerides, apo-B and apo-A1), high-sensitivity C-reactive protein (hsCRP), and N-
terminal prohormone of brain natriuretic peptide (NT-proBNP) at 6 and 12 months; 
(vii) mean levels of systolic and diastolic blood pressure, heart rate and arterial 
stiffness at 6 and 12 months; and (viii) echocardiographic measures of systolic 
function, diastolic function and global cardiac function in a sub-set of 150 participants 
at 12 months. Tertiary outcomes are listed in the Web-Appendix, and include 12-
month assessments of: (i) reported  fractures at all sites and at specific sites; (ii) 
reported falls; (iii) muscle and joint pain; (iv) grip strength; (v) Short Physical 
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Performance battery; (vii) Geriatric Depression Sccores; (viii) respiratory infections;  
(ix) Height, weight and BMI; (x) bone density of wrist and heel; and (xi) estimated 
GFR and urinary albumin/creatinine ratio. 
  
Sample size and statistical analyses 
Based on the reported mean seasonally adjusted 25(OH)D levels of 55 (SD 20) 
nmol/L among post-menopausal women between the ages of 65 and 74 years (21), 
a dose of 50 µg of vitamin D3 may be required to increase the mean concentration of 
25(OH)D by 25-35 nmol/L. However, there is uncertainty about whether the 
relationship between vitamin D dose and the increase in 25(OH)D is linear. The 
study was designed to have good power to detect even a small difference in mean 
25(OH) concentrations at 12 months between the two active doses.  Specifically, with 
100 participants in each group and an assumed SD of 20 nmol/L, this study has 90% 
power (at 2p=0.01) to detect a true difference in mean 25(OH)D between the two 
active doses at 12 months of just 11 nmol/L. (The minimum detectable difference will 
be even smaller than this due to the use of analysis of covariance to assess 
comparisons: see Web-Appendix.)  
The primary efficacy assessment will be an “intention-to-treat” analysis among all 
randomized participants comparing daily dietary supplementation with vitamin D3 
100µg vs vitamin D3 50µg on: (1) the mean 25(OH)D concentrations at 12 months 
and (2) the proportion of individuals with levels of 25(OH)D above 90 nmol/L at 12 
months. Pre-specified subgroup analyses of the co-primary outcomes will include 
subdivisions by: sex; age (<70 vs ≥70 years); higher or lower body mass index 
(BMI); baseline plasma concentrations of 25(OH)D; estimated glomerular filtration 
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rate; and estimated dietary calcium intake; or presence or absence of prior 
cardiovascular disease or cancer. No allowance will be made for multiple 
comparisons in the assessment of the co-primary endpoints with the statistical 
significance of each being based on a 2p<0.05 criterion.  
Secondary and tertiary analyses of particular outcomes will compare the two active 
doses (separately and/or when combined) with placebo. (A detailed Statistical 
Analysis Plan is provided in the Web-Appendix). Allowance will be made in their 
interpretation for multiple hypothesis testing (taking into account, if relevant, the type 
of measure and evidence from other studies) (22, 23). But, the more extreme the p-
value (or, analogously, the further the confidence interval is from zero) after any 
allowance has been made for the nature of the particular comparison, the more 
reliable the comparison and, hence, the more definite any finding will be considered. 
 
Randomization and blinding 
Table 1 shows a summary of the study procedures. Study visits were conducted by 
trained study nurses at the participant’s home (but the final visit also included an 
additional visit to the General Practice: see below). At the first visit (month 0), 
eligibility was assessed and relevant medical history and medication, calcium intake, 
and baseline measures recorded. If willing and eligible, participants were 
randomized in a ratio of 1:1:1 to vitamin D3 100 µg (4000 IU), vitamin D3 50 µg 
(2000 IU), or placebo daily. Randomization was performed by a central 
randomization service at the Clinical Trial Service Unit (CTSU), University of Oxford 
using a minimisation algorithm balanced for age group [65-69, 70-74, 75+ years], 
gender, body mass index (BMI), smoking history, ethnicity and history of fracture to 
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assign a double-blind treatment allocation and a treatment allocation number. 
Vitamin D3 50 µg in soft gel capsules and matching placebo capsules were provided 
by Tischcon Corporation (Westbury, New York, USA), and packaged in labelled 
child-proof bottles by Sharp Clinical Services (Crickhowell, Powys, UK). At the 
randomization and 6 month visits, participants were provided with two bottles of 
medication, each containing 210 capsules (each containing 50 µg vitamin D3 or 
matching placebo) sufficient to last 7 months, and instructed to take one capsule 
from each bottle daily. Participants were asked to return all study treatment bottles at 
the 6 and 12 month visits.   
 
Post-randomization follow-up 
About 100 participants were randomly selected for a blood sample at 1 month (Table 
1). All participants were to have follow-up visits from the study nurse at 6 and 12 
months (Table 1). Compliance and adverse events were evaluated at each visit 
along with selected tests. Depression scores were assessed at 6 and 12 months 
using a 4-point Geriatric Depression Score (24). Spot urine samples were collected 
at the final home visit. Participants were invited to attend a special clinic at their local 
General Practice for a bone scan to assess heel and wrist bone density and a short 
physical performance battery (25).  
 
Safety 
At each visit non-serious adverse events (NSAEs) thought related to the study 
treatment or that resulted in the participant stopping treatment, and all serious 
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adverse events (SAEs) were recorded in the electronic case report forms. 
Participants were provided with a 24-hour Freefone number to contact a clinician at 
CTSU should they wish to discuss trial-related medical problems.  
 
Cardiovascular assessments 
At each visit blood pressure and arterial stiffness were measured after 10 minutes of 
rest in the seated position (26). A finger probe (Pulsetrace PCA 2) placed on the 
right forefinger recorded the ‘digital volume pulse’ using photoplethysmography over 
30-60 seconds. This was followed by blood pressure and brachial artery arterial 
stiffness measurements made over 2 minutes using a TensioClinicTM® arteriograph. 
Left ventricular function was assessed by echocardiography in a randomly selected 
subset of 151 participants at the final visit (who provided separate consent for this 
examination). Any significant abnormalities were to be reported to the participant’s 
GP.  
Musculoskeletal parameters 
A history of falls in the last 6 months and fractures at any time was recorded at 
randomization, 6 and 12 months. Participants were asked to rate from 1 to 10 their 
level of physical activity, and the presence and severity of any muscle and, 
separately, joint pain, if present. Hand grip strength was assessed using a JamarTM 
J00105 hydraulic dynamometer, as previously described (27). A modified short 
physical performance battery at the final visit evaluated the time taken for five 
consecutive chair rises, the time to walk 3 metres, and a balance score calculated 
from the time that balance was held in the tandem, semi-tandem, and side-by-side 
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stances (25). Heel and wrist bone mineral density were measured using an 
OsteoSys EXA-3000 scanner (OsteoSYS, Seoul, Korea). 
 
Laboratory analyses 
Blood samples were collected at each visit into 2 standard 10 ml tubes (one 
containing EDTA and one lithium heparin) and at baseline and 12 months also into a 
PAXgene blood RNA tube (Pre-Analytix, Qiagen, Hombrechtiken, Germany). 
Samples were taken to the Horton Hospital Clinical Chemistry laboratory, Banbury, 
Oxfordshire, processed, fractionated into aliquots within 4 hours of blood collection 
and stored in a -80ºC freezer. Lithium heparin plasma was used to measure plasma 
levels of calcium and albumin at the Horton Hospital Clinical Chemistry laboratory 
prior to starting study treatment. Plasma samples were stored at the Wolfson 
Laboratory in CTSU, Oxford for future determination of plasma levels of PTH, 
25(OH)D, lipids, hsCRP and inflammatory cytokines at CTSU. Buffy coats were also 
stored from the randomization and 12 month visits for future extraction of DNA to 
measure markers related to vitamin D. Urine samples were collected at the final visit 
and frozen (-80 ºC) for future measurement of urinary albumin to creatinine ratio.   
 
Data collection and management 
All questionnaire and clinical data were collected electronically using portable 
computers and encrypted to ensure confidentiality, data accuracy and protection of 
patient safety. BEST-D was conducted in accordance with the principles of the 
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International Conference on Harmonisation Guidelines for Good Clinical Practice 
(ICH-GCP), and relevant regulations.  
Ethics committee approval and funding 
BEST-D received approval from the National Research Ethics Service (NRES) 
Committee South Central – Oxford B, the Thames Valley Primary Care Research 
Partnership, a Clinical Trial Authorisation from MHRA and is included on the National 
Institute for Health Research (NIHR) Trial portfolio. The University of Oxford acted as 
sponsor and funding was provided by the Clinical Trial Service Unit and 
Epidemiological Studies Unit, University of Oxford and the British Heart Foundation.  
 
Results 
Characteristics of study participants 
From the registered patients at the practice in this age group, 932 were invited to 
participate, 313 (33%) agreed to have a randomization visit from the study nurse and 
305 participants were successfully randomized between 24 September 2012 and 14 
March 2013 (Figure 1). Eight participants visited were not randomized (6 declined 
and 2 were ineligible) and 619 declined or ignored the invitation to participate. The 
final study visit for the last participant was held on 10 March 2014. Among surviving 
participants, 296 completed a 6-month visit, 290 completed a 12-month visit, 272 
had their bone density measured and 151 had cardiac echocardiography.  
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Baseline characteristics 
Among the 305 participants, the overall mean age was 72 (SD 6) years, 51% were 
men, 14% had a prior history of IHD, 6% had stroke/TIA, 9% had diabetes and 39% 
had hypertension. Overall, 30% had any prior history of fracture and 13% had a 
history of a fall in the last 6 months. Table 2 also shows the use of medication for 
prevention of cardiovascular disease, mean levels of body mass index, blood 
pressure and grip strength; and estimated calcium intake. While use of anti-
hypertensive drugs, anti-platelet agents and statins were appropriate for the 
proportions with prior vascular disease and diabetes in this general population, 
routine use of non-prescribed (“over-the-counter”) preparations of calcium and 
vitamin D supplements was uncommon (albeit this partly reflected the study design). 
 
Discussion 
Although severe vitamin D deficiency is associated with rickets in children and 
osteomalacia in adults (28), there is no consensus about routine supplementation 
with vitamin D for bone health. The UK dietary Reference Nutrient Intake (RNI) for 
vitamin D is 10 µg/day (400 IU) for adults aged 65 years and older and pregnant or 
lactating women. The RNI has not been established for otherwise healthy adults < 65 
years old because of the assumption that sufficient vitamin D can be made after 
exposure to sunlight.  
 In 1992, Chapuy et al (5) reported that supplementation with 20 µg (800 IU) vitamin 
D plus calcium 1200 mg daily for 18 months significantly reduced non-vertebral 
fractures (160 vs 215; p < 0.001) including hip fractures (80 vs 110; p = 0.004) in 
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3,270 elderly women living in nursing homes or apartments for elderly people in 
France. Over the last 20 years, several large, long-term trials, and several study-
level and individual participant-level meta-analyses have assessed the effect of 
vitamin D on fractures, but the results have been conflicting (6-14), possibly because 
the doses of vitamin D used were insufficient to maintain optimum levels of 25(OH)D. 
However, there have been few large trials of vitamin D that used adequate doses of 
vitamin D to achieve the blood levels of 25(OH)D that were predicted by the 
observational studies to be associated with lowest risk. While there is no consensus 
about the optimum levels of 25(OH)D for bone health, the available evidence 
suggests that it may be close to 90 nmol/L, the level reached by healthy UK adults at 
the end of the summer (17), and below which PTH levels may be elevated (15, 16) 
and the level in observational studies associated with the lowest risk of vascular and 
non-vascular mortality (4).   
BEST-D is the first randomized placebo-controlled trial to assess the effects of two 
higher daily doses of vitamin D, 100 µg and 50 µg (equivalent to 4000 IU and 2000 
IU), in older adults living in the UK, on plasma levels of 25(OH)D, PTH, calcium, 
phosphate and albumin. An additional advantage of choosing 4000 IU daily is to 
maximize mean levels and the proportion greater than 90 nmol/L of 25(OH)D levels 
after taking account of anticipated non-compliance of about 10-15% with allocated 
study treatment. The detailed clinical and biochemical monitoring at 0, 6 and 12 
months should provide reliable data on the safety of higher doses of vitamin D. The 
results of this trial should establish the optimum daily dose of vitamin D to be used in 
future randomized trials in the UK that evaluate whether vitamin D supplementation 
confers the musculoskeletal and other health benefits suggested by observational 
studies (29-31).   
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Appendix: BEST-D Collaborative Group 
Writing Committee: Robert Clarke1,* Connie Newman2,* Joseph Tomson1,* Harold 
Hin3,* Rijo Kurien1, Jolyon Cox1, Michael Lay1, Jenny Sayer1, Michael Hill1, Jonathan 
Emberson1, Jane Armitage1.* (*contributed equally). 
1
 Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, 
 UK; 
2
. Division of Endocrinology & Metabolism, New York University School of Medicine, 
New York, USA. 
3.
 Hightown Surgery, Banbury, Oxfordshire, UK. 
Steering Committee: Jane Armitage (Chief Investigator and Chair), Harold Hin and 
Robert Clarke (Lead Investigators), Michael Hill (Laboratory Director), Joseph 
Tomson, Connie Newman, and Richard Haynes (Clinician Members), Anne Dawson 
(Lay Member), Jonathan Emberson (Statistician), Michael Lay (Computing) and 
Jenny Sayer (Administrative Coordinator).   
Medication: Kevin Murphy. 
Computing: Michael Lay, Jolyon Cox, Rijo Kurien. 
Clinical Biochemistry, Horton Hospital, Banbury: Tim James and Peter Tandy and 
Wolfson Laboratory, Clinical Trial Service Unit, Oxford: Michael Hill  
Nurses: Lynn Peach, Enid Frost, Caroline Boulton, Barbara White.  
Research Assistant: Jessica Hin. 
Echocardiography: Joseph Tomson, Linda Arnold. 
Administrators: Kate Gillingham, Jenny Sayer.  
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Table 1: Schedule of study procedures 
Study Procedure Month 
0 1 6 12 
History  
• Medical history and consent x    
• Assessment of dietary calcium x    
• Assessment of fractures and falls x  x x 
• Geriatric depression score (4 parts)   x x 
Physical measurements  
• Height and weight x   x 
• Blood pressure, arterial stiffness x  x x 
• Grip strength, muscle pain x  x x 
• Short physical performance 
   x 
• Heel and wrist DEXA 
   x 
• Echocardiography    x 
Blood and urine collection  
• Plasma biochemistry* x x x x 
• RNA markers x   x 
• Buffy coats for DNA markers x  x x 
• Urinary albumin/creatinine 
   x 
Study treatment  
• Issue study treatment x  x  
• Assess compliance 
  x x 
• Monitor adverse events 
  x x 
* Total cholesterol, LDL-C, HDL-C, triglycerides, apolipoprotein A, apolipoprotein B. 25-hydroxy-
vitaminD (25[OH]D); parathyroid hormone; (PTH), albumin, calcium, phosphate, alkaline 
phosphatase, creatinine, C-reactive protein (CRP);  n-terminal brain natiuretic peptide (nBNP). 
Plasma biochemistry measurements  at 1 month will be analyzed in a sub-set of 100 participants. 
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Table 2: Baseline characteristics of study participants, by allocated treatment 
Mean (SD) or % 
4000 IU/day 
(n=102) 
2000 IU/day 
(n=102) 
Placebo 
(n=101) 
Age, years 71 (6) 72 (6) 72 (6) 
Male 51% 50% 51% 
Current smoker 7% 7% 7% 
Dietary calcium (mg/day) 724 (287) 695 (292) 713 (302) 
Prior disease    
Heart disease* 20% 11% 11% 
Stroke/TIA 5% 8% 6% 
Hypertension 39% 43% 35% 
Diabetes 9% 9% 9% 
Fracture 30% 29% 30% 
Any fall in the past 6 months 13% 15% 12% 
Medication    
Any antihypertensive drugs 43% 49% 40% 
Statins 29% 27% 21% 
Any anti-platelet drugs 18% 19% 15% 
Vitamin D (<=400 IU/day) 6% 8% 11% 
Calcium 2% 1% 3% 
Physical measurements    
Height, cms 168 (10) 168 (10) 167 (10) 
Weight, kgs 77 (17) 78 (15) 79 (15) 
Body mass index, kg/m2 27 (5) 27 (4) 28 (5) 
Grip strength, kg 25 (11) 25 (11) 25 (11) 
Systolic blood pressure, mm Hg 132 (22) 132 (17) 129 (18) 
Diastolic blood pressure, mm Hg 77 (11) 77 (10) 76 (12) 
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Web-Appendix: Statistical Analysis Plan  
1 Background 
This Statistical Analysis Plan describes the outcomes, comparisons and statistical methods that will 
be used to assess the biochemical efficacy and safety of 100µg (4000 IU) and 50µg (2000 IU) vitamin 
D3 in the BEST-D trial. The nature of further secondary analyses and content of subsequent 
publications cannot be specified in detail but, where appropriate, the general analytical approach is 
described. All analyses and reports will be prepared by the Clinical Trial Service Unit, University of 
Oxford.  
2 Outcomes 
2.1 Co-primary outcomes 
The two co-primary outcomes are: 
 Mean plasma 25(OH)D concentrations at 12 months, 
 Percentage of participants with a 25(OH)D concentration >90 nmol/L at 12 months.  
2.2 Secondary outcomes 
The secondary outcomes are: 
 Mean plasma 25(OH)D concentrations at 1 and at 6 months; 
 Percentage of participants with a 25(OH)D concentration >90 nmol/L at 1 and 6 months;  
 Percentage of participants with a PTH concentration in the reference interval (1.1-6.8 
pmol/L) at 1, 6 and 12 months; 
 Percentage of participants with an albumin-corrected calcium concentration1 above the 
reference interval (2.15-2.55 mmol/L) at 1, 6 and 12 months; 
 Mean plasma concentrations at 6 and 12 months of albumin (g/L), phosphate (mmol/L), 
creatinine (mmol/L), and alkaline phosphatase (IU); 
 Total cholesterol (mmol/L), LDL-C (mmol/L), HDL-C (mmol/L), triglycerides (mmol/L), 
apolipoprotein A (g/L) and apolipoprotein B (g/L) at 6 and 12 months; 
 hsCRP at 6 and 12 months; 
 NT-proBNP at 6 and 12 months; 
 Systolic and diastolic blood pressure (mmHg), heart rate and arterial stiffness at 6 and 12 
months; 
                                                             
1 Calculated by calcium in mmol/L = 0.02 x (40 – plasma albumin [g/L]) 
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 Echocardiographic measures of systolic function, diastolic function and global cardiac 
function (sub-set at 12 months only). 
2.3 Tertiary outcomes 
The tertiary outcomes are 12 month assessments of: 
 Fractures at all sites and specific sites (n, %) 
 Falls (n, %) 
 Muscle pains (self-assessed visual analogue score 0-10) 
 Physical activity  (self-assessed visual analogue score 0-10) 
 Joint pains (self-assessed visual analogue score 0-10)  
 Respiratory infections (number) 
 Geriatric Depression Score (1-4) 
 Weight (kg) 
 Height (cm) 
 BMI (kg/m2) 
 Grip strength (kg) 
 Short physical performance battery tests 
o 5 chair rises (sec) 
o Balance in tandem position (sec) 
o Balance in semi-tandem position (sec) 
o Balance side by side (sec) 
o 3 metre walk (sec) 
 Bone density at the wrist (T-score and Z-score) 
 Bone density at the heel (T-score and Z-score) 
 Estimated GFR (ml/min/1.73 m2) 
 Urinary albumin/creatinine ratio. 
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3 Comparisons 
3.1 Primary comparison of the co-primary outcomes 
The primary comparison of the two co-primary outcomes (defined in section 2.1) will compare all 
participants allocated 100 µg vitamin D3 daily with all participants allocated 50 µg vitamin D3 daily. 
3.2 Secondary comparisons of the co-primary outcomes 
The secondary comparisons of the two co-primary outcomes will compare: 
 Participants allocated 100 µg vitamin D3 daily versus participants allocated placebo; 
 Participants allocated 50 µg vitamin D3 daily versus participants allocated placebo; 
 Participants allocated any active vitamin D3 dose (50 µg or 100 µg daily) versus participants 
allocated placebo. 
3.3 Tertiary comparisons of the co-primary outcomes 
Tertiary comparisons of the two co-primary outcomes will compare participants allocated 100 µg 
vitamin D3 daily with participants allocated 50 µg vitamin D3 daily, separately by the following 
baseline characteristics: 
 Sex (Male, Female) 
 Age (<70, ≥70 years) 
 BMI (<25, ≥25 to <30, ≥30 kg/m2) 
 Plasma 25(OH)D concentrations (≤50, >50 nmol/L) 
 Dietary calcium intake (≤700, >700 mg/day) 
 eGFR calculated by the CKD-epi equation (≤75, >75 ml/min/1.73 m2) 
 Prior history of cardiovascular disease2 (Yes, No)  
3.4 Comparisons of secondary and tertiary outcomes 
All secondary outcomes will be compared between: 
 Participants allocated 100 µg vitamin D3 daily versus participants allocated placebo 
 Participants allocated 50 µg vitamin D3 daily versus participants allocated placebo 
 Participants allocated any active vitamin D3 dose (50 µg or 100 µg daily) versus participants 
allocated placebo. 
                                                             
2 Defined as a history of heart disease, stroke or TIA 
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Tertiary outcomes will only be formally compared between participants allocated any active vitamin 
D3 dose (50 µg or 100 µg daily) versus participants allocated placebo. 
4 Safety and tolerability outcomes 
The safety and tolerability of 100µg and 50µg vitamin D3 will be assessed from the following 
information. 
4.1 Serious adverse events (SAEs) 
All SAEs, regardless of whether the SAE is considered related to study treatment, will be recorded 
and grouped by body system or organ affected. The numbers and proportions of participants with 
SAEs in each group (vitamin D3 100µg, vitamin D3 50µg and placebo) will be described. SAEs of 
interest include: 
 Incident cardiovascular disease events (myocardial infarction or stroke or any arterial 
revascularisation procedure); 
 Incident cancer (any cancer excluding non-melanoma skin cancer); 
 Death, hospitalisation, persistent or significant disability, or any important medical event, 
including hypercalcaemia or kidney stones. 
Comparisons will include each individual dose versus placebo and both active doses combined 
versus placebo. 
4.2 Reported reasons for stopping study treatment 
All reasons for stopping treatment will be recorded and listed in relevant categories by treatment 
allocation.  All adverse events, including non-serious adverse events, that cause participants to 
discontinue study treatment will be recorded and grouped by treatment allocation according to 
body system or organ. The numbers and proportions of participants in each treatment group with 
non-serious adverse events and serious adverse events that result in discontinuation of study 
treatment will be described. 
4.3 Biochemical safety data 
The biochemical safety data collected include calcium, phosphate, albumin, creatinine, alkaline 
phosphatase, and urinary albumin/creatinine. The analyses of these data are described in sections 2, 
3 and 5.1. 
5 Details of analyses 
5.1 Methods of analysis 
The assessments of efficacy and safety will involve comparisons among all randomized participants 
in their originally allocated treatment group irrespective of compliance during the scheduled 
treatment period (i.e., “intention-to-treat” analyses) (32, 33). Where a baseline value exists, 
between group comparisons of mean biomarker levels (or other physical measures) will be made by 
analysis of covariance, after adjustment for each participant’s baseline value (and, where necessary, 
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after transformation). Between group comparisons of proportions will be made using standard 
methods for 2x2 contingency tables. Missing values of particular biomarkers or physical measures 
will be imputed using multiple imputation (with 10 imputed data sets) with results across 
imputations being combined using the methods of Rubin. Results will be compared with those from 
complete-case analyses. 
5.2 Allowance for multiplicity of comparisons 
No allowance will be made for multiple comparisons in the primary assessment of the co-primary 
endpoints (section 3.1) and a two sided p value of <0.05 will be considered significant for each. For 
other analyses, allowance will be made in their interpretation for multiple hypothesis testing (32, 33) 
taking into account, if relevant, the type of measure and evidence from other studies. But, the more 
extreme the P-value (or, analogously, the further the lower limit of the confidence interval is from 
zero) after any allowance has been made for the nature of the particular comparison, the more 
reliable the comparison and, hence, the more definite any finding will be considered. 
5.3 Tests for heterogeneity of effects 
When a number of subgroups are considered, chance alone may lead to there being no apparent 
effect in several subgroups in which the effect of treatment really is about the same as that 
observed overall. In such circumstances, “lack of direct evidence of effect” is not good “evidence of 
lack of effect”, and clearly significant overall results would provide strong evidence of effects in 
some small subgroups where the results considered in isolation, are not conventionally significant. 
Instead, tests for heterogeneity (or, where appropriate, trend) in the effect of treatment allocation 
on differences in 25(OH)D between individuals allocated 100µg vitamin D3 and individuals allocated 
50µg vitamin D3 will be performed to assess whether or not the effect in any particular subgroup is 
clearly different from the overall effect. 
Web-Appendix References 
A1: Collins R, MacMahon S. Reliable assessment of the effects of treatment on mortality and major 
morbidity, I: clinical trials. Lancet. 2001;357(9253):373-80. 
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Dear Dr Armitage 
 
Study title: BEST-D (Biochemical efficacy and safety trial of vitamin 
D): a dose-finding trial assessing biochemical and 
vascular effects of high dose vitamin D 
REC reference: 12/SC/0243 
Protocol number: CTSU BEST-D 
 
Thank you for your letter of 11 May 2012, responding to the Committee’s request for further 
information on the above research and submitting revised documentation. 
 
The further information has been considered on behalf of the Committee by the Chair.  
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described in the application form, protocol and supporting 
documentation as revised, subject to the conditions specified below. 
 
Ethical review of research sites 
 
NHS sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start of 
the study (see "Conditions of the favourable opinion" below). 
 
 
 
 
 Non-NHS sites 
 
The Committee has not yet been notified of the outcome of any site-specific assessment 
(SSA) for the non-NHS research site(s) taking part in this study.  The favourable opinion 
does not therefore apply to any non-NHS site at present.  We will write to you again as 
soon as one Research Ethics Committee has notified the outcome of a SSA.  In the 
meantime no study procedures should be initiated at non-NHS sites. 
 
Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the start of 
the study. 
 
Management permission or approval must be obtained from each host organisation prior to 
the start of the study at the site concerned. 
 
Management permission ("R&D approval") should be sought from all NHS organisations 
involved in the study in accordance with NHS research governance arrangements. 
 
Guidance on applying for NHS permission for research is available in the Integrated 
Research Application System or at http://www.rdforum.nhs.uk.   
 
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites ("participant identification centre"), guidance should be sought 
from the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation.  
 
Sponsors are not required to notify the Committee of approvals from host organisations 
 
It is the responsibility of the sponsor to ensure that all the conditions are complied 
with before the start of the study or its initiation at a particular site (as applicable). 
 
Approved documents 
 
The final list of documents reviewed and approved by the Committee is as follows: 
  
Document    Version    Date    
Advertisement  1.0, Poster  04 April 2012  
Covering Letter    12 April 2012  
Evidence of insurance or indemnity  Sponsor Letter  11 April 2012  
Evidence of insurance or indemnity    11 April 2012  
GP/Consultant Information Sheets  1.0     
Investigator CV    11 April 2012  
Investigator's Brochure  1.0  23 March 2012  
Letter from Sponsor  Letter of Authorisation  11 April 2012  
Letter of invitation to participant  1.0  04 April 2012  
Other: Calcium Information  1.0  11 April 2012  
Other: BEST-D Colour Logo    11 April 2012  
Other: CV for Dr Tomson    12 March 2012  
Other: Personal Safety Lone Worker Policy  3  01 July 2008  
 Other: Short Geriatric Depression Scale       
Participant Consent Form  2.0  11 June 2012  
Participant Information Sheet  2.0 11 June 2012  
Protocol  1.1  11 June 2012  
REC application  3.4  16 April 2012  
Response to Request for Further Information    11 May 2012  
Sample Diary/Patient Card  1.0, D-STIL  16 March 2012  
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK. 
 
After ethical review 
 
Reporting requirements 
 
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
 Notifying substantial amendments 
 Adding new sites and investigators 
 Notification of serious breaches of the protocol 
 Progress and safety reports 
 Notifying the end of the study 
 
The NRES website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures. 
 
Feedback 
 
You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure.  If you wish to make your views 
known please use the feedback form available on the website. 
 
Further information is available at National Research Ethics Service website > After Review  
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With the Committee’s best wishes for the success of this project 
 
Yours sincerely 
 
 
Prof Margaret Rees 
Chair 
 
Email: scsha.oxfordRECB@nhs.net  
 
Enclosures: “After ethical review – guidance for researchers” [Emailed] 
 
Copy to: Ms Heather House 
heather.house@admin.ox.ac.uk  
 
Mrs Dot Powers 
dot.powers@seoxon-pct.nhs.uk  
  
 

